

#### **Clinical Audit / Service Evaluation Action Plan**

Ref no: NS 278 (original AP unable to be found, contents taken from Risk and Governance audit report)

Clinical Audit Title	Review of patching Chiari malformations intra-operatively versus not patching				
Date audit complete		Date action plan completed			
Auditor		Name of policy / guideline			
Division	Neurosurgery	Source of policy / guideline			

#### Audit Rationale:

Please summarize the rationale of the audit for the members of the Clinical Audit Group (please limit to one or two sentences)

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Patients who had a patch after a chiari decompression spent less time in hospital and had fewer complications / further surgery
- Key success:

Please concisely state the key success identified by the project – if none identified please state N/A

- That there was a difference between those that were patched and those that weren't
- Finds written up and submitted for publication (awaiting reviewers commetns)

## **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

N/A

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

• That the project supports patching of Chiari patients routinely. One other surgeon has changed to this technique, the other who does Chiari decompressions, is considering it,

Presentation / Dissemination of Project
Date findings were presented / disseminated:
Department where discussed or presented:

# Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)					
2)					
3)					
Re-audit date If r	no re-audit planned please give reasons v	why?			
Will this be an on-going audit? Ye	s 🗌 No 🔲				
Are there any potential barriers / prob	plems to prevent the implementation of the	ne above actions	? Yes 🗌 N	o 🗌	
If yes to the above please state who t	he issues have been referred to:				
Name	Designation	_ Date referre	ed		
Signature:	Date:				
Have any issues been logged on the Please provide details of issue(s) log					



# **Project Prioritisation Assessment Tool**

Audit title: Review of patching Chiari malformations intra-operatively versus not patching

If the project is mandatory please specify what priority level:-

**Priority level** 

Level 1, 2 & 3

Level 4

Level 5

**Audit team resource** 

Category A – Full support

Category B – Moderate support

Category C – Minimal support

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'					
Criteria		Tick all that apply	Score		
High cost			(x3)		
High volume			(x2)		
High risk			(x3)		
Known quality issue			(x3)		
Wide variation in practice					
NICE / NCEPOD related audit			(x3)		
Defined measurable standards available					
Re-audit / repeat service evaluation			(x2)		
Topic is a key clinical interest for the departme division		(x2)			
Multidisciplinary project					
National / regional or multicentre project			(x2)		
Total		0c			
Priority levels and audit team support					
Priority level Priority		score			
Level 1 – External 'must do' Category		' A			
Level 2 – Internal 'must do' Category		/ A			
Level 3 – High local priority	> 10				
Level 4 – Medium local priority	4 – 9				
Level 5 – Low local priority < 4					

Version 2019 Review date: 2021

Full practical assistance offered

Level of practical assistance will be negotiated and agreed with project lead

Advice, registration and monitoring

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type	: - Clini	cal Au	dit ⊠	Service E	Evaluatio	n 🗆	
Audit / Service Eva not patching	luation Title: F	Review	of pate	ching C	chiari mal	formatio	ons intra-operatively	versus
Division: Neurology	<sup>,</sup> □ Neurosurge	ery ⊠ F	Please	specify	departme	ent Click	here to enter text.	
Project Lead:								
Contact No: Bleep	No: Click here to	o enter t	ext.					
Email address:								
Audit / service eval	luation superv	isor:						
Other professional (Please provide nam Click here to enter tex	nes and roles w	-				on, analy	rsis etc.)	
superior to leaving the dura open. One surge	ntanalysis which e dura open. Tra eon changed his p	ditionall practice	y the te 2 years	chnique ago, an	of choice d is trying t	at the Wa	post fossa decompressi Iton Centre has been to e the other surgeons to g the dura in patients at	leave the do
Methodology								
years will be examin examined by looking	ed. Patient de gat EP2 surgica so be examine	mograp al, inpat	hics, le ient, an	ngth of nd outpa	stay, com atient reco	nplication ords. Ass	nation surgery in the ps, and outcomes will be cociated COMI scores lura left open and thos	oe from
Aims / Objectives								
To establish whethe patient cohort.	r there is any b	enefit to	patchi	ing the	dura durir	ng Chiari	malformation surgery	in our
Standards / Criteria	a Details (serv	<u>ice eva</u>	luation	N/A)				
There are no publishe Centre previously.	d standards, alth	ough co	mplicat	ion rate	s of >25%	have been	published from the Wa	ilton
Guideline / Standar	rds available:	Yes		No	$\boxtimes$			
If yes, please attach	a copy or prov	ide web	link to	the mo	st current	version:	Click here to enter text	
Name of Standard	<b>/ guideline:</b> Clid	ck here t	o enter	text.				
Source of Standard	d / guideline:	NSF			NICE		Royal College	

Trust □ Oth	State other: Click here to enter text.
Review/assessment of g	uideline/standard undertaken to ensure it is appropriate & can be measure
Is the audit / service eva High volume High risk High cost Known quality issue Wide variation in practice	Yes □ No ⊠ Yes □ No ⊠ Yes □ No ⊠ Yes □ No ⊠
Sample No: about 50 Pr	ocedure codes to identify sample: sample already found
http://www.raosoft.com/sa	nplesize.html - link to tool that may be used to calculate sample size
Are you planning to pub	ish your audit/service evaluation findings nationally
(e.g. Medical journal)?	Yes □ No ⊠
Is this a re-audit or if ser	vice evaluation, has service been reviewed previously? Yes □ No ☒
Is this project part of an	agreed departmental rolling programme? Yes □ No ☒
Rolling programme dura	ion (number of years): Click here to enter text.
Rolling programme frequency	ency: Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary:	Single disciplinary: □
Is Clinical Audit Team su If yes, please specify type  ◆ Population Identificatio  ◆ Design of data collecti (If not required please, att  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case notes	of assistance required:
_Depending on the avail may be required.	ability of information from the electronic patient record, some case notes
Patient Contact / Involve or care please explain how in Will the audit involve dir	,
How will the patient be i	volved?
Patient Questionnaire	□ At clinic appointment □
Other (please give details)	ick here to enter text.

Has approval been sought from the Patient Information Panel?	Yes		No		N/A	$\boxtimes$		
nticipated start date:15/12/19								
Anticipated project completion date: 25/1/20								
Anticipated Action Plan Submission date: Click here to enter text.								
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QU</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD AUDIT TEAM.</li> </ul>	COPY	OF TH	IE PRE					
Departmental Clinical Audit Lead (Signature)  Comments Click here to enter text.		Date:	Click ł	nere	to ente	er text.		
	_							
Divisional Clinical Audit Lead (Signature)						er text.		
Is this topic a key clinical interest for the department / division?	Ye	s $\square$		N	1o 🗆			



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 279

Clinical Audit Title	Horsley ITU compliances with guidelines for best practice for care of NGT during enteral feeding and route for medication administration.				
Date audit complete	2019	Date action plan completed			
Auditor		Name of policy / guideline	Reducing harm caused by misplaced nasogastric feeding		
		-	tubes in adults, children and infants.		
Division	HITU	Source of policy / guideline	NPSA.		

#### **Audit Rationale:**

Please summarize the rationale of the audit for the members of the Clinical Audit Group (please limit to one or two sentences)

Currently I am undertaking an Msc programme in Advanced Healthcare practice, back in 2017 for one of my module I had to undertake a clinical audit and critically evaluate the audit to meet specific learning outcomes. I decided to undertake an audit looking at compliance of trust and national standards with checks of NGT positions and pH test during enteral feeding and medication administration. In accordance to the action plan of this

standards with checks of NGT positions and pH test during enteral feeding and medication administration. In accordance to the action plan caudit, a further audit needs completing to review compliance of trust and national standards.

(Previous audit conducted results: Overall findings were satisfactory however compliance fell down when documenting checking the NGT prior to administration to feed or medication with 1 out 10 audited charts not completing this documentation. Also 2 out of the 10 audited charts didn't have documentation that pH of aspirations obtained was checked.)

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- 1. NGT position at nose documented and which nostril- 100% compliance.
- 2. NGT position checked when starting feed and in same position- 100% compliance.
- 3. NGT position checked before administrating medication and in same position- 100% compliance.
- 4. NGT aspirate checked- 100% compliance.
- 5. Aspirate pH checked- 90% compliance.

#### Key success:

Please concisely state the key success identified by the project – if none identified please state N/A

- Improvement in compliance since first audit
- •

Key concerns:					
Please concisely state the key concern	ns identified by the project using bull	let points– if none identifie	d please state	N/A	
Recommendations discussed:					
Please concisely summarise the recon  This audit has completed.	nmendations that were discussed fo	llowing the completion of t	the project		
•	s part of the critical care network aud	lits.			
Presentation / Dissemination of Pro					
Date findings were presented / dissem Department where discussed or presented					
implementation e.g SOP, protocol,	named lead, timescale and reportabl standardised template, presentation	or meeting minutes etc		_	
Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)					
2)					
3)					
Re-audit date If	f no re-audit planned please give r	reasons why?			
Will this be an on-going audit?	′es □ No x□				
Are there any potential barriers / pro	oblems to prevent the implementa	ation of the above actions	s? Yes □ N	lo x□	

If yes to the above ple	f yes to the above please state who the issues have been referred to:			
Name	Designation	Date referred _		
Signature:	Date:	8/7/22	_	
	logged on the risk register? of issue(s) logged on the risk		N/A	

# **Project Prioritisation Assessment Tool**

**Audit title:** Horsley ITU compliances with guidelines for best practice for care of NGT during enteral feeding and route for medication administration.

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify what priority level:-

Level 1 – External 'must do' Level 2 'Inter	nal 'must do'	
Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk		(x3)
Known quality issue		(x3)
Wide variation in practice		
NICE / NCEPOD related audit		(x3)
Defined measurable standards available		

У

**2**c

#### Priority levels and audit team support

National / regional or multicentre project

Re-audit / repeat service evaluation

Multidisciplinary project

**Total** 

Topic is a key clinical interest for the department / division

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

<b>Priority level</b>	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

Version 2019 Review date: 2021

(x2)

(x2)

(x2)

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
	<b>valuation Title:</b> Horsley ITU compliances with guidelines for best practice for care of NGT ing and route for medication administration.
Division: Neurolo	gy □ Neurosurgery ⊠ Please specify department Horsley ITU
Project Lead:	
Contact No:	Bleep No: Click here to enter text.
Email address:	
Audit / service ev	valuation supervisor:
	als involved / project team members details ames and roles within the project eg data collection, analysis etc.) text.
had to undertake a undertake an audit during enteral feed	tionale ertaking an Msc programme in Advanced Healthcare practice, back in 2017 for one of my module clinical audit and critically evaluate the audit to meet specific learning outcomes. I decided to looking at compliance of trust and national standards with checks of NGT positions and pH testing and medication administration. In accordance to the action plan of this audit, a further auditoreview compliance of trust and national standards.
Methodology	
	ompliance with checks of nasogastric tubes positions and pH tests in accordance to lices following a previous audit
Aims / Objectives	<u>s</u>
To monitor staff or aspirate pH levels	n Horsley ITU compliance with documentation of nasogastric tube position checks and prior to use.
Standards / Crite	ria Details (service evaluation N/A)
misplaced nasogast	ut in trust SOP of nasogastric feeding and in the NPSA guidelines 'Reducing harm caused by ric tubes in adults, children and infants.' My criteria would be a sample of 10 patients in critical sogastric tube and are being fed via the nasogastric tube.
Guideline / Stand	dards available: Yes ⊠ No □
If yes, please atta	ch a copy or provide web link to the most current version: Click here to enter text.
Name of Standar and infants.	<b>d / guideline:</b> Reducing harm caused by misplaced nasogastric feeding tubes in adults, childre
Source of Standa	ard / guideline: NSF □ NICE □ Royal College □ Other □ State other: NPSA

Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured ${\rm Yes}\ oxdot {\rm No}\ oxdot$ No $\ oxdot$					
Is the audit / service evaluation High volume High risk High cost Known quality issue Wide variation in practice	Yes □ No ⊠ Yes □ No ⊠ Yes □ No ⊠ Yes □ No ⊠				
Sample No: 10 Procedure codes to identify sample: Click here to enter text.					
http://www.raosoft.com/sam	nplesize.html - link to tool that may be used to calculate sample size				
Are you planning to publi	sh your audit/service evaluation findings nationally				
(e.g. Medical journal)?	Yes □ No ⊠				
Is this a re-audit or if serv	rice evaluation, has service been reviewed previously? Yes 🗵 No 🗆				
Is this project part of an a	greed departmental rolling programme? Yes □ No ☒				
Rolling programme durati	ion (number of years): Click here to enter text.				
Rolling programme freque	ency: Monthly □ Quarterly □ Biannually □ Annually □				
Multidisciplinary:	Single disciplinary: □				
Is Clinical Audit Team sup If yes, please specify type of  ◆ Population Identification  ◆ Design of data collection (If not required please, attack  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	of assistance required:				
Patient Contact / Involven or care please explain how in Will the audit involve dire	, ,				
How will the patient be in	volved?				
Patient Questionnaire	☐ At clinic appointment ☐				
Other (please give details) Cli	ck here to enter text.				
Has approval been sough	t from the Patient Information Panel? Yes □ No □ N/A ⊠				
Anticipated start date:Click					
Anticipated project comp	letion date: Click here to enter text.				

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: 21/12/2019			
Comments Click here to enter text.				
Divisional Clinical Audit Lead (Signature)		Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?		Yes □	No □	



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 281

Clinical Audit Title	VTE pharmacological prophilaxis prescribing in neurosurgical patients		
Date audit complete	03/03/2020	Date action plan completed	10/03/2020
Auditor		Name of policy / guideline	VTE Policy
Division	Neurosurgery	Source of policy / guideline	

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Failure to prescribe pharmacological prophylaxis in neurosurgical patients was identified in 9.8% of our patients
- Improved compliance with policy on pharmacological VTE prophylaxis is necessary

### **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

- Clear identification that there is a failure (9.8%) to prescribe pharmacological VTE prophylaxis in neurosurgical patients when this is clearly indicated.
- Establishing the need for better compliance and clearer pharmacological VTE prophylaxis policy

#### **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- Deviation from the previous VTE prophylaxis hospital policy.
- Non-compliance with the VTE policy of 9.8 % was recorded.
- Failure to prescribe pharmacological VTE prophylaxis may have catastrophic consequences for our patients.

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

- Auditing a new VTE prophylaxis policy to see if there are any improvements in the compliance.
- Clear guidelines published and available.
- Patients, unless clearly contraindicated, should have VTE pharmacological prophylaxis prescribed.
- Discussion with the team involved responsible for individual patient care in cases which may be controversial; review of the documentation and a clear plan in the notes.
- Familiarising staff, doctors and pharmacists with the new VTE policy.

Version: 2019

Presentation / Dissemination of Project		
Date findings were presented / disseminated:	13/03/2020	
Department where discussed or presented:	Neurosurgery	
		 _

# Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
Insufficient compliance with the previous VTE prophylaxis policy.	Application of the new VTE prophylaxis policy. Re-auditing the results and the compliance.		1 week	Enclosed	NS governance and risk
2)					
3)					
4)					
Re-audit date18/03/2020	If no re-audit planned please	give reasons wh	ıy?		
Will this be an on-going audit? Ye	s No X				
Are there any potential barriers / prol	olems to prevent the implementation of t	he above actions	s? Yes 🗌 N	o <b>X</b>	
If yes to the above please state who	the issues have been referred to:				
Name	Designation	Date referre	ed		
Signature:	Date:				

Version: 2019

Have any issues been logged on the risk register? Y	es 🗌	No 🗌	N/A	Χ			
Please provide details of issue(s) logged on the risk r	egister:						

Version: 2019



# **Project Prioritisation Assessment Tool**

## Audit title: VTE prophilaxis prescribing in neurosurgical patients

If the project is mandatory please specify what priority level:-

Level 1 – External 'must do'

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 2 'Internal 'must do'

Criteria	lick all th	at apply Score
High cost		(x3)
High volume	У	(x2)
High risk		(x3)
Known quality issue	У	(x3)
Wide variation in practice	У	
NICE / NCEPOD related audit	У	(x3)
Defined measurable standards available		
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department division	nt /	(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	9c	
Priority levels and audit team support		
Priority level	Priority score	
Level 1 – External 'must do'	Category A	
Level 2 – Internal 'must do'	Category A	
Level 3 – High local priority	> 10	
Level 4 – Medium local priority	4 – 9	
Level 5 – Low local priority	< 4	
Priority level Audit team resource		

Filolity level	Addit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

Clinical Audit Registration Form Version 3 - 2019

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □		
Audit / Service Evaluation Title: VTE prophilaxis prescribing in neurosurgical patients			
Division: Neurology	<b>Division:</b> Neurology $\square$ Neurosurgery $\boxtimes$ Please specify department $Click$ here to enter text.		
Project Lead: Davor	Dasic		
Contact No: Ble	eep No: Click here to enter text.		
Email address:			
Audit / service evalu	ation supervisor:		
	involved / project team members details es and roles within the project eg data collection, analysis etc.)		
Background / Ration	nale		
VTE prophylaxis. We ha	on the current neurosurgical compliance with the hospital policy and guidance in prescribing we noticed that some patients do not receive appropriate VTE prophylaxis, including as to be a deviation from the hospital VTE Policy.		
<u>Methodology</u>			
Retrospective study.	The data will be collected from the JAC system, Ep2 and our clinical notes.		
Aims / Objectives			
identify relevant issue	easons why some neurosurgical patients have no VTE / Dalteparin prescribed and es. We aim to address the factors leading to the non-compliance. After that we will to check if the compliance has improved. Our aim is to reach 100% compliance.		
Standards / Criteria	Details (service evaluation N/A)		
The Walton Centre VTE	Policy guidelines		
Guideline / Standard	ds available: Yes ⊠ No □		
If yes, please attach a	a copy or provide web link to the most current version: The Walton Centre VTE Policy		
Name of Standard /	guideline: VTE Policy		
Source of Standard Trust ⊠	/ guideline: NSF □ NICE ⊠ Royal College □ Other □ State other: Click here to enter text.		
Review/assessment Yes ⊠ No □	of guideline/standard undertaken to ensure it is appropriate & can be measured		

Clinical Audit Registration Form Version 3 - 2019

Ligh volume							
High volume	Yes □ No □						
High risk High cost	Yes □ No ⊠						
Known quality issue	Yes ⊠ No □						
	Yes ⊠ No □						
Wide variation in practice Yes ⋈ No □  Sample No: Click here to enter text. Procedure codes to identify sample: Click here to enter text. <a href="http://www.raosoft.com/samplesize.html">http://www.raosoft.com/samplesize.html</a> - link to tool that may be used to calculate sample size							
						Are you planning to publi	ish your audit/service evaluation findings nationally
						(e.g. Medical journal)?	Yes □ No ⊠
Is this a re-audit or if serv	vice evaluation, has service been reviewed previously? Yes □ No ☒						
Is this project part of an a	agreed departmental rolling programme? Yes □ No ☒						
Rolling programme durat	ion (number of years): Click here to enter text.						
Rolling programme frequ	ency: Monthly □ Quarterly □ Biannually □ Annually □						
Multidisciplinary:	Single disciplinary: □						
Rolling programme durat	ion (number of years): Click here to enter text.						
Is Clinical Audit Team supply yes, please specify type of Population Identification → Design of data collection (If not required please, atta → Database design → Data entry → Analysis → Presentation Collection of case notes	of assistance required:						
Patient Contact / Involver or care please explain how in Will the audit involve dire	ect patient contact? Yes   No   No						
	• • • • • • • • • • • • • • • • • • • •						
Other (please give details) Cl							
Has approval been sough	nt from the Patient Information Panel? Yes □ No □ N/A ☒						
Anticipated start date:15/	01/2020						

**Anticipated project completion date: 22/01/2020** Clinical Audit Registration Form Version 3 - 2019

**Anticipated Action Plan Submission date:** Addressing compliance and implanting relevant changes within a week.

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: 09/0	01/2020	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.		
Is this topic a key clinical interest for the department / division?	Yes ⊠	No □	

# **Project Prioritisation Assessment Tool**

Audit title: Staff Education around Point of Care Testing for INR and development of SOP

If the project is mandatory please specify what priority level:-

Level 1, 2 & 3

Level 4

Level 5

Category A – Full support

Category B – Moderate support

Category C – Minimal support

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'				
Criteria	Tick all that apply	Score		
High cost		(x3)		
High volume		(x2)		
High risk		(x3)		
Known quality issue		(x3)		
Wide variation in practice				
NICE / NCEPOD related audit		(x3)		
Defined measurable standards available	Y			
Re-audit / repeat service evaluation		(x2)		
Topic is a key clinical interest for the department / o	division	(x2)		
Multidisciplinary project				
National / regional or multicentre project		(x2)		
Total	1			
Priority levels and audit team support				
Priority level	Priority score			
Level 1 – External 'must do'	. – External 'must do' Category A			
Level 2 – Internal 'must do'	Category A			
Level 3 – High local priority	> 10			
Level 4 – Medium local priority	4 – 9			
Level 5 – Low local priority	< 4			
Priority level Audit team resource				

Version 2019 Review date: 2021

Full practical assistance offered

Level of practical assistance will be

Advice, registration and monitoring

negotiated and agreed with project lead

# **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ☒
Audit / Service Eval development of SOF	uation Title: Staff Education around Point of Care Testing for INR and
Division: Neurology	□ Neurosurgery   □ Please specify department Critical Care
Project Lead:	
Contact No: Bleep	No:
Email address:	
Audit / service evalu	uation supervisor:
	s involved / project team members details es and roles within the project eg data collection, analysis etc.) personally
Background / Ration	<u>nale</u>
	ss section of clinical staff. Assessing clinical staff knowledge & understanding of POCT n education programme then reassess their knowledge post education
<u>Methodology</u>	
Questionnaire pre & բ	post teaching session.
Aims / Objectives	
To ascertain knowled	ge of clinical staff that will potentially use POCT.
Standards / Criteria	Details (service evaluation N/A)
N/A	
Guideline / Standard	ds available: Yes ⊠ No □
If yes, please attach a	a copy or provide web link to the most current version: Click here to enter text.
Name of Standard /	guideline: Click here to enter text.
<b>Source of Standard</b> Trust □	/ guideline: NSF □ NICE □ Royal College □ Other □ State other: Click here to enter text.
<b>Review/assessment</b> Yes ⊠ No □	of guideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / service	
High volume High risk	Yes □ No ⊠ Yes □ No ⊠
High cost	res □ No ⊠ Yes □ No ⊠

' '	Yes □ No ⊠ Yes □ No ⊠
Sample No: Approx 20 Pro	cedure codes to identify sample: Click here to enter text.
http://www.raosoft.com/samp	lesize.html - link to tool that may be used to calculate sample size
Are you planning to publisl	n your audit/service evaluation findings nationally
(e.g. Medical journal)?	Yes □ No ⊠
Is this a re-audit or if service	e evaluation, has service been reviewed previously? Yes $\square$ No $\boxtimes$
Is this project part of an ag	reed departmental rolling programme? Yes □ No ☒
Rolling programme duratio	n (number of years): Click here to enter text.
Rolling programme frequer	ncy: Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary:	Single disciplinary: □
<ul> <li>◆ Database design</li> <li>◆ Data entry</li> <li>◆ Analysis</li> <li>◆ Presentation</li> <li>Collection of case notes</li> </ul>	assistance required:  tool
or care please explain how in the Will the audit involve direct	,
How will the patient be invo	olved?
Patient Questionnaire	At clinic appointment □
Other (please give details) Click	here to enter text.
Has approval been sought	from the Patient Information Panel? Yes $\square$ No $\square$ N/A $\boxtimes$
Anticipated start date:Janu	ary 2020
Anticipated project comple	tion date: May 2020
Anticipated Action Plan Su	bmission date:May 2020

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □

AUDIT TEAM.

PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL

# Staff Questionnaire Point of Care Testing- Pre Education

Define Point of Care Testing (POCT)
Who can undertake POCT?
Can you give examples of POCT used within the trust?
Can you name other POCT available on the market?
Name 5 benefits of POCT for the patient
•
•
•
Name 3 benefits for staff
•
•
Name 3 benefits for organisation
•
•
Can you identify any disadvantages of POCT?
Are you aware that all POCT devices need to be quality control checked before used for patient testing?  • Yes  • No  • Not sure
How much does it cost for an INR sample to be taken & processed by the labatory
•
•
(will give 3 options awaiting current costings)
How much does it cost to do POCT
•
(will give 3 options once decided on brand to be trialled)
Thank-you for completing the questionnair



#### Clinical Audit / Service Evaluation Action Plan

#### Ref no:

Clinical Audit Title	Patterns of recurrence and growth following surgical resection of intracranial meningioma		
Date audit complete	10/09/2021	Date action plan completed	22/01/2022
Auditor		Name of policy / guideline	N/A
Division	Department of	Source of policy / guideline	N/A
	Neurosurgery		

#### **Audit Rationale:**

Please summarize the rationale of the audit for the members of the Clinical Audit Group (please limit to one or two sentences)

Surgery is required for symptomatic meningioma. Incomplete resection, leaving residual tumour (Simpson grade 4 resection) is seen in 1/3 of cases due to anatomical location and proximity./involvement of critical neurovascular structures. The growth rates of the remaining tumour are currently unknown, and could be used to impact the frequency and duration of MRI surveillance used at follow up.

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Of 236 residual meningioma identified over a 17 year period, The absolute growth rate was 0.11cm³ per year and the relative growth rate was 4.3% per year. Only 5% had symptoms of clinical progression of their residual tumour.
- Factors associated with growth of the residual tumour were skull base location, use of adjuvant radiotherapy, and elevated Ki-67 index (a pathology marker of tumour activity).

#### Key success:

Please concisely state the key success identified by the project – if none identified please state N/A

- Only 5% of patients with a residual meningioma develop clinical symptoms due to regrowth of their tumour
- 50% of patients have significant growth (40%) at 5 years of follow up, however 84% of patients are successfully managed conservatively for this.

#### **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

• Adjuvant radiotherapy being a significant predictor of progression of a residual tumour, when this should reduce the incidence of progression. This is likely to be due to the fact that adjuvant radiotherapy is administered to selected patient based on risk of tumour regrowth, rather than radiotherapy causing regrowth.

#### **Recommendations discussed:**

Please concisely summarise the recommendations that were discussed following the completion of the project
Patients can be monitored conservatively if a residual tumour is identified, and the patient is asymptomatic.
<ul> <li>If tumours grow without causing clinical symptoms, they can still be managed conservatively in most cases without further intervention</li> </ul>
No recommendation could be made about the frequency or duration of MRI surveillance.

Presentation / Dissemination of Project
Date findings were presented / disseminated: 25/09/21.
Department where discussed or presented: European Association of Neuro-Oncology (EANO) 2021 meeting
Manuscript in preparation for publication in peer-reviewed journal

# Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)					
2)					
3)					
Re-audit dateN/A re-auditing not suitable	If no re-audit planned please give rea	asons why?	F	Rare condition ar	nd outcome means
Will this be an on-going audit? Yes No X					
Are there any potential barriers / problems to prevent the implementation of the above actions? Yes \( \subseteq \text{No } X					

If yes to the above please state who the issues have been referred to:				
Name	Designation	Date referred	-	
Signature:	Date:			
Have any issues been logged on the risk register? Yes \( \subseteq \text{No} \subseteq \text{N/A} \subseteq \text{Please provide details of issue(s) logged on the risk register:}				

# **Project Prioritisation Assessment Tool**

Audit title: Patterns of recurrence and growth following surgical resection of intracranial meningioma

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'				
Criteria	Tick all that apply	Score		
High cost		(x3)		
High volume	Y	(x2)		
High risk		(x3)		
Known quality issue		(x3)		
Wide variation in practice	Y			
NICE / NCEPOD related audit	Y	(x3)		
	N.			
Defined measurable standards available	Y			
Re-audit / repeat service evaluation		(x2)		
Topic is a key clinical interest for the department /	division	(x2)		
Multidisciplinary project	Y			
National / regional or multicentre project	Y	(x2)		
Total	10c			
Priority levels and audit team support				
Priority level	Priority score			
Level 1 – External 'must do'	Category A			
Level 2 – Internal 'must do'	Category A			
Level 3 – High local priority	> 10			
Level 4 – Medium local priority	4 – 9			
Level 5 – Low local priority	< 4			

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ret No: -	Project Type: - Clinical Audit X Service Evaluation			
Audit / Service Evalue intracranial meningion	uation Title: Patterns of recurrence and growth following surgical resection of ma			
Division: Neurology	□ Neurosurgery X □ Please specify department Click here to enter text.			
Project Lead:				
Contact No: Click her	e to enter text. Bleep No: Click here to enter text.			
Email address:				
Audit / service evaluation supervisor: Click here to enter text.				
Other professionals involved / project team members details (Please provide names and roles within the project eg data collection, analysis etc.)				

## **Background / Rationale**

Meningiomas are the most common intracranial tumour and account for  $\sim$ 1/3 of all primary brain tumours. Symptomatic meningiomas are managed by surgical resection. There are three histological grades (WHO grades 1-3): Grade I: Benign - 70-80% of cases.

Grade II: Atypical – 20-30% of all cases.

Grade III: Anaplastic – 1-3% of all cases.

Extent of surgical resection is classified according to the Simpson grade (1-5).

- Grade 1: Complete resection including resection of underlying bone and underlying bone and associated dura: 9% symptomatic recurrence at 10 years.
- Grade 2: Complete removal and coagulation of dural attachment: 19% symptomatic recurrence at 10 years.
- Grade 3: Complete removal without resection of dura and coagulation: 29% symptomatic recurrence at 10 years.
- Grade IV: Subtotal resection: 44% symptomatic recurrence at 10 years.
- Grade V: Simple decompression with or without biopsy: 100% symptomatic recurrence at 10 years.

The management and recurrence rate are determined by both Simpson grade and WHO grade. Due to the risk of recurrence patients undergo follow-up with clinical and MRI assessment at intervals of 6-12 months. Some patients will be discharged (e.g. after 5 years) whilst others remain on follow-up for decades. There is wide variation in follow-up practice between clinicians and centres. Even when patients develop radiological recurrence continued follow-up with MRI is often advised – especially in older patients where the recurrent tumour is unlikely to become life-limiting. Although there are guidelines from NICE and the European Association for Neuro-Oncology (EANO) there is still variation in the frequency of MRI follow-up.

#### **Methodology**

Retrospective case note audit of all patients diagnosed between 1/1/07 and 31/12/17. Review of clinical presentation, extent of surgical resection (Simpson grade), WHO tumour grade, epilepsy rates, MRI features, frequency of MRI follow-up and recurrence rate and growth of meningiomas.

# Aims / Objectives

To determine variation in use and frequency of follow-up MRI in patients undergoing surgical resection of intracranial meningioma and to assess adherence to the current NICE 2018 guidelines and EANO 2016 guidelines.

Output: to standardise follow-up schedule for patients with meningioma

Standards / Criteria Details (service evaluation N/A)
NICE 2018 guidelines, EANO 2016 meningioma guidelines (see title page appended below).
Guideline / Standards available: Yes X □ No □
If yes, please attach a copy or provide web link to the most current version: <a href="https://www.nice.org.uk/guidance/ng99">https://www.nice.org.uk/guidance/ng99</a>
Name of Standard / guideline: Brain tumours (primary) and brain metastases in adults. NICE guideline Published: 11 July 2018. www.nice.org.uk/guidance/ng99
Source of Standard / guideline: NSF □ NICE X □ Royal College □  Trust □ Other □ State other: Click here to enter text.
Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured Yes x $\square$ No $\square$
Is the audit / service evaluation issue:  High volume Yes X □ No □  High risk Yes □ No X □  High cost Yes □ No X □  Known quality issue Yes □ No X □  Wide variation in practice Yes X □ No □
Sample No: ~500 cases identified from Walton Centre neuropathology database between 2007 – 2017
Procedure codes to identify sample: Not needed
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes X $\square$ No $\square$
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No X □
Is this project part of an agreed departmental rolling programme? Yes ☐ No X ☐
Rolling programme duration (number of years): Click here to enter text.
<b>Rolling programme frequency:</b> Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary: X □ Single disciplinary: □
Is Clinical Audit Team support required? Yes X□ No □  If yes, please specify type of assistance required:

Population Identification	
<ul> <li>Design of data collection tool</li> </ul>	
	of the tool to be used) – to be developed
<ul> <li>Database design</li> </ul>	
◆ Data entry	
♦ Analysis	
♦ Presentation	
Collection of case notes	X □ Total number _20 / per week
Patient Contact / Involvement – (If particular please explain how in this section Will the audit involve direct patient	
How will the patient be involved?	
Patient Questionnaire   At clini	c appointment $\square$
Other (please give details) Click here to	enter text.
Has approval been sought from the	Patient Information Panel? Yes □ No □ N/A □
Anticipated start date:1/09/20	
Anticipated project completion dat	e: 30/8/21
Anticipated Action Plan Submissio	n date:30/11/21
PLEASE ATTACH A COPY OF YOUR D	ATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SER EVALUATION REPORT.</li> </ul>	VICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGN AUDIT TEAM.</li> </ul>	ED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL
Departmental Clinical Audit Lead (	Signature) Date: 11/10/19
Comments Click here to enter text.	
Divisional Clinical Audit Lead (Sign	ature) Date: 28/01/20
Is this topic a key clinical interest f	or the department / division? Yes □ No ⊠

# EANO guidelines for the diagnosis and treatment of meningiomas



Roland Goldbrunner, Giuseppe Minniti, Matthias Preusser, Michael D Jenkinson, Kita Sallabanda, Emmanuel Houdart, Andreas von Deimling, Pantelis Stavrinou, Florence Lefranc, Morten Lund-Johansen, Elizabeth Cohen-Jonathan Moyal, Dieta Brandsma, Roger Henriksson, Riccardo Soffietti, Michael Weller

Although meningiomas are the most common intracranial tumours, the level of evidence to provide recommendations for the diagnosis and treatment of meningiomas is low compared with other tumours such as high-grade gliomas. The meningioma task force of the European Association of Neuro-Oncology (EANO) assessed the scientific literature and composed a framework of the best possible evidence-based recommendations for health professionals. The provisional diagnosis of meningioma is mainly made by MRI. Definitive diagnosis, including histological classification, grading, and molecular profiling, requires a surgical procedure to obtain tumour tissue. Therefore, in many elderly patients, observation is the best therapeutic option. If therapy is deemed necessary, the standard treatment is gross total surgical resection including the involved dura. As an alternative, radiosurgery can be done for small tumours, or fractionated radiotherapy in large or previously treated tumours. Treatment concepts combining surgery and radiosurgery or fractionated radiotherapy, which enable treatment of the complete tumour volume with low morbidity, are being developed. Pharmacotherapy for meningiomas has remained largely experimental. However, antiangiogenic drugs, peptide receptor radionuclide therapy, and targeted agents are promising candidates for future pharmacological approaches to treat refractory meningiomas across all WHO grades.

#### Introduction

Meningiomas are the most common primary intracranial tumours, of which most are classified as WHO grade I lesions, with a minority classified as WHO grade II or grade III lesions on the basis of local invasiveness and cellular features of atypia.¹ The vast majority of patients can be cured by surgery alone, particularly patients with WHO grade I tumours in favourable locations (eg, convexity meningiomas, and easily accessible skull-base meningiomas). Beyond surgery, various radiotherapy approaches are often used to increase local control, especially if surgery alone seems insufficient. By contrast, pharmacotherapy has thus far only had a minor role in the management of meningiomas.

Although management might appear to be fairly standardised across the world, controlled clinical trials are uncommon, so standards of care are defined by local experience, long-standing traditional procedures, and experience-based practice. However, numerous situations occur in which more than one approach appears feasible. For example, is intervention needed for incidental meningiomas that have unclear growth kinetics? Do all suspected meningioma lesions require histological verification of the diagnosis? In cases in which radiotherapy is considered, when is the right time and what is the right fractionation approach? How will medical therapy develop in the future and what is the role of molecular profiling? Defining standards of care and outlining answers to some of these questions is the purpose of this Review.

#### Methods

The European Association of Neuro-Oncology (EANO) meningioma task force assessed the available literature, sorted the scientific evidence into classes I–IV. and rated

recommendations at levels A-C, according to the European Federation of the Neurological Societies guidelines.2 Class I denotes evidence derived from prospective, randomised, controlled clinical trials; class II is evidence derived from prospective studies, including observational studies, cohort studies. and case-control studies; class III evidence is derived from retrospective studies; and class IV evidence is from uncontrolled case series, case reports, and expert opinions. Regarding the recommendations A-C, A requires one or more class I studies or two consistent class II studies, B requires one or more class II studies or overwhelming class III evidence, and C requires two or more consistent class III studies. When sufficient evidence for recommendations was not available, the task force offered advice as a good practice point. We summarise recommendations for the diagnostic and therapeutic management of patients with meningioma general, including epidemiology and clinical presentation, pathogenesis and risk factors, diagnostic procedures, therapeutic decision making, surgical and radiotherapeutic approaches, and pharmacotherapy (appendix). WHO grading is displayed in panel 1.3 Specific recommendations for the therapeutic management of meningiomas of WHO grades I-III are outlined in figure 1.

#### Meningioma WHO grade I

Meningiomas can be diagnosed by MRI and additional CT in most cases (figure 2).<sup>4</sup> They usually present as solitary round tumours, with close contact to the dura mater and strong enhancement after contrast injection. The typical appearance of meningioma is isointense on T1-weighted imaging, isointense or hyperintense on fluid-attenuated inversion recovery, and with high

#### Lancet Oncol 2016; 17: e383-91

Center of Neurosurgery, Department of General Neurosurgery, University of Cologne, Cologne, Germany (Prof R Goldbrunner MD, P Stavrinou MD): Radiation Oncology Unit, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy (G Minniti MD): IRCCS Neuromed, Pozzilli, Italy (G Minniti); Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria (M Preusser MD); Department of Neurosurg The Walton Centre NHS Foundation Trust, Liverpool, UK (M D Jenkinson MD); Department of Neurosurgery University Hospital San Carlos. Universidad Cumplutense de Madrid, Madrid, Spain (K Sallabanda MD): Department of Oncologia Radioterapia Robotizada—CyberKnife, IMOncology Madrid Arturo Soria, Madrid, Spain (K Sallabanda); Service de Neuroradiologie, Hôpital Lariboisière, Paris, France (Prof E Houdart MD): Department of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany (Prof A von Deimling MD); CCU Neuropathology German Cancer Center (DKFZ). Heidelberg, Germany of Neurosurgery, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium (F Lefranc MD); Department of Neurosurgery, Bergen University Hospital, Bergen, Norway (Prof M Lund-Johansen MD); Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway (Prof M Lund-Johansen); Department of Radiation Oncology, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France



#### Clinical Audit / Service Evaluation Action Plan

Ref no: 285

Clinical Audit Title	Service evaluation to review recognition and management of delayed ischaemic deficit in aneurysmal subarachnoid haemorrhage				
Date audit complete	July 2021	Date action plan completed			
Auditor		Name of policy / guideline	Subarachnoid haemorrhage guidelines to support practice		
Division	Neurosurgery	Source of policy / guideline	Walton Centre		

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Despite the high cost of Intensive care/rehabilitation; the patient outcomes for those treated consistently and aggressively improved outcomes
- Highlighted the value of thorough review and goal setting in management of the SAH patient
- Fluid balance charting on the specialist ward was of a good standard
- Inconsistency in diagnosing DID by radiological means
- Patient management could be supported by use of TCDs in a beneficial way
- Inconsistency in management goal setting
- Inconsistency in nursing care
- Inconsistency in recognising and diagnosing DID and prompt proactive management with ongoing monitoring by

# Key success:

Please concisely state the key success identified by the project – if none identified please state N/A

• The project proved that care and outcomes on the whole was good for this group of patients

#### Key concerns:

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- Inconsistencies or failures of management of DID
- Inconsistencies in diagnosing DID
- Inadequate fluid balance charting

#### **Recommendations discussed:**

Please concisely summarise the recommendations that were discussed following the completion of the project

- Teaching for ward staff ( To be addressed at Friday teaching session and teaching sessions)
- Teaching for registrars (To be addressed at registrar training)
- CTA should be requested for all patients who are displaying symptoms that may be reflective of DID

Version: 2019

- Ward rounds should be thorough and consistent, setting BP and Fluid balance goals each day until patient is stable.
- All patients with symptomatic DID should be managed in the critical care unit until safe to transfer.
- Patient care will benefit from management supported by TCDs to minimise the impact of unnecessary prolonged care and use of inotropes, radiological examination and support timely transfer from critical care.

Presentation / Dissemination of Project	
Date findings were presented / disseminated:	_
	•
Department where discussed or presented:	_
	•

# Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g. SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
Reduced knowledge and need for education on management of SAH patients highlighted by varied practice and inconsistent management plans at ward round Risk of failure to recognise deterioration and rescue	- To be addressed at Friday teaching session, PNF and teaching sessions - Ongoing teaching at Neuro course and new starters - Ward link nurses - Nursing care plans -registrar teaching		3 months	S	
Inconsistent recognition of vasospasm leading to delays and inconsistent management	CTA should be requested for all patients who are displaying symptoms that may be reflective of DID  Registrar training		2 months	NICE 2021	

Version: 2019

	<ul> <li>All neurovascular CNS protocol to request CTA</li> </ul>					
Inconsistent and partial evaluation and review at ward rounds risking failure to rescue and/or pick up deterioration and poor management plans	<ul> <li>Dissemination at neuro meeting</li> <li>Ward rounds should be and consistent, setting Fluid balance goals eac patient is stable.</li> </ul>	vascular thorough BP and	6 months			
Patients not always managed at the right level of care made worse by lack of co-horting – risk of poor management and failure to rescue	<ul> <li>Neurovascular team diswith ICU and recommendagreed</li> <li>Need now greater with absolution of specialist high staff turnover</li> <li>All patients with symptoms should be managed in the care unit until safe to train</li> </ul>	the wards and matic DID the critical	(ongoing discussion)			
SAH patients will beneftit from TCDs to support care and reduce number of CTAs/ radiation	ANP training for TCD Patient care will benefit management supported		6 months	NICE 2021		
Fluid balance charts are inconsistently completed and often to a poor standard risking poor management and failure to recognise deterioration	<ul> <li>Ongoing audit and pres fluid balance compliance highlight it importance i</li> <li>Fluid balance audit</li> </ul>	e to	3 months			
Re-audit date _ 2022						
Will this be an on-going audit? Yes ☐ No ☐						
Are there any potential barriers / problems to prevent the implementation of the above actions? Yes No						
If yes to the above please state who the issues have been referred to:						
Name _ Designati	on	Date referred				
Signature:Date:						

Version: 2019

Have any issues been logged on the risk register? Yes No	N/A
Please provide details of issue(s) logged on the risk register:	

Version: 2019



## **Project Prioritisation Assessment Tool**

## **Audit title:**

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandator	y please specify what priority level:-
Level 1 – External 'must do'	Level 2 'Internal 'must do' 🗌

Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk		(x3)
Known quality issue		(x3)
Wide variation in practice	Y	
NICE / NCEPOD related audit		(x3)
Defined measurable standards available	Y	
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division	Y	(x2)
Multidisciplinary project	Y	
National / regional or multicentre project		(x2)
Total	5c	

## Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

<b>Priority level</b>	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ☒
	luation Title: service evaluation to review recognition and management of deficit in aneurysmal subarachnoid haemorrhage and compare outcomes at onths
Division: Neurology	☐ Neurosurgery ☒ Please specify department <b>neurovascular team</b>
Project Lead:	
Contact No: Bleep	No:
Email address:	
Audit / service eval	uation supervisor:
	s involved / project team members details nes and roles within the project eg data collection, analysis etc.) t.
Background / Ratio	<u>nale</u>
management of the di Centre has proven tha	re agreed for management of aneurysmal subarachnoid haemorrhage. Those guidelines advise sease and complications; the most devastating being delayed ischaemic deficit. The Walton t its outcomes for aSAH are amongst the best in the UK as determined by HES data. This care is team work and a multidisciplinary team approach to excellence in care.
<u>Methodology</u>	
physiological parame	rts, observations and management including observation and response to changes in eters will be audited to compare treatment versus outcome at baseline and after 3 collected using the SAH data base
<u>Audit</u>	
	a aims to prove that swift recognition, aggressive management and tight control of the ers of patients with aneurysmal subarachnoid haemorrhage in both level 2 and 3 care 3 months
All patients who have assessed	been assessed as having delayed ischaemic deficit from the SAH data base 2019 will be
Standards / Criteria	Details (service evaluation N/A)
guidelines	
Guideline / Standar	rds available: Yes ⊠ No □
If yes, please attach	a copy or provide web link to the most current version: available on intranet

Clinical Audit Registration Form Version 3 - 2019

Name of Standard / guid	leline: Guide	elines for mar	nagement of ane	urysmal su	barachnoid haemorrha	ge
Source of Standard / gui Trust ⊠ Oth		NSF   State other:	NICE European and		Royal College guidelines	
Review/assessment of g Yes ⊠ No □	juideline/st	andard und	lertaken to en	sure it is	appropriate & can be	e measured
Is the audit / service evaluation High volume High risk High cost Known quality issue Wide variation in practice	Yes □ Yes □ Yes □ Yes □	No ⊠ No ⊠ No ⊠				
Sample No: 38 Procedu	re codes to	identify sa	ımple: SAH da	ıta base		
http://www.raosoft.com/sa	amplesize.ht	ml - link to to	ool that may be	used to c	calculate sample size	
			·			
Are you planning to pub	lish your a	udit/service	e evaluation fi	ndings na	tionally	
BNVG Yes ⊠	No □					
Is this a re-audit or if ser	rvice evalua	ation, has s	ervice been re	eviewed p	reviously? Yes [	□ No 🛛
Is this project part of an	agreed de	oartmental	rolling progra	mme?	Yes □ No I	⊠
Rolling programme dura	ation (numb	er of years	): Click here to e	enter text.		
Rolling programme freq	uency: Mo	nthly 🗆 G	Quarterly 🗆 - E	3iannually	☐ Annually ☐	
Multidisciplinary: ⊠		Singl	e disciplinary:			
Rolling programme dura						
Is Clinical Audit Team su If yes, please specify type  ◆ Population Identification  ◆ Design of data collection  (If not required please, att  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case notes	upport reques of assistantian tool	uired? ce required:	Yes 🗵  Description be used)  Description in the content of the co		No □ 2_ / per week	
Patient Contact / Involve or care please explain how in Will the audit involve dir How will the patient be in	n this section rect patient	)	es patient contac		o <u>t</u> part of the patients us	ual treatment

Clinical Audit Registration Form Version 3 - 2019

Patient Questionnaire						
Other (please give details) clinic letters, and mRS scores as determined at c	outpatie	ent att	enda	nce a	nd SA	H data base
Has approval been sought from the Patient Information Panel?	Yes		No		N/A	$\boxtimes$
Anticipated start date: March 2020						
Anticipated project completion date: June 2020						
Anticipated Action Plan Submission date: Sept 2020						
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QU</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD AUDIT TEAM.</li> </ul>	А СОРУ	OF TH	E PRE			
Departmental Clinical Audit Lead (Signature)	D	ate:	Click ł	nere t	o ente	er text.
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)	D	ate:	Click h	nere t	o ente	er text.
Is this tonic a key clinical interest for the denartment / division?	Yes			N	lo 🗆	

# Service review of outcomes following delayed deficit after aSAH Date of SAH Date of transfer Date of treatment Reason for delay if > 48 hours Best WFNS / GCS in A+E Fisher grade Hydrocpehalus? Y/N Care immediately post treatment (level 2, 3?) How long spent in ICU? Date patient become symptomatic of vasospasm? Symptoms? Who noticed? (senior surgeon/junior surgeon/anaesthetist/specialist nurse/ward nurse/ICU nurse/other) When noticed?: Ward round/other? Was this confirmed radiologically? (MR/CTA/TCD) Fluid balance 24 hours prior to deterioration? Fluid balance in 4 hours prior to deterioration? MAP / BP at deterioration MAP/BP prior to deterioration? Treatment: HHH/ HH/ close watch/ regular TCDs accurate fluid balance) Has fluid balance target been set for management? Has MAP/BP target been set for management? Length of stay on ICU? Date of discharge Length of stay in hospital? Discharge destination

mRS at discharge

mRS at 3 months

## **Project Prioritisation Assessment Tool**

Audit title: Blood glucose monitoring for patients on high dose steroid's

If the project is mandatory please specify what priority level:-

**Priority level** 

Level 1, 2 & 3

Level 4

Level 5

Audit team resource

Category A – Full support

Category B – Moderate support

Category C – Minimal support

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'					
Criteria	Tick all that apply	Score			
High cost		(x3)			
High volume		(x2)			
High risk		(x3)			
Known quality issue	Y	(x3)			
Wide variation in practice					
NICE / NCEPOD related audit		(x3)			
Defined measurable standards available					
Re-audit / repeat service evaluation	Y	(x2)			
Topic is a key clinical interest for the department / c	division	(x2)			
Multidisciplinary project					
National / regional or multicentre project		(x2)			
Total	5b				
Priority levels and audit team support					
Priority level	Priority score				
Level 1 – External 'must do'	Category A				
Level 2 – Internal 'must do'	Category A				
Level 3 – High local priority	> 10	-			
Level 4 – Medium local priority	4 – 9				
Level 5 – Low local priority	< 4				

Version 2019 Review date: 2021

Full practical assistance offered

Level of practical assistance will be negotiated and agreed with project lead

Advice, registration and monitoring

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service Ev	aluation Title: Blood glucose monitoring for patients on high dose steroid's
Division: Neurolog	y □ Neurosurgery ⊠ Please specify department <b>Cancer Services</b>
Project Lead:	
Contact No: Blee	ep No:
Email address:	
Audit / service eva	aluation supervisor:
	als involved / project team members details mes and roles within the project eg data collection, analysis etc.)
Background / Rati To review complia	i <u>onale</u> ance of blood glucose monitoring for brain tumour patients oh high dose steroids.
Methodology	
	P2 audit to review blood glucose charts and nursing documentation. Is the date nted? Have the BM's been monitored daily? Have raised BM's been actioned?
	ndard of care by reviewing compliance. Highlight areas for development and npare results to last year's findings.
<b>Evaluate effective</b>	ia Details (service evaluation N/A) ness of the algorithm, ward education and attendance at ward meetings/safety nad a effect on patient care.
Guideline / Standa	ards available: Yes 🗵 No 🗆
If yes, please attac	h a copy or provide web link to the most current version: Click here to enter text.
Name of Standard	I / guideline: BM Algorithm
Source of Standar Trust ⊠	rd / guideline: NSF
Review/assessme Yes ⊠ No □	ent of guideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / servi	ce evaluation issue:
High volume	Yes □ No ⊠
High risk High cost	Yes □ No ⊠ Yes □ No ⊠
LIIGH GUSI	

Wide variation in practice Yes □ No □  Wide variation in practice Yes □ No □
Sample No: Click here to enter text. Procedure codes to identify sample: Click here to enter text.
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes □ No ⊠
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes ⊠ No □
Is this project part of an agreed departmental rolling programme?  Yes □ No ☒
Rolling programme duration (number of years): Click here to enter text.
Rolling programme frequency: Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary: □ Single disciplinary: □
Is Clinical Audit Team support required? Yes ⋈ No ☐  If yes, please specify type of assistance required:  Population Identification ☐  Design of data collection tool ☐  (If not required please, attach a copy of the tool to be used)  Database design ☐  Data entry ☐  Analysis ☐  Presentation ☐  Collection of case notes ☑ Total number 40(20 cairns/20 outlying wards) / per week 10
Patient Contact / Involvement - (If project involves patient contact that is <u>not</u> part of the patients usual treatment or care please explain how in this section) Will the audit involve direct patient contact?  Yes □ No ⊠
How will the patient be involved?
Patient Questionnaire ☐ At clinic appointment ☐
Other (please give details) Review of casenotes/EP2
Has approval been sought from the Patient Information Panel? Yes □ No □ N/A ⊠
Anticipated start date:Feb 2020
Anticipated project completion date: April 2020
Anticipated Action Plan Submission date:May 2020

• PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.

- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

			_	
Departmental Clinical Audit Lead (Signature)	Date: Click here to enter text.			
Comments Click here to enter text.				
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.			
Is this topic a key clinical interest for the department / division?	Yes □	No □		



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 287

Clinical Audit Title	Investigating clinical outcomes of Long-standing overt ventriculomegaly in adults (LOVA)			
Date audit complete	25/06/2021 Date action plan completed 30/06/2021			
Auditor		Name of policy / guideline	N/A	
Division	Neurosurgery	Source of policy / guideline	N/A	

#### **Summary of Findings:**

- Long standing overt ventriculomegaly (LOVA) is a heterogenous group of conditions, with varied clinical presentations in the audit.
- Both Endoscopic third ventriculostomy (ETV) and Ventriculoperitoneal shunt (VPS) lead to symptom resolution in over 80% of LOVA patients when used as a first line treatment, but VPS is associated with a significantly higher risk of post-operative complications, including infection.

#### **Key success:**

- At the Walton Centre, 84% of patients treated for LOVA with any operation will report symptom resolution or improvement at 1 year after surgery. There is no difference between the success rates of ETV and VP shunts (84 and 85% respectively)
- The complication rate for ETV as a first line treatment was only 4%, in comparison to 45% with a VP shunt

#### **Key concerns:**

• Patients with LOVA are still managed without formal guidelines- many patients are managed conservatively, some undergo ETV, and some VP shunt.

#### Recommendations discussed:

- Both ETV and VPS have similar success rates for symptomatic improvement when used for LOVA.
- Consider that VPS has a significantly higher infection rate when deciding which intervention to select in adult hydrocephalus patients.

#### **Presentation / Dissemination of Project**

Date findings were presented / disseminated: 1. SBNS Annual meeting Dundee (25th September 2021, Oral presentation)

2. European Association of Neurosurgical Societies (EANS) 2021 meeting (7<sup>th</sup>-8<sup>th</sup> October 2021, Oral presentation)

Department where discussed or presented: Society of British Neurosurgeons (SBNS), European Association of Neurosurgical Societies (EANS)

Version: 2019

## Actions agreed following recommendations discussed:-

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1) Highlight the issue of LOVA patient management to neurosurgeons at the Walton Centre, to inform them of the significant difference in complication rates between the two procedures.	Present the local data at the next available Walton Centre audit research meetings.  If this is not possible, or the next meeting is not in the foreseeable future due to COVID, the findings could be communicated in a consultants meeting or trust newsletter.		Present to local consultants when next audit presentatio n meeting is available.	Record of attendance to meeting, consultant feedback	
Communicate findings to consultant neurosurgeon who is also the CSF lead at the Walton Centre	Email completed manuscript to MM (CSF lead at the Walton Centre) for review and discussion.		Submitted to MM 14/10/2021	Email receipt	
Inform radiologist teams of the study findings, to increasingly recognise LOVA on reporting scans	Contact consultant radiologist to advise on best way to inform radiologists of need to refer LOVA diagnoses for specialist appointments when possible.		October 2021- January 2022	Email receipt/in- person meeting	
Will this be an on-going audit?  Are there any potential barriers / p  If yes to the above please state w	problems to prevent the implementation of the issues have been referred to:	he above actions			
Name Design	nation Date referred				
Signature:	Date:23/10/2021				
Have any issues been logged on f	he risk register? Yes No x N/A				
Please provide details of issue(s)	logged on the risk register:				

Version: 2019

Version: 2019

## **Project Prioritisation Assessment Tool**

#### Audit title: Investigating clinical outcomes of Long-standing overt ventriculomegaly in adults (LOVA)

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is m Level 1 – Externa	nandatory please specify what prior $\Box$	-	vel:- nternal 'must do' 🔲	
Criteria		Tick all that apply	Score	
High cost				(x3)
High volume				(x2)
High risk				(x3)
Known quality isso	ne			(x3)
Wide variation in	practice		Y	
NICE / NCEPOD related audit			(x3)	
Defined measural	ole standards available			
Re-audit / repeat service evaluation			(x2)	
Topic is a key clinical interest for the department / division		n	(x2)	
Multidisciplinary project		Y		
National / regional or multicentre project			(x2)	
Total			2c	
Priority levels an	d audit team support			
Priority level Priori		ty score		
Level 1 – External 'must do' Categor		ry A		
Level 2 – Internal 'must do' Categor		gory A	ory A	
Level 3 – High local priority > 10				
Level 4 – Medium local priority 4 – 9				
Level 5 – Low local priority < 4				
Priority level	Audit team resource			
Level 1, 2 & 3			Full practical assistance offer	ed

Level 4

Level 5

Category B – Moderate support

Category C – Minimal support

Version 2019 Review date: 2021

Level of practical assistance will be

Advice, registration and monitoring

negotiated and agreed with project lead

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit ⊠	Service Evaluation □		
Audit / Service Evaluation Title: Investigating clinical outcomes of Long-standing overt ventriculomegaly in adults (LOVA)				
Division: Neurology	☐ Neurosurgery ⊠ Please specify	department Department of Neurosurgery		
Project Lead:				
Contact No: Bleep	No:			
Email address:				
Audit / service evalu	ation supervisor:			
Other professionals involved / project team members details (Please provide names and roles within the project eg data collection, analysis etc.) Abdurrahman Islim (data analysis, general advice), members of the audit team (audit approval), Clinical coding and informatics (to identify and acquire cases)				

#### **Background / Rationale**

Long-standing overt ventriculomegaly in adults (LOVA) is a unique form of hydrocephalus that develops during childhood, but manifests symptoms during adulthood. It is presumed that the hydrocephalus arrests before becoming clinically detectable, with most patients presenting typically in the 5th and 6th decades. The exact mechanism of this phenomenon remains unclear. LOVA defines a cohort of adult patients with symptoms of chronic hydrocephalus (mainly headache, cognitive decline, imbalance and visual disturbance), a head circumference more than 2 standard deviations above the 98th centile and overt tri-ventriculomegaly on neuroimaging, in the absence of a secondary cause for aqueduct stenosis in adulthood.

Only a small number of case series have been published in this condition (three most recent papers have 14, 16 and 4 total cases respectfully) (Rekate 2007, Ved et al 2016, Xiao et al 2019), and thus ambiguity exists with regards to the exact aetiology, presentation of the condition, and preferred treatment paradigms. Endoscopic third ventriculostomy (ETV) has been suggested as an effective surgical intervention in these patient groups if symptomatic, however the case series patient numbers and overall statistical power supporting this are small. Being able to conduct a robust, retrospective review of cases, their presentation, clinical status, and surgical outcomes if pertinent would greatly enhance the existing literature and help guide treatment paradigms in this condition if successful.

#### Methodology

This will be a retrospective study cohort of all cases of LOVA diagnosed at the Walton Centre between 2008 and 2019. Upon Audit approval, the project lead will liaise with the audit department. clinical coding and informatics team. We will use defined search terms to identify all cases diagnosed or treated at the Walton Centre between the two study times. This will include identifying key terms such as 'LOVA', 'Adult onset ventriculomegaly', 'late/adult onset hydrocephalus', 'operation ETV' etc. These will be used to generate an excel spreadsheet of cases identified, which will then be screened for eligibility by the project lead. If eligible, these cases will be inputted into a password protected, anonymised excel spreadsheet, delineating the clinical outcomes, surgical interventions if applicable, and clinical follow up over time. This information will be acquired through a combination of searching the PACS and EP2 databases to delineate the relevant clinical information and management. Once this has been completed and reviewed by the project supervisor, we will carry out statistical analysis of data acquired using a statistical software programme such as SPSS Version 25. Once this has been completed, if the number of cases identified exceeds those listed above in the literature, we will hope to disseminate the findings in a scientific manuscript, submitting this to a scientific journal to consider for publication. The inclusion criteria is as follows: All cases of LOVA diagnosed or managed at the Walton Centre from

#### 2008-2019.

Exclusion criteria: All cases where LOVA was not the actual diagnosis, identified outside study period, previous history of congenital hydrocephalus/previous shunt procedure <18 yrs.

#### Aims / Objectives

Identify number of cases of LOVA diagnosed or treated at the Walton Centre between 2008 and 2019.

Investigate and delineate the clinical presentation, patient characteristics and clinical outcome of patients with LOVA.

Evaluate the use of endoscopic third ventriculostomy (ETV) as a surgical treatment option in LOVA patients if pertinent.

### Standards / Criteria Details (service evaluation N/A)

Standards / Onteria Details (service evaluation WA)
None at present, may be identified later on as the project develops.
Guideline / Standards available: Yes □ No ⊠
If yes, please attach a copy or provide web link to the most current version: Click here to enter text.
Name of Standard / guideline: Click here to enter text.
Source of Standard / guideline: NSF □ NICE □ Royal College □ Trust □ Other □ State other: Click here to enter text.
Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured Yes $\ \square$ No $\ \boxtimes$
Is the audit / service evaluation issue:   High volume Yes □ No ⋈   High risk Yes □ No ⋈   High cost Yes □ No ⋈   Known quality issue Yes □ No ⋈   Wide variation in practice Yes ⋈ No □
Sample No: 10-50 anticipated, may be more/less depending on case/volume/exclusion criteria
Procedure codes to identify sample: To consult with clinical coding and informatics prior to search, but will include: 'LOVA', 'Adult onset ventriculomegaly', 'late/adult onset hydrocephalus', 'operation ETV', 'long standing overt ventriculomegaly in adults'
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes ⊠ No □
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ☒
Is this project part of an agreed departmental rolling programme? Yes □ No ☒
Rolling programme duration (number of years): Click here to enter text.
Rolling programme frequency: Monthly $\square$ Quarterly $\square$ Biannually $\square$ Annually $\square$

Multidisciplinary:	e aiscip	linary:				
Is Clinical Audit Team support required?  If yes, please specify type of assistance required:  ◆ Population Identification  ◆ Design of data collection tool  (If not required please, attach a copy of the tool to		⊠ d)	No			
<ul><li>Database design</li><li>Data entry</li></ul>	$\boxtimes$					
• Analysis						
Presentation						
Collection of case notes	⊔ To	otal numb	er/ pe	er week		
Patient Contact / Involvement – (If project involve or care please explain how in this section) Will the audit involve direct patient contact?	s patier	t contact t	that is <u>not</u> par □ No	t of the pati	ents usual treatn	nen
How will the patient be involved?						
Patient Questionnaire   At clinic appointment	nt 🗆					
Other (please give details) Click here to enter text.						
Has approval been sought from the Patient Info	ormatio	on Panel	? Yes □	No □	N/A ⊠	
Anticipated start date: Click here to enter text.						
Anticipated project completion date: Click here t	o enter	text.				
Anticipated Action Plan Submission date: Click h	nere to (	enter text.				
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION	OOT NC	. / PATIENT	QUESTIONNA	IRE.		
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATION REPORT.</li> </ul>	IONS PLE	EASE ATTAC	CH A COPY OF	THE PREVIO	JS AUDIT OR SERV	′ICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DI AUDIT TEAM.</li> </ul>	VISIONA	AL AUDIT LE	EAD BEFORE SU	JBMISSION 1	O THE CLINICAL	
Departmental Clinical Audit Lead (Signature)			_ Date	: Click here	to enter text.	_
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)			_ Date	: Click here	to enter text.	
Is this topic a key clinical interest for the depar	rtment	/ divisior	n? Yes [	7	No. □	



## **Project Prioritisation Assessment Tool**

### Audit title: VTE prophilaxis prescribing in neurosurgical patients

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please speci	fy what priority level:-
Level 1 – External 'must do'	Level 2 'Internal 'must do'

Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk	Y	(x3)
Known quality issue	Y	(x3)
Wide variation in practice	Y	
NICE / NCEPOD related audit	Y	(x3)
Defined measurable standards available	Y	
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division	Y	(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	13	3A

#### Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

Clinical Audit Registration Form Version 3 - 2019

## Clinical Audit / Service Evaluation Registration Form

#### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

#### Service evaluation

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

#### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

### **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □		
Audit / Service Evaluation Title: VTE prophilaxis prescribing in neurosurgical patients			
Division: Neurolog	y $\square$ Neurosurgery $\boxtimes$ Please specify department $Click$ here to enter text.		
Project Lead:			
Contact No:	Bleep No: Click here to enter text.		
Email address:			
Audit / service eva	aluation supervisor:		
	als involved / project team members details mes and roles within the project eg data collection, analysis etc.)		
Background / Rat	ionale		
This project is focuse prescribing VTE prop	ed on the current neurosurgical compliance with the hospital new policy and guidance in hylaxis.		
<u>Methodology</u>			
Retrospective study	y. The data will be collected from the JAC system, Ep2 and our clinical notes.		
Aims / Objectives			
	100% compliance auditing a new VTE prophylaxis policy to see if there are any e compliance following the implmentation of the new VTE Policy <u>Standards / Criteria</u> valuation N/A)		
The Walton Centre V	TE Policy guidelines		
Guideline / Standa	ards available: Yes 🗵 No 🗆		
If yes, please attac	h a copy or provide web link to the most current version: The Walton Centre VTE Policy		
Name of Standard	I / guideline: VTE Policy		
<b>Source of Standa</b> l Trust ⊠	rd / guideline: NSF □ NICE ⊠ Royal College □ Other □ State other: Click here to enter text.		
<b>Review/assessme</b> Yes ⊠ No □	ent of guideline/standard undertaken to ensure it is appropriate & can be measured		

Is the audit / service evaluation issue:

Clinical Audit Registration Form Version 3 - 2019

High volume	Yes ⊔ No ⊠ Yes ⊠ No □
High risk High cost	Yes □ No ⊠
Known quality issue	Yes ⊠ No □
Wide variation in practice	Yes ⊠ No □
Sample No: Click here to er	nter text. <b>Procedure codes to identify sample:</b> Click here to enter text.
http://www.raosoft.com/san	nplesize.html - link to tool that may be used to calculate sample size
	<u> </u>
Are you planning to publ	ish your audit/service evaluation findings nationally
(e.g. Medical journal)?	Yes □ No ⊠
Is this a re-audit or if serv	vice evaluation, has service been reviewed previously? Yes □ No ☒
Is this project part of an a	agreed departmental rolling programme? Yes □ No ☒
Rolling programme durat	tion (number of years): Click here to enter text.
Rolling programme frequ	ency: Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary:	Single disciplinary: $\square$
Rolling programme durat	cion (number of years): Click here to enter text.
Is Clinical Audit Team su  If yes, please specify type of  Population Identification  Design of data collection  (If not required please, attanno  Database design  Data entry  Analysis  Presentation  Collection of case notes	of assistance required: □
Patient Contact / Involver or care please explain how in Will the audit involve dire	•
How will the patient be in	volved?
Patient Questionnaire	□ At clinic appointment □
Other (please give details) Cl	ick here to enter text.
Has approval been sough	nt from the Patient Information Panel? Yes □ No □ N/A ⊠
Anticipated start date:15/	01/2020
Anticipated project comp	letion date: 22/01/2020
Anticipated Action Plan Swithin a week.	Submission date: Addressing compliance and implanting relevant changes

Clinical Audit Registration Form Version 3 - 2019

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

			_
Departmental Clinical Audit Lead (Signature)	Date: 09/0	01/2020	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes ⊠	No □	



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 289

Clinical Audit Title	VTE pharmacological prophylaxis prescribing in neurosurgical patients – Re-audit			
Date audit complete	18/03/2020	Date action plan completed	18/03/2020	
Auditor		Name of policy / guideline	VTE Policy	
Division	Neurosurgery	Source of policy / guideline		

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Evidence of significant improvement in prescribing pharmacological prophylaxis in neurosurgical patients.
- Improved compliance with the new VTE policy.
- Failure to prescribe pharmacological VTE prophylaxis was noted in only 1 out of 71 patients audited on that day. That constitutes 1.4% (P<0.05 Chi-square test). Previously non-compliance was at 9.8%
- Very important role of pharmacists in maintaining the required standards on VTE prophylaxis..

#### **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

- Clear identification of improvement in prescribing pharmacological VTE prophylaxis in neurosurgical patients following the introduction of the new VTE quidelines.
- Compliance was improved from 9.8% of non-compliance to only 1.4% non-compliance following the introduction of the new VTE protocol.
- This improvement is statistically significant. Initially the audit registered non-compliance in 5 out of 51 patients. The re-audit registered non-compliance in only 1 out of 71 patients audited in March 2020. This represents Chi-square statistic value of 4.4737. This gives a P value of 0.3442. Hence this is significant change at P<0.05
- The VTE guidelines were followed.
- The discussions with the teams involved responsible for patients' care contributed to this significant improvement.

#### **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- Maintenance of the current level of compliance, even further improvement so that there are no non-compliant cases, may be challenging with the time.
- Although the re-audit demonstrated success of the new VTE protocol and significant improvement in compliance (Chi-square P value = 0.3442, and P<0.05), if we use Yates correction the Chi-square with the correction is 2.8585, thus giving the P value = 0.0908.

Version: 2019

#### **Recommendations discussed:**

Please concisely summarise the recommendations that were discussed following the completion of the project

- Maintenance of the current level of compliance.
- Continuous insistence on the new VTE protocol, so that there are no non-compliant cases.
- Familiarisation with the new VTE protocol for all staff remains to be essential.
- Very important and continuous role of pharmacists, doctors and nurses in maintaining the required standards related to the VTE prophylaxis.

Presentation / Dissemination of Project		
Date findings were presented / disseminated:	15/04/2020	
Department where discussed or presented:	Neurosurgery	

#### Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
Maintenance of required standards in prescribing the pharmacological VTE prophylaxis as per our new guidelines and the policy	No need for another re-audit at the present. There is clear evidence that the neurosurgery department has accepted and closely followed the new VTE policy. I would recommend a second audit in 6 to 12 months time. This is in order to check if the standards on the VTE prophylaxis are maintained.				
2)					
3)					
4)					

Version: 2019

improvement in compliance with the new patients. The improvement went from 9.8 significant change with the P value (Chi-s	VTE protocol and significant improvement in % of non-compliant cases to 1.4% of non-corquare test) of 0.3442. Thus P<0.005. Further	y? This is the re-audit. It demonstrated a significant prescribing pharmacological prophylaxis in neurosurgical inpliancy (1/71) with the new VTE protocol. This demonstrates a follow up may be necessary in the future, in order to check that wed through, and pharmacological prophylaxis is appropriately
Will this be an on-going audit? Yes	□ No X	
Are there any potential barriers / problem	ems to prevent the implementation of the	above actions? Yes No X
If yes to the above please state who th	e issues have been referred to:	
Name	Designation	Date referred
Signature:	Date:	
Have any issues been logged on the ris	sk register? Yes No No N/A X	
Please provide details of issue(s) logg	ed on the risk register:	

Version: 2019



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 290 & 306

Clinical Audit Title	CovidSurg		
Date audit complete	26 <sup>th</sup> May 2020	Date action plan completed	20 <sup>th</sup> April 2021
Auditor		Name of policy / guideline	N/A
Division	Neurosurgery/Crit Care	Source of policy / guideline	N/A

#### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Participation in global multi-centre study looking at the outcome of patients who undergo surgery following COVID infection. Data from study generate 4 peer-reviewed publications, details below:
- Paper 1 Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery.
- Paper 2 Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks.
- Paper 3 Preoperative testing strategies were adjusted for confounding using mixed-effects models. Results: Of 8784 patients (432 hospitals, 53 countries), 2303 patients (26.2%) underwent preoperative testing: 1458 (16.6%) had a swab test, 521 (5.9%) CT only, and 324 (3.7%) swab and CT. Pulmonary complications occurred in 3.9% while SARS-CoV-2 infection was confirmed in 2.6%. After risk adjustment, having at least one negative preoperative nasopharyngeal swab test (adjusted odds ratio 0.68, 95% confidence interval 0.68-0.98, p=0.040) was associated with a lower rate of pulmonary complications. Swab testing was beneficial before major surgery and in areas with a high 14-day SARS-CoV-2 case notification rate but not before minor surgery or in low risk areas. To prevent one pulmonary complication in major or minor surgery the respective number needed to swab test was 18 and 48 in high, and 73 and 387 in low risk areas.
- Paper 4 As global roll out of SARS-CoV-2 vaccination proceeds, patients needing elective surgery should be prioritized ahead of the general population.

Version: 2019

Key success:  Please concisely state the key success  • Positive results published in peer		•			
Key concerns:					
• N/A					
Recommendations discussed:					
Presentation / Dissemination of Proje					
Date findings were presented / dissemin		shed has its own date			
Department where discussed or present			ıp have been h	eld and papers	s distributed
· 		, , , , ,	•		
*Please ensure each action has a na implementation e.g SOP, protocol, s.	amed lead, timescale and repo tandardised template, present		on plan below.	Please list the	evidence of the action
issue	Action required	for action	Timescale	Evidence	(group/meeting)
Nil action due to the rapidity of COVID pandemic and change in guidelines		TOT GOLIOTI			(group/mooting)
Re-audit date  If no re-audit planned please give reasons why? One-off study by a group external to ourselves.					
		•	, , , , ,		
Will this be an on-going audit? Yes ☐ No ☒					
Are there any potential barriers / prol	ນiems to prevent the implen	nentation of the above actions	s? Yes ∐ N	o 📙	
If yes to the above please state who t	he issues have been referre	ed to:			
Namo	Designation	Date referre	nd.		

N/A

Date:\_\_\_

Have any issues been logged on the risk register? Yes

Signature:\_\_

Version: 2019

Please provide details of issue(s) logged on the risk register:	

Version: 2019



## **Project Prioritisation Assessment Tool**

#### Audit title: CovidSurg

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify what priority level:-

Level 1 – External 'must do'	$\neg$	Level 2 'Internal 'must do'	
ECVELT EXCELLIGITION IN COLUMN		Level 2 iliterilar illast ao	í

Criteria	Tick all that apply	Score
High cost	Y	(x3)
High volume		(x2)
High risk	Y	(x3)
Known quality issue		(x3)
Wide variation in practice	Y	
NICE / NCEPOD related audit		(x3)
Defined measurable standards available		
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project	Y	
National / regional or multicentre project		(x2)
Total	8	4B

#### Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4-9
Level 5 – Low local priority	< 4

<b>Priority level</b>	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

## Clinical Audit / Service Evaluation Registration Form

#### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

## **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against best practice, evidence based clinical standards (this may include Royal College, British Association, NICE or Local guidance etc.)

#### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type:	- Clinic	al Audi	t⊠ S	Service E	evaluation	n 🗆		
Audit / Service Eva	uation Title: C	ovidSu	rg						
Division: Neurology	□ Neurosurge	ry 🛭 P	lease sp	ecify o	lepartme	nt <b>Neur</b> c	surgery		
Project Lead:									
Contact No: Click he	re to enter text.	Bleep	No:						
Email address:									
Audit / service eval	uation supervi	sor:							
<b>Other professionals</b> ( <i>Please provide nam</i> Click here to enter text	es and roles wi					on, analy	/sis etc.)		
Background / Ratio There is an urgent no Capturing real-world group of patients who	eed to understa data and sharir	ng interr	national	experie	ence will	inform th	ne manage	ment of this	complex
<u>Methodology</u>									
This investigator-led, study does not colled at hospital-level. The theatre, this includes 30 days after surgery (ii) clinical diagnosis days after surgery, the	et any patient id inclusion criter obstetrics.ANE , based on(i) p (no COVID-19	entifiabl ia are:• 0•The pa ositive ( lab test	e inform Patient atient ha COVID- or CT c	nation ( ts unde ad CO\ 19 lab t hest pe	including ergoing A /ID-19 in est or co erformed	no date NY type fection d mputed ).If COVI	s) and data of surgery iagnosed v tomograph D-19 infec	a will not be in an opera vithin 7 day: y (CT) ches tion is diagr	analysed ating s before d at scan.Of aosed >30
Aims / Objectives									
To determine 30-day future risk stratificatio	•					who und	ergo surge	ry. This will	inform
Standards / Criteria	Details (servi	ce evalı	uation I	N/A)					
See attached documer	its.								
Guideline / Standar	ds available:	Yes		No	$\boxtimes$				
If yes, please attach	a copy or provi	de web	link to th	ne mos	t current	version:	Click here t	o enter text.	
Name of Standard / for all procedures.	guideline: No	guideline	es for thi	s area b	out will co	mpare m	ortality to S	BNS age adjı	usted rates
Source of Standard Trust □	/ guideline: Other ⊠	NSF State of	□ other:		NICE		Roy	al College	

Yes $oxtimes$ No $oxtimes$	ideiine/standa	ira unaerta	iken to ens	ure it is app	propriate d	s can be n	neasured
Is the audit / service evaluation High volume High risk High cost Known quality issue Wide variation in practice	Yes □ No Yes ⋈ No Yes ⋈ No Yes □ No						
Sample No: not known ye	t Procedure c	odes to id	entify sam <sub>l</sub>	<b>ple:</b> Click her	e to enter t	ext.	
http://www.raosoft.com/sam	<u>plesize.html</u> - I	ink to tool t	hat may be	used to cald	culate sam	ple size	
Are you planning to publis	sh your audit/	service eva	aluation fin	dings natio	nally		
(e.g. Medical journal)?	Yes ⊠	No □					
Is this a re-audit or if serv	ice evaluation	, has servi	ce been re	viewed pre	viously?	Yes □	No ⊠
Is this project part of an a	greed departn	nental rolli	ng progran	nme?	Yes	□ No 🛛	
Rolling programme durati	on (number o	f years): Cl	ick here to e	nter text.			
Rolling programme freque	ency: Monthly	□ Quar	terly 🗆 B	iannually □	Annuall	ly □	
Multidisciplinary:		Single dis	sciplinary:				
Is Clinical Audit Team sup If yes, please specify type o  ◆ Population Identification  ◆ Design of data collection (If not required please, attack  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	f assistance re	equired:    	] <b>used)</b> ] ] ]	No			
Patient Contact / Involven or care please explain how in t Will the audit involve direc	his section)		atient contact	t that is <u>not</u> p □ No		atients usua	l treatment
How will the patient be inv	olved?						
Patient Questionnaire	At clinic app	pointment					
Other (please give details) Clie	ck here to enter	text.					
Has approval been sough	t from the Pat	ient Inform	ation Pane	<b>!? Y</b> es [	□ No □	□ <b>N/A</b> 🛭	$\leq$
Anticipated start date: Ma	arch 2020						

## Anticipated project completion date: September 2020

**Anticipated Action Plan Submission date:**Click here to enter text.

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □	



## **Project Prioritisation Assessment Tool**

#### Audit title: Neurosurgical referral and decision patterns in the wake of COVID 19

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project	is manda	tory pleas	e specify w	hat priority l	evel:	-	

	and a process of the second second
Level 1 – External 'must do'	Level 2 'Internal 'must do'

Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk		(x3)
Known quality issue		(x3)
Wide variation in practice		
NICE / NCEPOD related audit		(x3)
Defined measurable standards available		
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	0	5C

### Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

## Clinical Audit / Service Evaluation Registration Form

#### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

## **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against best practice, evidence based clinical standards (this may include Royal College, British Association, NICE or Local guidance etc.)

#### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type:	- Clinica	I Audit	□ Se	ervice E	valuatio	on X		
Audit / Service Eval	uation Title: N	leurosur	gical r	eferral	and de	cision p	atterns	in the wake	of COVID
Division: Neurology	□ Neurosurge	ry X Plea	se spe	cify de <sub>l</sub>	oartmen	t Neuro	surgery	,	
Project Lead:									
Contact No: Bleep	No: Click here t	o enter te	ext.						
Email address:									
Audit / service evalu	ıation supervi	sor: Clic	ck here	e to en	ter text	t.			
Other professionals (Please provide name	-	-				on, anal <u></u>	ysis etc. <sub>,</sub>	)	
Background / Ration All neurosurgical on-cal Since the start of the Co the decisions made hav there has been a chang is. This will be combine country during this time	ll referrals are pr OVID 19 pandem we been altering a ge in the manage ed with data fron	nic, it appe as well. To ment of t	ears that he audit he refer	t referra aims to ral since	als may ho add two COVID,	ave beer o fields to and the	n changing the orion	ng and it is sugg on database – o o briefly explai	gested that one to ask if n what that
<u>Methodology</u>									
All on call referrals re in by the on call neuro pandemic on rate of r	osurgical regist	rar. The	se will b	e used	l to exar	nine the	effects	of the COVID	
Aims / Objectives To see if there is a no pandemic.	oticeable chang	je in refei	rals or	decisic	n to trea	at/admit	in light o	of the COVID	19
Standards / Criteria	Details (servi	ce evalua	ation N	<u>/A)</u>					
This will be compared t	o data from prev	vious refe	rrals, fo	r which	we have	more th	an 5 yeaı	rs worth of dat	a
Guideline / Standard	ds available:	Yes [		No	Х				
If yes, please attach a	a copy or provid	de web lir	nk to th	e most	current	version:	Click he	re to enter tex	t.
Name of Standard /	guideline: Click	k here to e	enter tex	ĸt.					
Source of Standard Trust □	/ guideline: Other □	NSF [	☐ her: Clid	ck here	NICE to enter	□ text.	R	Royal College	

Review/assessment of gu Yes □ No □	ideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / service evaluation High volume High risk High cost Known quality issue Wide variation in practice	Yes □ No X Yes □ No X Yes □ No X Yes □ No X
Sample No: approximately sample: N/A	y 40-50 patients a day during the study Procedure codes to identify
http://www.raosoft.com/sam	nplesize.html - link to tool that may be used to calculate sample size
Are you planning to publi	sh your audit/service evaluation findings nationally
(e.g. Medical journal)?	Yes X No □
Is this a re-audit or if serv	ice evaluation, has service been reviewed previously? Yes X No □
Is this project part of an a	greed departmental rolling programme? Yes □ No X
Rolling programme durati	on (number of years): N/A
Rolling programme freque	ency: Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary:	Single disciplinary: □
Is Clinical Audit Team sup If yes, please specify type of  ◆ Population Identification  ◆ Design of data collection (If not required please, attack  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	f assistance required:
Patient Contact / Involven or care please explain how in a Will the audit involve dire	,
How will the patient be in	volved?
Patient Questionnaire	☐ At clinic appointment ☐
Other (please give details) Cli	ck here to enter text.
Has approval been sough	t from the Patient Information Panel? Yes □ No □ N/A X
Anticipated start date:1st	of April or as soon after that as possible once/if approval given.

Anticipated project completion date: 1st July or up to 6 months. (if covid 19 pandemic last longer

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.		
Is this topic a key clinical interest for the department / division?	Yes □	No □	



# **Project Prioritisation Assessment Tool**

Audit title: AUDIT ON ANAESTHESIA MANAGEMENT OF EMOBLISATION OF INTRACRANIAL AV MALFORMATION

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify what priority level:-						
Level 1 – External 'must do' Level 2 'Internal 'must do'						
Criteria	Tick all that app	ly Score				
High cost		(x3)				
High volume		(x2)				
High risk		(x3)				
Known quality issue		(x3)				
Wide variation in practice	Y					
NICE / NCEPOD related audit		(x3)				
Defined measurable standards available						
Re-audit / repeat service evaluation		(x2)				
Topic is a key clinical interest for the department /	division	(x2)				
Multidisciplinary project						
National / regional or multicentre project		(x2)				
Total	C1					
Priority levels and audit team support		•				
Priority level	Priority score					
Level 1 – External 'must do'	Category A					
Level 2 – Internal 'must do'	Category A					
Level 3 – High local priority	> 10					
Level 4 – Medium local priority	4-9					
Level 5 – Low local priority	< 4					
Priority level Audit team resource						

Level 1, 2 & 3

Level 4

Level 5

Category A – Full support

Category B – Moderate support

Category C – Minimal support

Full practical assistance offered

Level of practical assistance will be negotiated and agreed with project lead

Advice, registration and monitoring

### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

## Service evaluation

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

#### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

## **Service Evaluation:**

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

Ref No: - Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service Evaluation Title: AUDIT ON ANAESTHESIA MANAGEMENT OF EMOBLISATION OF INTRACRANIAL AV MALFORMATION
<b>Division:</b> Neurology $\square$ Neurosurgery $\boxtimes$ Please specify department $Click$ here to enter text.
Project Lead:
Contact No: Bleep No:
Email address:
Audit / service evaluation supervisor:
Other professionals involved / project team members details (Please provide names and roles within the project eg data collection, analysis etc.)
Background / Rationale
Intracranial AV Malformation is managed by either surgical excision or embolisation by intervention radiologist. Later one is minimal invasive with good outcome. During recent year there is significant change in technique of embolisation of AV Malformation. In recent years most of AV Malformation are embolised through arterial and venous route, which is observed as better than the arterial route alone.
Newer technique of embolisation needs intraprocedure hypotension during venous phase of embolisation. This audit is to review the current practise.
<u>Methodology</u>
<ol> <li>Retrospective audit of all patients who underwent arterial and venous embolisation of intracranial AV Malformation 2) Patient data collection form attached</li> </ol>
Aims / Objectives
To evaluate current practise, measure the outcomes and associated complications
Standards / Criteria Details (service evaluation N/A)
Not available
Guideline / Standards available: Yes □ No ⊠
If yes, please attach a copy or provide web link to the most current version:
Name of Standard / guideline: Click here to enter text.
Source of Standard / guideline: NSF □ NICE □ Royal College □  Trust □ Other □ State other: Click here to enter text.
Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured Yes $\square$ No $\square$

Is the audit / service eval	uation issue:							
High volume	Yes □ No ⊠							
High risk	Yes □ No ⊠							
High cost	Yes □ No ⊠							
Known quality issue	Yes □ No ⊠							
Wide variation in practice	Yes ⊠ No □							
Sample No: 15-20 Procedure codes to identify sample: Click here to enter text.								
http://www.raosoft.com/sar	mplesize.html - link to tool that may be used to calculate sample size							
Are you planning to publ	ish your audit/service evaluation findings nationally							
(e.g. Medical journal)?	Yes ⊠ No □							
Is this a re-audit or if serv	vice evaluation, has service been reviewed previously? Yes □ No ☒							
Is this project part of an	agreed departmental rolling programme? Yes □ No ☒							
Rolling programme durat	tion (number of years): Click here to enter text.							
Rolling programme frequ	<b>lency:</b> Monthly □ Quarterly □ Biannually □ Annually □							
Multidisciplinary: ⊠	Single disciplinary: $\square$							
<ul> <li>If yes, please specify type</li> <li>◆ Population Identificatio</li> <li>◆ Design of data collection</li> <li>(If not required please, attander)</li> <li>◆ Database design</li> <li>◆ Data entry</li> <li>◆ Analysis</li> <li>◆ Presentation</li> <li>Collection of case notes</li> </ul>	n							
Patient Contact / Involve or care please explain how in Will the audit involve dire	,							
How will the patient be in	volved?							
Patient Questionnaire	□ At clinic appointment □							
Other (please give details)	lick here to enter text.							
Has approval been sough	ht from the Patient Information Panel? Yes □ No □ N/A □							
Anticipated start date: So	oon after Audit approval							
Anticipated project comp	oletion date: 3 months from audit approval							
Anticipated Action Plan S	Submission date: 6 months from audit approval							

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click here to enter text.			
Comments Click here to enter text.				
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.			
Is this topic a key clinical interest for the department / division?	Yes □	No □		



### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

## **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

## Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service Ev COVID Pandemic	aluation Title: Audit of Stroke Thrombectomy Times & Outcomes during the
Division: Neurolog	y □ Neurosurgery ⊠ Please specify department <b>Anaesthesia</b>
Project Lead:	
Contact No: Blee	ep No:
Email address:	
Audit / service eva	aluation supervisor:
-	als involved / project team members details mes and roles within the project eg data collection, analysis etc.) ext.
Background / Rat	ionale_
current COVID Pande done in terms of extra and facilitate decont plan to audit some o our routine practice service and our practi	ectomy for stroke is a service provided by our trust currently 9am-5pm 7 days a week. During the emic extra precautions are being implemented. They include changes in the way this service is ra PPE, Location of Anaesthesia induction & extubation, recovery-with a view to minimise AGPs amination. This has increased the time scales involved in every part of the patient journey. We f the times involved to determine the influence the effect of the COVID specific modifications to in terms of the timing and outcomes. This will inform us and help us modify and improve this tice to the benefit of patients in terms of outcomes since the whole process is timecritical. Also is going to be longterm and this miniaudit will help us improve and modify our practice.
Methodology	
Revascularisation from Patients' Clid 4. Likely to review sheet. These will be 2018/19. This will lassosciation with	lini audit; 2. Review & Record -Arrival to Femoral Puncture, Arrival to a, Duration of Anaesthesia, Postprocedure destination -The above will be retrieved nical, Radiology, Theatre, Anaesthesia records; 3. Study period- 17/3/20-17/5/20; ~20 patients during this period. For other details please refer Audit Data be compared with our previous figures from similar Audits conducted in nelp us determine the quantum of the delays due to COVID precautions and their outcomes. We will obtain future outcomes using the scoring systems used for rom the clinical records.
Aims / Objectives	
Review modify a	and improve the current practice.
Standards / Criter	ia Details (service evaluation N/A)
N/A	
Guideline / Standa	ards available: Yes □ No ⊠

If yes, please attach a copy or provide web link to the most current version: Click here to enter text.

Name	of Standard / Royal College	•	ne: e of	Standard / gui	deline:	NSF		NICE	
Trust		Other	$\boxtimes$	State other: tim	es from pre	vious Au	dits fror	m the Pre COVID	period
<b>Reviev</b> Yes ⊠		of guid	leline/s	tandard undert	aken to en	sure it is	appro	priate & can be	measured
High vo High ri High co Known	sk		Yes  Yes  Yes  Yes  Yes	No ⊠ No ⊠ No ⊠					
Sampl	e No: About 2	0 cases	Proce	edure codes to	identify sa	mple: Cli	ick here	to enter text.	
http://v	www.raosoft.com	m/samp	<u>lesize.h</u>	tml - link to tool	that may be	e used to	calcula	ate sample size	
Are yo	ou planning to	publisł	n your a	audit/service e	/aluation fi	ndings r	nationa	lly	
(e.g. N	ledical journal)	? `	Yes ⊠	No □					
Is this	a re-audit or i	f servic	e evalu	ation, has serv	vice been re	eviewed	previo	u <b>s</b> ly? Yes ⊠	No ⊠
Is this	project part o	f an ag	reed de	partmental rol	ling progra	mme?		Yes □ No 🗵	
Rolling	g programme	duratio	n (num	ber of years):	Click here to	enter text			
Rolling	g programme	frequen	ıcy: Mo	onthly 🗆 Qua	rterly 🗆 🛭	Biannuall	ly 🗆	Annually □	
Multidi	sciplinary:			Single o	isciplinary:	$\boxtimes$			
If yes,  ◆ Po  ◆ De  (If not in the proof of the proof o	ical Audit Tea please specify pulation Identifi sign of data col required please tabase design ta entry alysis esentation tion of case not	type of cation lection lection e, attach	assistar tool			mber	No / per	week	
or care	t Contact / Inv please explain h e audit involve	ow in thi	is sectioi	n)	patient contac	ct that is <u>r</u>	<u>not</u> part No	of the patients usu	al treatment
How w	vill the patient	be invo	lved?						
Patient	t Questionnaire		At clin	ic appointment					
Other	(please give deta	ails) Click	here to	enter text.					

Has approval been sought from the Patient Information Panel?	Yes □	No 🗆	N/A	$\boxtimes$		
Anticipated start date:May-June 2020						
Anticipated project completion date: Jan 2021						
Anticipated Action Plan Submission date:2 months after the date of completion.						
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QU	ESTIONNAI	RE.				
• FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.	COPY OF T	HE PREVIO	US AUDI	T OR SERVICE		
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD AUDIT TEAM.</li> </ul>	BEFORE SU	BMISSION '	TO THE (	CLINICAL		
Departmental Clinical Audit Lead (Signature)	Date:	12/05/20				
Comments Own project-in appropriate for me to comment						
Divisional Clinical Audit Lead (Signature)	Date:	Click here	to ente	er text.		
Is this topic a key clinical interest for the department / division?	Yes ⊠		No 🗆			



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 294

Clinical Audit Title	Audit on Anaesthetic management and outcome of patients undergoing posterior circulation stroke thrombectomy				
Date audit complete	30/06/20	Date action plan completed	22/04/21		
Auditor		Name of policy / guideline			
Division	Neurosurgery	Source of policy / guideline			

## **Summary of Findings:**

- 14 patients underwent mechanical thrombectomy for PCS during the audit period.
- Of these 11 were male and 3 were female.
- Age distribution ranged from 44 to 79 years.
- Mean NIHSS score was 13 with a range of 1 to 42.
- Onset of symptoms to arrival time at the hospital ranged from 240 to 1020 minutes.
- Mean door-to-needle time was 23 minutes.
- 12 procedures were performed under GA and 2 patients had conscious sedation.
- 7 of the 12 GA cases were GA transfers from referring hospitals.
- All the patients had vertebra-basilar involvement and were transferred to critical care after the procedure.
- Both the patients in the conscious sedation group survived with a good functional outcome.
- 50% of the patients who received a GA died within 3 months of the procedure. 5 patients had a failed procedure and 1 patient suffered a reocclusion of the vessel after successful thrombectomy.
- 6 of the 14 patients had died at 90 days. (Mortality rate:42%)

## **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

• Our overall mortality is comparable to the one quoted in the literature (W Brinjikji et al. Conscious Sedation Versus General Anesthesia During Endovascular Acute Ischemic Stroke Treatment: A Systematic Review and Meta- Analysis. AJNR Am J Neuroradiol 2015 Mar;36(3):525-9

## **Key concerns:**

N/A

## **Recommendations discussed:**

Version: 2019

- Although there was increased mortality in GA group (50%) when compared to sedation group (0%) in our audit, our sample size was small we could not conclude any one technique is superior to other. There was no observed difference in the outcomes between the GA group and LA/sedation group in a large study of 1200 patients
- Some of these patients (58%) were already intubated prior to transfer; therefore we cannot choose a particular technique.

Presentation / Dissemination of Project	
Date findings were presented / disseminated: 10/09/20	
Department where discussed or presented: Anaesthetic departmental audit meeting.	
A stiene save of fellowing was a way and stiene discussed.	

## Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Re-audit date: None	In a second	A stirm no mains d	Mana ad Ia ad	T:	Fideline	Danastalala 4a		
1) None  Re-audit date: None If no re-audit planned please give reasons why? Will collect the data as part of the stroke thrombectomy audit.  Will this be an on-going audit? Yes  No X  Are there any potential barriers / problems to prevent the implementation of the above actions? Yes  No X  If yes to the above please state who the issues have been referred to:  Name Designation Date referred  Signature: Date:  Have any issues been logged on the risk register? Yes  No X N/A	Issue	Action required	Named lead	Timescale	Evidence	Reportable to		
Re-audit date: None	4) 11		for action			(group/meeting)		
Will this be an on-going audit? Yes No X  Are there any potential barriers / problems to prevent the implementation of the above actions? Yes No X  If yes to the above please state who the issues have been referred to:  Name Designation Date referred  Signature: Date: No X No X No X	1) None							
Will this be an on-going audit? Yes No X  Are there any potential barriers / problems to prevent the implementation of the above actions? Yes No X  If yes to the above please state who the issues have been referred to:  Name Designation Date referred  Signature: Date: No X No X No X								
Will this be an on-going audit? Yes No X  Are there any potential barriers / problems to prevent the implementation of the above actions? Yes No X  If yes to the above please state who the issues have been referred to:  Name Designation Date referred  Signature: Date: No X No X No X								
Will this be an on-going audit? Yes No X  Are there any potential barriers / problems to prevent the implementation of the above actions? Yes No X  If yes to the above please state who the issues have been referred to:  Name Designation Date referred  Signature: Date: No X No X No X	Po-audit dato: Nono If no ro-au	udit plannod places give reasons why? W	fill collect the data	as part of the	etroke thrombec	stomy audit		
Are there any potential barriers / problems to prevent the implementation of the above actions? Yes No X  If yes to the above please state who the issues have been referred to:  Name Designation Date referred  Signature: Date:  Have any issues been logged on the risk register? Yes No X N/A	Re-audit date. None ii iio re-at	duit plainled please give reasons wily?	iii collect the data	as part or the	Shoke unombed	normy addit.		
Are there any potential barriers / problems to prevent the implementation of the above actions? Yes No X  If yes to the above please state who the issues have been referred to:  Name Designation Date referred  Signature: Date:  Have any issues been logged on the risk register? Yes No X N/A	Will this he are an arrive sudit?	- □ N- V						
If yes to the above please state who the issues have been referred to:  Name Designation Date referred  Signature: Date:  Have any issues been logged on the risk register? Yes No X N/A	will this be an on-going audit? Ye	S   NO X						
If yes to the above please state who the issues have been referred to:  Name Designation Date referred  Signature: Date:  Have any issues been logged on the risk register? Yes No X N/A				•				
Name Designation Date referred  Signature: Date:  Have any issues been logged on the risk register? Yes No X N/A	Are there any potential barriers / prob	plems to prevent the implementation of the	ie above actions	? Yes ∐ No	o X∐			
Name Designation Date referred  Signature: Date:  Have any issues been logged on the risk register? Yes No X N/A								
Signature:Date:  Have any issues been logged on the risk register? Yes  No X N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/	If yes to the above please state who t	he issues have been referred to:						
Signature:Date:  Have any issues been logged on the risk register? Yes  No X N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/				_				
Have any issues been logged on the risk register? Yes No X N/A	Name	Designation	Date referre	d				
Have any issues been logged on the risk register? Yes No X N/A								
	Signature:	Date:						
	Have any issues been logged on the risk register? Yes No X N/A							
Please provide details of issue(s) logged on the risk register:								
	Please provide details of issue(s) logged on the risk register:							

Version: 2019



### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

## **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

## Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service Evalu	uation Title:
<b>Division:</b> Neurology	□ Neurosurgery ⊠ Please specify department <b>Anaesthesia</b>
Project Lead:	
Contact No: Bleep	No:
Email address:	
Audit / service evalu	nation supervisor:
	involved / project team members details es and roles within the project eg data collection, analysis etc.)
Background / Ratior	nale
	my for stroke of the posterior circulation and its anaesthetic management isn't studies like to review our institution's methodology and outcome.
<u>Methodology</u>	
1.Retrospective aud ~20 patients during	it; 2. Anaesthetic Chart review; 3. Study period 2013-2019; 4. Likely to review this period.
Aims / Objectives	
Review the current	practice; Effect of the type of anaesthesia on the outcome.
Standards / Criteria	Details (service evaluation N/A)
N/A	
Guideline / Standard	ds available: Yes □ No ⊠
If yes, please attach a	a copy or provide web link to the most current version: Click here to enter text.
Name of Standard / g	guideline: NICE guidelines for intervention evidence review 2018.
Source of Standard Trust □	/ guideline: NSF ☐ NICE ☒ Royal College ☐ Other ☐ State other: Click here to enter text.
Review/assessment Yes ⊠ No □	of guideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / service	
High volume	Yes □ No ⊠
High risk High cost	Yes □ No ⊠ Yes □ No ⊠
Known quality issue	Yes □ No ⊠

Wide variation in practice Yes ⊠ No □
Sample No: 10-20 Procedure codes to identify sample: Click here to enter text.
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes ⊠ No □
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ⊠
Is this project part of an agreed departmental rolling programme? Yes □ No ☒
Rolling programme duration (number of years): Click here to enter text.
Rolling programme frequency: Monthly $\square$ Quarterly $\square$ Biannually $\square$ Annually $\square$
Multidisciplinary: $\square$ Single disciplinary: $\boxtimes$
If yes, please specify type of assistance required:  ◆ Population Identification □  ◆ Design of data collection tool □  (If not required please, attach a copy of the tool to be used)  ◆ Database design □  ◆ Data entry  ◆ Analysis □  ◆ Presentation □  Collection of case notes □ Total number _5 _ / per week   Patient Contact / Involvement - (If project involves patient contact that is not part of the patients usual treatmer or care please explain how in this section)  Will the audit involve direct patient contact? Yes □ No ☑
How will the patient be involved?
Patient Questionnaire
Other (please give details) Click here to enter text.
Has approval been sought from the Patient Information Panel? Yes □ No □ N/A ⊠
Anticipated start date:June 2020
Anticipated project completion date: September 2020
Anticipated Action Plan Submission date:2 months from the date of completion.

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.

Departmental Clinical Audit Lead (Signature)		
Date: 20/5/20		
Comments		
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.
	Yes ⊠	No □

PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL

AUDIT TEAM.



### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

## **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

## Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

Ref No: -	HIST/349	Project Type: - Clinical Audit ⊠	Service Evaluation □
	rvice Evaluation 20 at the Walton		obtained on gliomas between June 2019
Division:	Neurology 🗆 Neur	rosurgery 🗵 Please specify depart	ment The Neuroscience Laboratories
Project Le	ead:		
Contact N	o: Bleep No: Clic	ck here to enter text.	
Email add	ress:		
Audit / se	rvice evaluation s	supervisor: Click here to enter	text.
-		ed / project team members detai roles within the project eg data colle	

## Background / Rationale

This is a re-audit to follow up the results obtained from 'Audit of molecular data obtained on gliomas between January 2018 to May 2019 at the Walton Centre'.

### **Methodology**

As before this retrospective study will include glioma cases which were sent for NGS analysis between June 2019 and May 2020. In-house IHC results (on IDH1, ATRX, H3.3K27M) and results of PCR, FISH and MGMT promoter methylation analysis performed on this cohort will also be taken into consideration. The data will be retrieved from laboratory information system and analysed.

#### Aims / Objectives

To review the completeness of the molecular diagnostic pathway and assess compliance with the NICE guidelines.

#### Standards / Criteria Details (service evaluation N/A)

The National Institute Health and Care Excellence (NICE) guidelines on Brain tumours (primary) and brain metastases in adults (published on 11 July 2018) recommend:

- 1. The use of following molecular markers to determine prognosis or guide treatment for glioma:
  - IDH1 and IDH2 mutations
  - ATRX mutations to identify IDH mutant astrocytomas and glioblastomas (GBM)
  - 1p/19q codeletion to identify oligodendrogliomas
  - Histone H3.3K27M mutations in midline gliomas
  - BRAF fusion and gene mutation to identify pilocytic astrocytoma (PA)
- 2. Test all high-grade glioma specimens for MGMT promoter methylation to inform prognosis and guide treatment.
- 3. Consider testing IDH-wildtype glioma specimens for TERT promoter mutations for prognostication.

Click here to enter text.

Guideline / Standards available: Yes ⊠ No □
If yes, please attach a copy or provide web link to the most current version: https://www.nice.org.uk/guidance/ng99/chapter/Recommendations
Name of Standard / guideline: As above.
Source of Standard / guideline: NSF □ NICE ☒ Royal College □  Trust □ Other □ State other: Click here to enter text.
Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured $\rm Yes~\boxtimes~No~\square$
Is the audit / service evaluation issue:   High volume Yes □ No ⋈   High risk Yes □ No ⋈   High cost Yes □ No ⋈   Known quality issue Yes □ No ⋈   Wide variation in practice Yes □ No ⋈
Sample No: 75 Procedure codes to identify sample: NGS code on TD-HC
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes □ No ⊠
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes ⊠ No □
Is this project part of an agreed departmental rolling programme? Yes □ No ☒
Rolling programme duration (number of years): ongoing
Rolling programme frequency: Monthly $\square$ Quarterly $\square$ Biannually $\square$ Annually $\square$
Multidisciplinary: □ Single disciplinary: □
Rolling programme duration (number of years): ongoing
Is Clinical Audit Team support required? Yes □ No ☑  If yes, please specify type of assistance required:  ◆ Population Identification □  ◆ Design of data collection tool □  (If not required please, attach a copy of the tool to be used)  ◆ Database design □  ◆ Data entry □  ◆ Analysis □  ◆ Presentation □  Collection of case notes □ Total number / per week

Clinical Audit Registration Form Version 3 - 2019

Patient Contact / Involvement – (If project involves patient contact that if or care please explain how in this section) Will the audit involve direct patient contact?  Yes	s <u>not</u> part o	of the patients usual treatmen
How will the patient be involved?		
Patient Questionnaire		
Other (please give details) Click here to enter text.		
Has approval been sought from the Patient Information Panel?	∕es □	No □ N/A ⊠
Anticipated start date: July 2020		
Anticipated project completion date: November 2020		
Anticipated Action Plan Submission date: December 2020		
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUE	STIONNAIR	Ε.
FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.	COPY OF TH	IE PREVIOUS AUDIT OR SERVICE
PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD E AUDIT TEAM.	BEFORE SUB	MISSION TO THE CLINICAL
Departmental Clinical Audit Lead (Signature Date: 02/06/2020		
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date:	Click here to enter text.
Is this topic a key clinical interest for the department / division?	Yes □	No ⊠



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 295 HIST/349

Clinical Audit Title	Re-audit of molecular data obtained on gliomas reported at WCFT between June 2019 and May 2020.		
Date audit	26/01/2021	Date action plan	26/01/2021
complete		completed	
Auditor		Name of policy /	Guidelines on brain tumours
		guideline	(primary) and brain metastases
Division	Neurosurgery, Anaesthesia, Critical Care, Pain and Pathology	Source of policy /	NICE
		guideline	

## **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

• Please see attached copy of the audit-

## Key success:

Please concisely state the key success identified by the project – if none identified please state N/A

- This audit showed that the gliomas reported at The Walton Centre between June 2019 and May 2020 are in concordance with the 2018 NICE guidelines.
- Shortfalls identified in the previous audit (HIST 347) have not recurred.

## **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

N/A

## Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

• Since the revised 4<sup>th</sup> edition of WHO classification (2016), a lot has changed in CNS tumour diagnosis and pathologists at the Walton Centre have strived to keep up with the changes. Our data has now been audited twice against the NICE guidelines (2018). RCPath published a Molecular diagnostic algorithm for adult gliomas in March 2020 which is far more advanced than the NICE guidelines. Currently we follow the standards published by the RCPath. The 5<sup>th</sup> edition of the WHO classification of CNS tumours is overdue. It is expected to incorporate some important changes as outlined in cIMPACT recommendations. In view of this a fresh audit will be planned once all the recommended changes

Version: 2019

have been implemented in the	department.					
Presentation / Dissemination of Proje			111			
Date findings were presented / dissemin	nated:Will be presented in the ne	<u>xt departmental al</u>	<u>iait meeting</u>			
Department where discussed or present	ted: The Neuroscience Labora	atories				
Actions agreed following recomm		atatad an the cati	ion plan bolow	Diagon list the	ovidence of the estica	
	amed lead, timescale and reportable group tandardised template, presentation or med		on pian below.	Please list trie	e evidence of the action	
Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)	
New WHO CNS Tumour Book			-	-	Neuropathology &	
is overdue and is expected in recommendations in the department.  Neuro-oncological services and is expected in recommendations in the department.					Neuro-oncology	
Re-audit dateXIf will be audited once changes recomme	no re-audit planned please give reasons nded by WHO are in place	s why?New Wh	HO Tumour Bo	ok is expected	in 2021. Our practice	
Will this be an on-going audit?			-			
Are there any potential barriers / pro	blems to prevent the implementation of	the above action	s? Yes 🗌 N	No 🗵		
If yes to the above please state who	the issues have been referred to:					
Name	Designation	Date referr	ed			
Signature: Date:						
Have any issues been logged on the	risk register? Yes No No N/A					
Please provide details of issue(s) log	ged on the risk register:					

Version: 2019



### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

## **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

## Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

Ret No: -	Project Type: - Clinical Audit   Service Evaluation
Audit / Service Ev base (CRANIAL)	aluation Title: CSF rhinorrhoea after endonasal intervention to the anterior skull
Division: Neurolog	y $\square$ Neurosurgery $\boxtimes$ Please specify department $Click$ here to enter text.
Project Lead:	
Contact No: B	leep No:
Email address:	
Audit / service eva	aluation supervisor:
-	lls involved / project team members details mes and roles within the project eg data collection, analysis etc.)

## Background / Rationale

The endonasal transsphenoidal approach (TSA) has emerged as the preferred approach in order to treat pituitary adenoma and related sellar pathologies owing to its superior effectiveness and safety profile when compared to transcranial approaches. The recently adopted expanded endonasal approach (EEA) has improved access to the ventral skull base whilst retaining the principles of minimally invasive surgery. Despite the advantages these approaches offer, cerebrospinal fluid (CSF) leak remains a common complication. There is currently a lack of comparative evidence to guide the best choice of skull base reconstruction, resulting in considerable heterogeneity of current practice. The aim of this study is to determine: (1) the scope of the methods of skull base repair; and (2) the corresponding rates of post-operative CSF rhinorrhoea in contemporary neurosurgical practice in the UK & Ireland.

### **Methodology**

We will adopt a multicentre, prospective, observational cohort design. All neurosurgical units (NSUs) in the UK and Ireland performing the relevant surgeries (TSA and EEA) will be eligible to participate. Eligible cases will be prospectively recruited over 6 months with 6 months of post-op follow-up. Anonymised data will be collected locally and submitted to a secure web-based central database (Castor Electronic Data Capture). Data points collected will include: demographics, tumour characteristics, operative data, and post-operative outcomes. Illustrations and clear definitions will be presented to support the accurate recognition of the various skull base repair techniques. The primary outcomes of the study will be: (1) methods of intra-operative skull base reconstruction used and (2) post-operative CSF rhinorrhoea requiring intervention (CSF diversion and/or operative repair). Pooled data will be analysed using descriptive statistics. All skull base repair methods used and the proportion of total surgeries that adhere to each method will be presented. CSF leak rates for TSA and EEA will be compared against rates listed in the literature.

## **Aims / Objectives**

The need for this multicentre, prospective, observational study is highlighted by the relative paucity of literature and the resultant lack of consensus on the topic. It is hoped that the results will give insight into contemporary practice in the UK and Ireland and inform future studies. Therefore, the aim of this study is to determine: (1) the scope of the methods of skull base repair; and (2) the corresponding rates of post-operative CSF rhinorrhoea in contemporary neurosurgical practice in the UK & Ireland.

## Standards / Criteria Details (service evaluation N/A) N/A Guideline / Standards available: Yes No $\boxtimes$ If yes, please attach a copy or provide web link to the most current version: Click here to enter text. Name of Standard / guideline: n/a Source of Standard / guideline: NSF NICE Royal College Trust □ Other State other: Click here to enter text. Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured Yes □ No □ Is the audit / service evaluation issue: High volume Yes □ No ⊠ Yes ⊠ No □ High risk Yes ⊠ No □ High cost Known quality issue Yes ⊠ No □ Wide variation in practice Yes ⊠ No □ Sample No: n/a Procedure codes to identify sample: n/a http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size Are you planning to publish your audit/service evaluation findings nationally Yes ⊠ No □ (e.g. Medical journal)? Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ☒ Is this project part of an agreed departmental rolling programme? Yes □ No 🛛 Rolling programme duration (number of years): n/a **Rolling programme frequency:** Monthly Quarterly Biannually □ Annually □ Multidisciplinary: Single disciplinary: Is Clinical Audit Team support required? Yes No XIf yes, please specify type of assistance required: Population Identification Design of data collection tool (If not required please, attach a copy of the tool to be used) Database design

☐ Total number \_\_\_\_ / per week \_\_\_\_

Data entry

Presentation

Collection of case notes

Analysis

Patient Contact / Involvement – (If project involves patient or care please explain how in this section)	contact i	that is <u>n</u>	<u>ot</u> part o	f the pati	ents usi	ual treatment
Will the audit involve direct patient contact?	Yes		No	$\boxtimes$		
How will the patient be involved?						
Patient Questionnaire $\Box$ At clinic appointment $\Box$						
Other (please give details) Click here to enter text.						
Has approval been sought from the Patient Information	Panel <sup>e</sup>	? Yes	s 🗆	No 🗆	N/A	$\boxtimes$
Anticipated start date:To be restarted nationally – delay	ed du	e to Co	vid			
Anticipated project completion date: 6 MONTHS DATA	COLLE	CTION	I,			
Anticipated Action Plan Submission date:12 MONTHS F NATIONAL TEAM RUNNING PROJECT	ROM	START	, PEND	ING RE	SULTS	FROM
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL /	PATIENT	CQUEST	ONNAIR	Ε.		
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE</li> <li>EVALUATION REPORT.</li> </ul>	SE ATTA	CH A CO	PY OF TH	E PREVIO	JS AUDI	T OR SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT TEAM.</li> </ul>	AUDIT LE	EAD BEF	ORE SUBI	MISSION 1	O THE C	LINICAL
Departmental Clinical Audit Lead (Signature)		_	Date: (	Click here	to ente	er text.
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)			Date: 0	Click here	to ente	er text.
Is this topic a key clinical interest for the department / o	divisio	n? \	′es □		No □	



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 297

Clinical Audit Title	Laterality of ACDF		
Date audit complete	15/09/2020	Date action plan completed	
Auditor		Name of policy / guideline	
Division	Neurosurgery	Source of policy / guideline	

## **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- 146 eligible patients identified
- 64 had right sided anterolateral approach to subaxial spine (R group)
- 82 had left sided anterolateral approach to subaxial spine (L group)
- Rate of dysphagia: 3/64 R (1 permanent, all C3/4 level involved), 2/82 L (permanent)
- Rate of dysphonia: 0/64 R, 2/82 (transient)
- Rate of Horner's syndrome: 0/146
- Rate of major vessel injury: 1/64 R, 0/82 L
- Early reoperation rate: 1/64 R (1 swelling, infection)
- Late reoperation rate: 0
- Rate of surgical site infection: 1/64 R (requiring washout and iv antibiotic treatment)
- No significant difference in PROMs (VAS, COMI as per Spine Tango Database)

## **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

• Confirmation that in anterolateral subaxial spine approaches for ACDF, side of approach does not significantly correlate with different early and late complication rate as well as patient reported outcome measures (COMI and VAS)

## Key concerns:

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- Retrospective analysis of database
- Mixed 1 and 2 level cases
- Mixed aetiology (myelopathy and radiculopathy)

Version: 2019

	mendations that were discussed following to binion is that no change of practice is neede			dings in the liter	ature
Presentation / Dissemination of Projection Date findings were presented / dissemi					
Department where discussed or preser	nted:				
implementation e.g SOP, protocol, s	amed lead, timescale and reportable group standardised template, presentation or mee	ting minutes etc			
Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)					
2)					
3)					
4)					
Re-audit date If no re-audit planned please give reasons why?					
Will this be an on-going audit? Ye  Are there any potential barriers / pro	es No Delems to prevent the implementation of	the above actions	s? Yes □ N	o 🗌	

Version: 2019

If yes to the above please state who the issues have been referred to:					
Name	Designation	Date referred			
Signature:	Date:				
Have any issues been logged on the risk register? Yes  No N/A					
Please provide details of issue(s) logged on the risk register:					

Version: 2019



### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

## **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

## Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service E	valuation Title: Laterality of ACDF
Division: Neurolo	ogy □ Neurosurgery ⊠ Please specify department Click here to enter text.
Project Lead:	
Contact No: Ex	t:
Email address:	
Audit / service e	valuation supervisor: Click here to enter text.
	nals involved / project team members details ames and roles within the project eg data collection, analysis etc.)
dysphagia and dysp Neurosurgery for la	ateral neck approach for cervical spine fusion is historically linked to higher incidence of whonia yet is routinely used in spinal care. Left sided approach has been used at Walton ast four years by two of the project members. No evidence in the literature or guidelines available ich side (if any) carries more prevalent or significant perioperative complications in comparative
<u>Methodology</u>	
operations done at	vsis of all right and left anterior cervical discectomy and fusion (ACDF) one or two levels primary Walton from Feb. 2016 to Feb. 2020 under two Consultant members of the project, who both right and left approaches. Independent data collection by ST member of the project.
Aims / Objective	<u>s</u>
approaches for ACE Dysphagia, Dyspho	ferences in the prevalence and nature of perioperative (early) complications in right and left DF, namely Postoperative Haematoma requiring evacuation, Recurrent Laryngeal Nerve Palsy, nia, Horner's syndrome, Pharyngeal or Oesophageal injury, Carotid Artery injury, Jugular Vein son for unintended return to the operating theatre in the first 30 days after the index procedure.
Standards / Crite	eria Details (service evaluation N/A)
1950's independen sided approach) an two different special both approaches. A	paches to the lower cervical spine for decompression and fusion have been described in the tly by Cloward (Neurosurgery, right sided approach) and Robinson (Orthopaedic Surgeon, left d are still taught and practiced today in this polarised fashion by spinal surgeons trained in the alties. Since 2016, Walton Neurosurgery has had Orthopaedic Consultants who are familiar with as the literature is non-conclusive with regards to the reasons behind why either approach should be useful to compare the internal Walton data to develop evidence and implement the service if

 $\boxtimes$ 

If yes, please attach a copy or provide web link to the most current version: Click here to enter text.

No

Guideline / Standards available: Yes

Name of Standard / guideline: Spine (Phila Pa 19 10.1097/BRS.obo13e318154c57e. Anterior Cervical Kostas N , Eftychia Z, Leonidas G et al.	
Source of Standard / guideline: NSF ☐ Trust ☐ Other ☐ State other: CI	NICE ⊠ Royal College □ lick here to enter text.
Review/assessment of guideline/standard under Yes $\boxtimes$ No $\square$	rtaken to ensure it is appropriate & can be measured
Is the audit / service evaluation issue:  High volume Yes □ No □  High risk Yes ☒ No □  High cost Yes □ No ☒  Known quality issue Yes □ No ☒  Wide variation in practice Yes ☒ No □	
Sample No: 130 Procedure codes to identify sa	mple: Click here to enter text.
http://www.raosoft.com/samplesize.html - link to too	ol that may be used to calculate sample size
Are you planning to publish your audit/service	evaluation findings nationally
(e.g. Medical journal)? Yes $\boxtimes$ No $\square$	
Is this a re-audit or if service evaluation, has ser	rvice been reviewed previously? Yes □ No 🛛
Is this project part of an agreed departmental ro	olling programme? Yes □ No ☒
Rolling programme duration (number of years):	Click here to enter text.
Rolling programme frequency: Monthly   Qu	arterly   Biannually   Annually
Multidisciplinary:	disciplinary:
Is Clinical Audit Team support required?  If yes, please specify type of assistance required:  ◆ Population Identification  ◆ Design of data collection tool  (If not required please, attach a copy of the tool to be a cop	Yes ⋈ No □  □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □
Patient Contact / Involvement – (If project involves or care please explain how in this section) Will the audit involve direct patient contact?	patient contact that is <u>not</u> part of the patients usual treatment $\square$ No $\square$
How will the patient be involved?	

Patient Questionnaire $\Box$ At clinic appointment $\Box$						
Other (please give details) Click here to enter text.						
Has approval been sought from the Patient Information Panel?	Yes		No		N/A	$\boxtimes$
Anticipated start date: asap						
Anticipated project completion date: Click here to enter text.						
Anticipated Action Plan Submission date: Click here to enter text.						
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QU	ESTION	INAIR	E.			
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.</li> </ul>	COPY	OF TH	E PRE	VIOU	S AUDI	T OR SERVIC
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD AUDIT TEAM.</li> </ul>	BEFOR	E SUB	MISSIC	ON TO	O THE C	CLINICAL
Departmental Clinical Audit Lead (Signature)	D	ate:	Click ł	nere t	o ente	er text.
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)	D	ate:	Click h	nere t	to ente	er text.
Is this topic a key clinical interest for the department / division?	Yes	s 🗆		Ν	lo 🗆	



#### Clinical Audit / Service Evaluation Action Plan

**Ref no:** NS 301

Clinical Audit Title	NS 201 - Re-audit of spinal deformity practice		
Date audit complete	28/09/2020	Date action plan completed	
Auditor		Name of policy / guideline	
Division	Neurosurgery	Source of policy / guideline	

## **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Rate of mechanical complications in adult spinal deformity surgery correlated with age, fusion to pelvis and extent of correction
- Rate of surgical site infection has decreased since routine use of Vancomycin powder
- No pedicle screws were revised for misplacement after routine use of intraoperative Ct / navigation

## **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

- Lower rate of pedicle screw misplacement since intraoperative CT implemented
- Lower rate of SSI since second since Vancomycin powder used

# Key concerns:

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- Mechanical complications increase since part I of Audit (pre 2019) with higher age and complexity of Patients treated
- Two catastrophic neurological complications (one stroke, one spinal cord injury) seen in two different Patients over 70

## Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

- To be discussed
- •

Presentation / Dissemination of Project	
Date findings were presented / disseminated:	
Department where discussed or presented:	_

Version: 2019

	nendations discussed:- amed lead, timescale and reportable group standardised template, presentation or mee		on plan below.	Please list the	evidence of the action
Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)					(0 00)
2)					
3)					
4)					
Re-audit date If	no re-audit planned please give reasons	why?			
Will this be an on-going audit?	es 🗌 No X				
Are there any potential barriers / pro	blems to prevent the implementation of	the above action	s? Yes 🗌 N	lo X	
If yes to the above please state who	the issues have been referred to:				
Name	Designation	Date referr	ed		
Signature:	Date:				
Have any issues been logged on the	risk register? Yes No No N/A				
Please provide details of issue(s) log	gged on the risk register:				

Version: 2019

Version: 2019

Review: 2020



## Audit title: Re-audit of spinal deformity practice

Level 1 – External 'must do'

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do'  Le	vel 2 'Internal 'must do'		
Criteria	Tick all that ap	oply Score	
High cost	Υ	(x3)	
High volume		(x2)	
High risk	Y	(x3)	
Known quality issue		(x3)	
Wide variation in practice	Υ		
NICE / NCEPOD related audit	Υ	(x3)	
Defined measurable standards available	Υ		
Re-audit / repeat service evaluation	Υ	(x2)	
Topic is a key clinical interest for the department /	division	(x2)	
Multidisciplinary project			
National / regional or multicentre project		(x2)	
Total	13	Lvl 3 Cat A	
Priority levels and audit team support			
Driority lovel	Priority score		

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

Review date: 2021 Version 2019

Ref No: - F	Project Type: - Clinical Audit ☐ Service Evaluation ☐
Audit / Service Evalua	tion Title: Re-audit of spinal deformity practice
<b>Division:</b> Neurology □	Neurosurgery $\ oxtimes$ Please specify department $Click$ here to enter text.
Project Lead:	
Contact No: Bleep N	o: Click here to enter text.
Email address:	
Audit / service evalua	tion supervisor:
-	nvolved / project team members details and roles within the project eg data collection, analysis etc.)
Background / Rationa Re-audit of spinal deform	le ity practice (first done in 2018)
<u>Methodology</u>	
PROMs and complication	s survey
Aims / Objectives To compare local practi	ice to international standards and highlight areas of improvement or strengths
Standards / Criteria D	etails (service evaluation N/A)
COMi scores	
Guideline / Standards	available: Yes ⊠ No □
If yes, please attach a d	copy or provide web link to the most current version: Click here to enter text.
Name of Standard / gu	uideline: Click here to enter text.
Source of Standard / g Trust □ C	guideline: NSF □ NICE ⊠ Royal College □  Other ⊠ State other: British Scoliosis Society
Review/assessment o Yes ⊠ No □	f guideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / service e	valuation issue: Yes □ No ⊠
High risk	Yes ⊠ No □
High cost	Yes ⊠ No □
Known quality issue	Yes □ No ☒
Wide variation in practi	ce Yes⊠ No□

Sample No: Click here to enter text. Procedure codes to identify sample: Click here to enter text.

http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size

Are you planning to publish your audit/service evaluation findings nationally				
(e.g. Medical journal)? Yes ⊠ No □				
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes ⊠ No □	J			
s this project part of an agreed departmental rolling programme? Yes □ No ☒				
Rolling programme duration (number of years): Click here to enter text.				
Rolling programme frequency: Monthly $\square$ Quarterly $\square$ Biannually $\square$ Annually $\square$				
Multidisciplinary: □ Single disciplinary: □				
Is Clinical Audit Team support required? Yes □ No ☑  If yes, please specify type of assistance required:  ◆ Population Identification □  ◆ Design of data collection tool □  (If not required please, attach a copy of the tool to be used)  ◆ Database design □  ◆ Data entry □  ◆ Analysis □  ◆ Presentation □  Collection of case notes □ Total number / per week				
Patient Contact / Involvement - (If project involves patient contact that is <u>not</u> part of the patients usual treatm or care please explain how in this section) Will the audit involve direct patient contact?  Yes □ No ☒	— ent			
How will the patient be involved?				
Patient Questionnaire    At clinic appointment				
Other (please give details) Click here to enter text.				
Has approval been sought from the Patient Information Panel? Yes $\square$ No $\square$ N/A $\boxtimes$				
Anticipated start date:as approved				
Anticipated project completion date: one month				
Anticipated Action Plan Submission date:Sept 2020				

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.
Is this topic a key clinical interest for the department / division?	Yes □	No □



## Clinical Audit / Service Evaluation Registration Form

#### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

## **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service Eval	uation Title: Omission of critical medicines in intensive care
Division: Neurology	☐ Neurosurgery ☒ Please specify department:
Project Lead:	
Contact No: - Blee	p No:
Email address:	
Audit / service evalu	uation supervisor:
	involved / project team members details es and roles within the project eg data collection, analysis etc.) xt.
Background / Ration Methodology Aims / Objectives Standards / Criteria	nale  Details (service evaluation N/A)
Please see attached	
Guideline / Standard	ds available: Yes ⊠ No □
If yes, please attach a	a copy or provide web link to the most current version: Medicines Policy
Name of Standard /	guideline: Section 3.3 of Medicines Policy (Critical Medicines and Missed Doses)
Source of Standard  Trust	
Review/assessment Yes ⊠ No □	of guideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / service High volume High risk High cost Known quality issue Wide variation in prac	Yes □ No ☒ Yes ☒ No □ Yes □ No ☒ Yes □ No ☒
Sample No: Weekly	for 6-8 weeks Procedure codes to identify sample: Click here to enter text.
http://www.raosoft.co	m/samplesize.html - link to tool that may be used to calculate sample size
Are you planning to	publish your audit/service evaluation findings nationally
(e.g. Medical journal)	

Is this a re-audit or if service evaluation, has service been reviewe	ed previously? Yes □ No 🏻
Is this project part of an agreed departmental rolling programme?	Yes □ No ☒
Rolling programme duration (number of years): Click here to enter	text.
Rolling programme frequency: Monthly □ Quarterly □ Biannu	ually □ Annually □
Multidisciplinary: $\square$ Single disciplinary: $\square$	
Rolling programme duration (number of years): Click here to enter	text.
Is Clinical Audit Team support required? Yes ☐  If yes, please specify type of assistance required:  Population Identification ☐  Design of data collection tool ☐  (If not required please, attach a copy of the tool to be used)  Database design ☐  Analysis ☐  Presentation ☐  Collection of case notes ☐  Total number _	No ⊠ / per week
Patient Contact / Involvement – (If project involves patient contact that or care please explain how in this section) Will the audit involve direct patient contact?  Yes	is <u>not</u> part of the patients usual treatment  No ⊠
How will the patient be involved?	
Patient Questionnaire   At clinic appointment	
Other (please give details) Click here to enter text.	
Has approval been sought from the Patient Information Panel?	Yes □ No □ N/A ⊠
Anticipated start date: August 2020	
Anticipated project completion date: October 2020	
Anticipated Action Plan Submission date: November 2020	
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL TO THE CLINICAL AUDIT TEAM.</li> </ul>	ASE ATTACH A COPY OF THE
Departmental Clinical Audit Lead (Signature)	Date: Click here to enter text.
Comments Click here to enter text.	
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.
Is this topic a key clinical interest for the department / division?	Yes ⊠ No □



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 304

Clinical Audit Title	Title Omission and delay of critical medicines in neurocritical care		
Date audit complete	25/11/20 Date action plan completed 12/01/21		
Auditor		Name of policy / guideline	Medicines Policy
Division	Pharmacy	Source of policy / guideline	Trust intranet

#### **Summary of Findings:**

- From 2173 doses of critical medicines reviewed, 37 (1.7%) inappropriately omitted or delayed
- Majority of delayed critical medicines were stat doses, which on average were delayed by 2 hours and 5 minutes
- Majority of omitted critical medicines were due to lack of documentation (i.e. not signed for as given, or no reason for omission documented)

#### **Key success:**

- Rate of omission/delay lower compared to other ICUs/Trusts according to literature
- No patients came to any harm from any of the delayed/omitted critical medicines
- No delays/omissions secondary to failure to adhere to neurosurgical post-operative instructions identified

### **Key concerns:**

- Poor documentation accounting for large proportion of inappropriately omitted critical medicines
- Neurosurgical administration of intrathecal antibiotics contributing largely to delayed critical medicines
- Need for awareness within nursing staff of which medicines deemed critical, and communication between prescribers and nurses re. stat doses

## Recommendations discussed:

- List of critical medicines to be incorporated into each patient's bedside folder
- Pharmacy bulletin to be emailed to Horsley staff and included in Horsley internal newsletter summarising audit findings and outcomes
- Pharmacy or medicines-related inductions for new nurses and doctors to be updated based on findings/concerns
- Senior nurse for clinical governance currently recruiting nurse to undertake re-audit 6-monthly (pharmacists to contribute to data analysis)
- ACCP previously agreed to undertake administration of intrathecal antibiotics on Horsley and are awaiting training and sign-off

## **Presentation / Dissemination of Project**

Date findings were presented / disseminated: Presented to Safer Medicines Group (05/01/21) and ITU Operational Group (12/01/21) Department where discussed or presented: as above

Version: 2019

Review: 2020

# Actions agreed following recommendations discussed:-

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
Raise awareness of critical medicines	List of critical medicines to be incorporated into each patient's bedside folder	Tor dollor	2 months	Printed in end-of-bed folder	(group/mooting)
Raise awareness of issues leading to inappropriate omission/delay of critical medicines	Pharmacy bulletin to be emailed to Horsley staff and included in Horsley internal newsletter summarising audit findings and outcomes		1 month	Pharmacy bulletin	
	Include audit findings/concerns in pharmacy-led induction for new doctors/nurses		3 months	Presentation	
3) Monitor progress following actions listed above	Re-auditing 6-monthly (with view to decrease frequency after 1 year)		6 months	Re-audit results	
Re-audit date Planned for April 2021	If no re-audit planned please give re	asons why?			
Will this be an on-going audit? Ye	s 🛭 No 🗌				
Are there any potential barriers / pro	olems to prevent the implementation of the	ne above actions	? Yes 🗌 No	o 🛛	
If yes to the above please state who	If yes to the above please state who the issues have been referred to:				
Name	Designation	_ Date referre	d		
Signature: Date: 12/01/21					
Have any issues been logged on the risk register? Yes □ No ⊠ N/A □					
Please provide details of issue(s) logged on the risk register:					

Version: 2019

Review: 2020



## Audit title: GlobalSurg/CovidSurg Week

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Inte	ernal 'must do'	
Criteria	Tick all that apply	Score
High cost		(x3)
High volume	Υ	(x2)
High risk	Υ	(x3)
Known quality issue		(x3)
Wide variation in practice		
NICE / NCEPOD related audit		(x3)
Defined measurable standards available		
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	5	Lvl 5 Cat B

## Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

## Clinical Audit / Service Evaluation Registration Form

#### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

## Service evaluation

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- · the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

### **Clinical Audit**

Measures existing practice against best practice, evidence based clinical standards (this may include Royal College, British Association, NICE or Local guidance etc.)

#### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

> Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service Eva	luation Title: GlobalSurg/CovidSurg Week
Division: Neurology	√ □ Neurosurgery ⊠ Please specify department <b>All neurosurgery subspec</b>
Project Lead:	
Contact No: B	leep No: N/A
Email address:	
Audit / service eval	uation supervisor:
-	s involved / project team members details nes and roles within the project eg data collection, analysis etc.)
Background / Ratio	onale_
1005 hospitals in 8 published in The L outcomes of surge show that surgery	ovidSurg project lead by Birmingham has entered data for 35,840 patients, from 36 countries. Results from the first analysis (including Walton data) has been ancet this month. The CovidSurg Cohort study has demonstrated the adverse by in SARS-CoV-2 infected patients. Early signals from CovidSurg-Cancer study following SARS-CoV-2 infection is associated with poor outcomes, even if weeks after initial diagnosis. However, more granular data are needed to
<u>Methodology</u>	
require data input	Surg Week is an international multi-centre prospective cohort study which will onto the online platform RedCap during a specified week in November 2020. A ed to this application.
Aims / Objectives	
• •	optimal timing for surgery in patients previously infected with SARS-CoV-2 global surgical indicators, such as perioperative mortality rates
Standards / Criteria	a Details (service evaluation N/A)
Clavien-Dindo grade. The evaluated in the contest.	at 30 days, 30 day pulmonary complications, 30 day venous thromboembolism, and 30 day These are routinely collected and auditable criteria for surgical patients, but will be specifically ext of previous COVID, COVID after surgery, and no COVID which will also be uploaded to the efore, no specific guideline exists for this purpose.
Guideline / Standa	rds available: Yes □ No ⊠
If yes, please attach	a copy or provide web link to the most current version: Click here to enter text.
Name of Standard	guideline: Not applicable

Source of Standard / guideline: NSF  $\square$  NICE  $\square$ 

Royal College

Trust □ Othe	State other: Click here to enter text.
Review/assessment of gu	uideline/standard undertaken to ensure it is appropriate & can be measured
Is the audit / service evaluation High volume High risk High cost Known quality issue Wide variation in practice	Yes ⋈ No □ Yes ⋈ No □ Yes □ No ⋈ Yes □ No ⋈
Sample No: Unknown Pr	ocedure codes to identify sample: Not necessary
http://www.raosoft.com/san	mplesize.html - link to tool that may be used to calculate sample size
Are you planning to publ	ish your audit/service evaluation findings nationally
(e.g. Medical journal)?	Yes ⊠ No □
Is this a re-audit or if serv	vice evaluation, has service been reviewed previously? Yes □ No ⊠
Is this project part of an a	agreed departmental rolling programme? Yes □ No ☒
Rolling programme durat	tion (number of years): Click here to enter text.
Rolling programme frequ	ency: Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary:	Single disciplinary: ⊠
Is Clinical Audit Team su If yes, please specify type of Population Identification Design of data collection (If not required please, atta Database design Data entry Analysis Presentation Collection of case notes	of assistance required: □
Patient Contact / Involver or care please explain how in Will the audit involve dire	,
How will the patient be in	volved?
Patient Questionnaire	□ At clinic appointment □
Other (please give details) Cl	ick here to enter text.
Has approval been sough	nt from the Patient Information Panel? Yes □ No □ N/A ⊠
Anticipated start date: Oc	ctober 2020

Anticipated project completion date: November 2020

Anticipated Action Plan Submission date: May 2021

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE not yet released.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □	



Audit title: Primrose – A national prospective observational study in breast cancer patients with central nervous system involvement in the UK

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do'   Level 2 'Internal 'must do'				
Criteria	Tick all that apply	Score		
High cost	у	(x3)		
High volume		(x2)		
High risk		(x3)		
Known quality issue	у	(x3)		
Wide variation in practice	У			
NICE / NCEPOD related audit	у	(x3)		
Defined measurable standards available	У			
Re-audit / repeat service evaluation		(x2)		
Topic is a key clinical interest for the department / division		(x2)		
Multidisciplinary project				
National / regional or multicentre project	У	(x2)		
Total	13	Lvl 3 Cat A		

## Priority levels and audit team support

If the project is mandatory please specify what priority level:-

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

## Clinical Audit / Service Evaluation Registration Form

#### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

## Service evaluation

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- · the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

### **Clinical Audit**

Measures existing practice against best practice, evidence based clinical standards (this may include Royal College, British Association, NICE or Local guidance etc.)

#### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

> Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
	valuation Title: Primrose – A national prospective observational study in breast vith central nervous system involvement in the UK
Division: Neurolog	gy □ Neurosurgery ৷ Please specify department <b>Neuro-Oncology</b>
Project Lead:	
Contact No: Ble	ep No:
Email address:	
Audit / service ev	aluation supervisor:
Other profession	als involved / project team members details
Background / Rat	<u>tionale</u>
prospective databadiagnosed CNS inv	use the trainee collaborative model to establish an observational ase that will aim to prospectively register all patients with newly olvement secondary to BC in the UK, and to collect data relating to nosis, management and outcome.
Methodology	
steering committe histological confirm The anonymous do neurosurgical cent participate in the study through	we multicentre audit co-ordinated by members of the PRIMROSE e, and will aim to register and collect data on patients with med locally advanced or metastatic BC who meet the entry criteria. The ata will be collected in a central database. All oncological and the ures in the UK treating BC or CNS disease will be eligible to the uture. Trainees from across the UK will be invited to participate in the National Research Collaborative network and other relevant s. Full details in attached protocol.
Aims / Objectives	
Secondary Objection nervous system in management of CN NICE guidelines for NCCN guidelines (vtreated for BC-relation of the secondary of the s	To report the survival of patients diagnosed with CNS disease secondary to BC ves: 1. To define the incidence of metastatic breast cancer (MBC) involving the central the UK. 2. To prospectively describe the current practice in diagnosis, staging and IS disease secondary to BC in relation to national and international guidelines including the the management of brain metastases in adults (NG99, July 2018), EANO (2017) and the ersion1.2018 Central Nervous System Cancers). 3. To evaluate the outcomes of patients ted CNS metastases in the UK. 4. To generate data to help guide best practice guidelines in orm and help in the development of potential prospective studies and clinical trials
Standards / Crite	ria Details (service evaluation N/A)
As detailed above	
Guideline / Stand	ards available: Yes ⊠ No □

If yes, please attach a copy or provide web link to the most current version: Click here to enter text.

Name of Standard	guideline: No	т аррисавіе			
Source of Standard Trust □	/ guideline: Other ⊠	NSF □ State other: EA	NICE ⊠ NO and NCCN	Royal College	
Review/assessment	t of guideline/	standard under	taken to ensure it is	appropriate & can be ı	measured
Is the audit / service High volume High risk High cost Known quality issue Wide variation in prac	Yes   Yes   Yes	□ No ⊠			
Sample No: Unknov	vn Procedure	codes to identi	fy sample: Not nec	essary	
http://www.raosoft.co	<u>m/samplesize</u>	.html - link to tool	that may be used to	calculate sample size	
Are you planning to	publish your	audit/service e	valuation findings n	ationally	
(e.g. Medical journal)	? Yes 🗵	□ No □			
Is this a re-audit or	if service eva	luation, has serv	vice been reviewed	previously? Yes □	No ⊠
Is this project part of	of an agreed c	lepartmental rol	ling programme?	Yes □ No ☒	
Rolling programme	duration (nur	nber of years): (	Click here to enter text.		
Rolling programme	frequency: N	/lonthly □ Qua	ırterly □ Biannuall	y □ Annually □	
Multidisciplinary:		Single o	lisciplinary: ⊠		
Is Clinical Audit Tea  If yes, please specify  ◆ Population Identif  ◆ Design of data co (If not required pleas)  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case no	type of assista fication ollection tool e, attach a cop	ance required:		No ⊠ _/ per week	
Patient Contact / Invorcare please explain will the audit involves	how in this secti	on)	patient contact that is $\underline{r}$	not part of the patients usua	al treatment
How will the patient	be involved?	•			
Patient Questionnaire	e □ At cl	inic appointment			

Other (please give details) Click here to enter text.

Has approval been sought from the Patient Information Panel?	Yes		No		N/A	$\boxtimes$
Anticipated start date:To be determined by Primrose team						
Anticipated project completion date: 2 years post-start						
Anticipated Action Plan Submission date:3 years post-start						
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUID</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD IN AUDIT TEAM.</li> </ul>	COPY	OF TH	IE PRE	VIOU	S AUDI	T OR SERVICE
Departmental Clinical Audit Lead (Signature)		ate:	Click l	nere 1	to ente	er text.
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)		ate:	Click l	nere 1	to ente	er text.
Is this topic a key clinical interest for the department / division?	Ye	s 🗆		Ν	lo □	



## Audit title: Audit on Anaesthetic management of elderly neuro surgical patients and outcome

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'					
Criteria	Tick all that apply	Score			
		( 2)			
High cost		(x3)			
High volume	у	(x2)			
High risk		(x3)			
Known quality issue		(x3)			
Wide variation in practice	у				
NICE / NCEPOD related audit		(x3)			
Defined measurable standards available	у				
Re-audit / repeat service evaluation		(x2)			
Topic is a key clinical interest for the department / division	у	(x2)			
Multidisciplinary project	у				
National / regional or multicentre project		(x2)			
Total	7	Lvl 4 Cat B			

## Priority levels and audit team support

If the project is mandatory please specify what priority level:-

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be
		negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

## Clinical Audit / Service Evaluation Registration Form

## **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

## Service evaluation

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

#### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### **Service Evaluation:**

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service Ev	aluation Title: Audit on Anaesthetic management of elderly neuro surgical ome
Division: Neurosu	urgery
Project Lead:	
Contact No: Blee	ep No: Click here to enter text.
Email address:	
Audit / service eva	aluation supervisor:
	als involved / project team members details mes and roles within the project eg data collection, analysis etc.)
Background / Rati	ionale_
complications eg AKI, outcomes and compa	high risk group for cranio-spinal surgery, carrying high mortality, higher risk of post op , CVS complications, delirium, sepsis etc. We plan to review our anaesthetic practice and patien are with the AAGBI guidelines for anaesthesia for elderly patients although there are no specific surgical patients available till date.
Methodology: Ref	trospective review of notes and blood results
2. To assess the	he outcomes of surgery both elective and emergency in > 80 year old patients he post op complication eg AKI and delirium, CVS/resp, sepsis etc. he length of stay and causes of delay discharge if any
	ia Details (service evaluation N/A) of the elderly, AAGBI
Peri operative care	of the elderly, AAGDI
Guideline / Standa	ards available: Yes ⊠ No □
https://doi.org/10.11	h a copy or provide web link to the most current version: 111/anae.12524 nes are for geriatric patients for general surgery, not for neuroanaesthesia
Name of Standard	I / guideline: Peri-operative care of the elderly 2014
	https://doi.org/10.1111/anae.12524

Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured

Source of Standard / guideline: AAGBI (Association of anaesthetists of Great Britain and Ireland)

Is the audit / service evaluat	ion issue: No
High volume	Yes ⊠ No □
High risk	Yes □ No ⊠
High cost	Yes □ No ⊠
. ,	Yes □ No ⊠
Wide variation in practice	res ⊠ Expected
Sample No: 150 Procedure	codes to identify sample: Click here to enter text.
http://www.raosoft.com/sample	esize.html - link to tool that may be used to calculate sample size
Are you planning to publish	your audit/service evaluation findings nationally
(e.g. Medical journal)? Y	es ⊠ No □
	e evaluation, has service been reviewed previously? No 🗵
	eed departmental rolling programme? No ⊠
	(number of years): Click here to enter text.
Rolling programme trequent	cy: Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary: ⊠	Single disciplinary: □
<ul> <li>If yes, please specify type of a</li> <li>◆ Population Identification</li> <li>◆ Design of data collection to (If not required please, attach )</li> <li>◆ Database design</li> <li>◆ Data entry</li> <li>◆ Analysis</li> <li>◆ Presentation</li> <li>Collection of case notes</li> </ul>	
Patient Contact / Involvement or care please explain how in this Will the audit involve direct	,
How will the patient be invol	ved?
Patient Questionnaire	At clinic appointment $\ \square$
Other (please give details) Click	here to enter text.
Has approval been sought fr	rom the Patient Information Panel? Yes $\square$ No $\square$ N/A $\boxtimes$
Anticipated start date: 01/09	
Anticipated project completi	on date: 30/04/21
Anticipated Action Plan Sub	mission date: 30/06/21

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: 3/0	08/20
<b>Comments</b> I fully support the planned Audit. This will enable us to revior the elderly perioperatively. In my opinion this fits in with the trust's or improving the care of the elderly. Apotential benefit of this will be to flagelderly leading to a wider review of hospital practice and potential imporpatients.	verall values g up any issu	and strategy for es concerning the
Divisional Clinical Audit Lead (Signature)	Date: Clic	ck here to enter text.
Is this topic a key clinical interest for the department / division?	Yes ⊠	No □



Audit title: Audit of Seizure Kits at the Walton Centre

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Internal 'must do'				
Criteria	Tick all that apply	Score		
High cost		(x3)		
High volume		(x2)		
High risk	Y	(x3)		
Known quality issue		(x3)		
Wide variation in practice				
NICE / NCEPOD related audit		(x3)		
Defined measurable standards available	Y			
Re-audit / repeat service evaluation		(x2)		
Topic is a key clinical interest for the department / division		(x2)		
Multidisciplinary project				
National / regional or multicentre project		(x2)		
Total	4	Lvl 4 Cat B		

## Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated
		and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

Ref No: -	Project Type: - Clinical Audit 🗵 Service Evaluation 🗆
Audit / Service Eval	uation Title: Audit of Seizure Kits at the Walton Centre
Division: Neurology	□ Neurosurgery   ☑ Please specify department Critical Care
Project Lead:	
Contact No: Bleep	No:
Email address:	
Audit / service evalu	uation supervisor:
	involved / project team members details es and roles within the project eg data collection, analysis etc.)

### **Background / Rationale**

Seizure Kits were introduced in 2018 at the Walton Centre in order to facilitate access to emergency antiepileptic drugs and equipment necessary for the treatment of patients with prolonged seizures. Surgical and Medical Response Team (SMART) led on the implementation of the kits across the Trust including decision on the contents, checklist for re-filling the bags by ward staff after use and procedure for date checking.

The new guideline for Status Epilepticus (SE) management at the Walton Centre was finalised and circulated in June 2020. Due to the change in practice the drug content of the Seizure Kits had to be updated to include additional medicines. This provided an opportunity to audit the management of Seizure Kits by ward staff.

### **Methodology**

All available seizure kits in the trust will be inspected on the day of the audit. Storage location, contents (including quantity and expiry date), labelling and presence of seal will be recorded and compared the checklist for re-filling of the seizure kits.

#### Aims / Objectives

The aim of this audit is to ensure that the Seizure Kits at the Walton Centre are managed according to established protocols.

The objectives of the audit are to ensure that Seizure Kits:

- Are stored safely and appropriately
- Have appropriate contents
- Are sealed and labelled with the shortest expiry date of the contents

The new SE guideline advises the use of IM midazolam (5mg/ml) as a third line benzodiazepine option. The availability of this formulation is restricted across the trust to Critical Care Area; however this formulation is available in the Intubation Kits which are supplied to wards by Pharmacy. Therefore the availability of the Intubation Kit will also be checked in order to ensure the access to the IM midazolam in an emergency situation.

## Standards / Criteria Details (service evaluation N/A)

It is expected that 100% of Seizure Kits in the Trust will be stored appropriately (Kit A in the emergency trolley and Kit B in a fridge), have the appropriate contents and are sealed and labelled with correct expiry date as per re-filling of seizure kits by ward staff checklist.

Guideline / Standards available: Yes ⊠ No □	
If yes, please attach a copy or provide web link to the most current version:	
Name of Standard / guideline: Checklist for re-filling of seizure kits.	
Source of Standard / guideline:       NSF       □       NICE       □       Royal College         Trust       ☑       Other       □       State other: Click here to enter text.	
Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be Yes $oxed{\boxtimes}$ No $oxed{\square}$	measured
Is the audit / service evaluation issue:  High volume Yes □ No □  High risk Yes □ No □  High cost Yes □ No □  Known quality issue Yes □ No □  Wide variation in practice Yes □ No □	
Sample No: all seizure kits available in the Walton Centre. Procedure codes to identify sample: <a href="http://www.raosoft.com/samplesize.html">http://www.raosoft.com/samplesize.html</a> - link to tool that may be used to calculate sample size	n/a
Are you planning to publish your audit/service evaluation findings nationally	
(e.g. Medical journal)? Yes □ No ⊠	
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes	□ No 🖾
Is this project part of an agreed departmental rolling programme? Yes ☐ No ☐	$\boxtimes$
Rolling programme duration (number of years): Click here to enter text.	
<b>Rolling programme frequency:</b> Monthly $\square$ Quarterly $\square$ Biannually $\square$ Annually $\square$	
Multidisciplinary: □ Single disciplinary: □	
Rolling programme duration (number of years): Click here to enter text.	
Is Clinical Audit Team support required? Yes □ No ☑  If yes, please specify type of assistance required:  ◆ Population Identification □  ◆ Design of data collection tool  (If not required please, attach a copy of the tool to be used)  ◆ Database design □  ◆ Data entry □  ◆ Analysis □  ◆ Presentation □  Collection of case notes □ Total number / per week	

Patient Contact / Involvement – (If project involves patient cor care please explain how in this section)	ontact t	hat is <u>r</u>	<u>ot</u> part c	f the pa	ntients usu	ual treatment
Will the audit involve direct patient contact?	Yes		No	$\boxtimes$		
How will the patient be involved?						
Patient Questionnaire $\Box$ At clinic appointment $\Box$						
Other (please give details) Click here to enter text.						
Has approval been sought from the Patient Information	Panel <sup>4</sup>	? Ye	s 🗆	No [	□ N/A	$\boxtimes$
Anticipated start date: Oct 2020						
Anticipated project completion date: Nov 2020						
Anticipated Action Plan Submission date: Dec 2020						
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL /	PATIENT	QUEST	IONNAIR	Ε.		
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEAS EVALUATION REPORT.</li> </ul>	SE ATTAC	СН А СО	PY OF TH	E PREVIO	OUS AUDIT	r or service
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL A AUDIT TEAM.</li> </ul>	AUDIT LE	AD BEF	ORE SUB	MISSION	I TO THE C	LINICAL
Departmental Clinical Audit Lead (Signature)		_	Date:	Click he	re to ente	r text.
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)		_	Date:	Click he	re to ente	r text.
Is this topic a key clinical interest for the department / d	livisior	1? \	′es □		No □	



Audit title: Deep Brain Stimulation Service during Covid-19

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify wha	t priority level:-
Level 1 – External 'must do'	Level 2 'Internal 'must do'

Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk		(x3)
Known quality issue		(x3)
Wide variation in practice		
NICE / NCEPOD related audit		(x3)
Defined measurable standards available		
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division	Y	(x2)
Multidisciplinary project	Y	
National / regional or multicentre project		(x2)
Total	3	Lvl 5 Cat C
	3	` ′

## Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ⊠
Audit / Service Eva	duation Title: Deep Brain Stimulation Service during Covid-19
Division: Neurology	$ u$ $\square$ Neurosurgery $\boxtimes$ Please specify department $Click$ here to enter text.
Project Lead:	
Contact No: B Email address:	leep No:
Audit / service eva	luation supervisor:
	s involved / project team members details nes and roles within the project eg data collection, analysis etc.)
Background / Ration We are keen to maint our service during the	ain and improve the quality of the Deep Brain Stimulation service, and in particular evaluate
Methodology	
them it- post, face to	tative. Patients will be asked after the review if they will participate and then we will give face or over the phone. We will follow IG guidance already obtained. We will be asking all ew (if we think it is appropriate) to participate for the next 4 months.
Aims / Objectives Establish the standard information and learn	I that the dbs service achieves, identify opportunities for improvement and share the ing
Standards / Crite	eria Details (service evaluation N/A)
NA	
Guideline / Standa	rds available: Yes □ No ⊠
If yes, please attach	a copy or provide web link to the most current version: Click here to enter text.
Name of Standard	/ guideline: NA
Source of Standard Trust □	d / guideline: NSF ☐ NICE ☐ Royal College ☐ Other ☐ State other: Click here to enter text.
Review/assessmer	nt of guideline/standard undertaken to ensure it is appropriate & can be measured

is the audit / service evail	
High volume	Yes □ No ☒
High risk	Yes □ No ☒
High cost	Yes □ No ☒
Known quality issue	Yes □ No ☒
Wide variation in practice	Yes □ No ⊠
Sample No: Click here to en	ter text. Procedure codes to identify sample: Click here to enter text.
Are you planning to publi	sh your audit/service evaluation findings nationally
(e.g. Medical journal)?	Yes □ No ⊠ potentially posters or presentations
Is this a re-audit or if serv	rice evaluation, has service been reviewed previously? Yes $\square$ No $\boxtimes$
Is this project part of an a	greed departmental rolling programme? Yes □ No ☒
Rolling programme durat	ion (number of years): ongoing
Rolling programme freque	ency: Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary:	Single disciplinary: □
Rolling programme durat	ion (number of years): ongoing
Is Clinical Audit Team sup If yes, please specify type of  ◆ Population Identification  ◆ Design of data collection (If not required please, attack  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case notes	of assistance required:
Patient Contact / Involver or care please explain how in Will the audit involve dire	,
How will the patient be in	volved?
Patient Questionnaire	☑ At clinic appointment □
Other <i>(please give details)</i> Cli	ck here to enter text.
Has approval been sough	t from the Patient Information Panel? Yes ⊠ No □ N/A □
Anticipated start date: as	ар
Anticipated project comp	letion date: TBC, possibly January 2021
Anticipated Action Plan S	ubmission date:

Clinical Audit Registration Form Version 3 - 2019

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	k here to enter text.	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes ⊠	No □	



Audit title: How has COVID-19 influenced the referral pattern within a physiotherapy spinal triage service?

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify what priority level:-				
Level 1 – External 'must do'	Level 2 'Internal 'must do'			

	(-2)
	(-2)
	(x3)
	(x2)
	(x3)
	(x3)
	(x3)
	(x2)
	(x2)
	(x2)
0	Lvl 5 Cat C
	0

### Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

Ref No: -	Project Type: - Clinical Audit  Service Evaluation x
	valuation Title: How has COVID-19 influenced the referral pattern within a pinal triage service?
Division: Neuros	urgery MCAS
Project Lead:	
Contact No: Blee	p No: N/A
Email address:	
Audit / service ev	valuation supervisor:
Other profession	als involved / project team members details

(Please provide names and roles within the project eg data collection, analysis etc.)

## **Background / Rationale**

MCAS (Musculoskeletal assessment service) which is a spinal Physiotherapy specialist-led triage service prior to COVID-19 saw all patients with spinal pain in face to face clinics. Where after assessment a decision was made as to where they should be referred to. Most commonly to Physiotherapy, Pain clinic, urgent root block injection clinic, Neurosurgery or discharged with advice. Since June 2020 following the COVID-19 outbreak the MCAS service resumed seeing the majority of patients via telephone consultation, with a few patients selected to attend a face to face clinic usually after an initial assessment via telephone consultation. My project is my dissertation for my MSc which I am studying at MMU where I am looking to see if there is a change in referral pattern for face to face consultations in 2019 to telephone consultations in 2020. I wish to evaluate the effectiveness of telephone consultations compared to face to face consultations in order to develop the MCAS service moving forward to inform as to whether to include telephone consultations as part of normal practice post COVID-19 pandemic. I will also look at patient satisfaction regarding telephone consultation compared to face to face consultations to help inform future practice.

#### Methodology

The electronic database of the Walton Centre will be examined to identify all new and revisit patients who attended an MCAS clinic who were referred to The Walton centre during August September and October in 2019. Prospective data is currently being collected by the MCAS practitioners for the months of August September and October 2020. The electronic data base will be examined also for the months of August September and October 2020 to ensure no clinics or patients were missed. If any patient outcomes are unclear, the letter for the patient will be manually searched to find the outcome.

Study design: Retrospective and prospective observational study

### **Participants**

- Adults (aged >16 years old)
- Seen in MCAS clinics referred to The Walton Centre.
- Patients with spinal pain with or without radicular pain

The data to be collected are patient demographics - age, sex and diagnosis.

Discharge destination i.e. where they were referred usually Pain clinic, neurosurgery, physiotherapy locally, back to GP for a change of medication, urgent nerve root block injection service or discharge with advice.

Whether a new patient or a revisit.

To identify the number of patients who required a face to face consultation and to determine the factors which made that decision

To include 2 questions asking the patients who were selected to attend a face to face clinic how satisfied they were with the telephone and face to face consultations.

Data will be initially transferred to an excel spreadsheet and then exported to SPSS Statistics where data analysis will be performed. Results will be analysed to identify if there are any changes to referral pattern of patients with spinal pain who attend the MCAS service comparing telephone consultations to face to face consultations and to determine the proportion of patients who require a face to face consultation.

## Aims / Objectives

To determine the changes in referral pattern from face to face consultations to telephone consultations.

To identify why patients are selected to attend a face to face clinic

To assess patient satisfaction of those patients who attended a face to face clinic following a telephone consultation.

## Standards / Criteria Details (service evaluation N/A)

Guideline / Standard	ls available:	Yes		No				
If yes, please attach a copy or provide web link to the most current version: Click here to enter text.								
Name of Standard / guideline: Click here to enter text.								
Source of Standard and Trust □	/ guideline: Other □	NSF State		lick here	NICE to enter t	ext.	Royal College	

eview/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured $_{\rm es}~\square$ No $\square$					
Is the audit / service evalu High volume High risk High cost Known quality issue Wide variation in practice	Yes □ No x Yes □ No x Yes □ No x Yes □ No x				
Sample No: 1200-1400 Pro August/September/October		tify sample: Pat	ients attendin	g MCAS clinics	during
http://www.raosoft.com/sam	plesize.html - link to to	ol that may be us	ed to calculat	e sample size	
Are you planning to publis	sh your audit/service Yes x No 🗆		ngs nationall	у	
ls this a re-audit or if servi	ce evaluation, has se	ervice been revie	ewed previou	sly? Yes □	No x
ls this project part of an aલ્	greed departmental re	olling programm	ne?	Yes □ No x	
Rolling programme duration	on (number of years):	: Click here to ente	er text.		
Rolling programme freque	ency: Monthly □ Qu	uarterly □ Biar	nnually 🗆 🛭 A	nnually □	
Multidisciplinary:	Single	disciplinary:	(		
Is Clinical Audit Team sup If yes, please specify type of  Population Identificat  Design of data collect (If not required please, attack  Database design  Data entry  Analysis  Presentation  Collection of case notes	f assistance required: tion ction tool	Yes   be used)  D  Total number	No er/ per w	x /eek	
Patient Contact / Involvem or care please explain how in to Will the audit involve direc	his section)	s patient contact th	aat is <u>not</u> part o □ No	f the patients usu X	al treatment
How will the patient be inv	olved?				
Patient Questionnaire	At clinic appointmer	nt 🗆			
Other (please give details) Clid	ck here to enter text.				
Has approval been sought	from the Patient Info	ormation Panel?	Yes □	No □ N/A	Х

**Anticipated start date: November 2020** 

**Anticipated project completion date: March 2020** 

Anticipated Action Plan Submission date: September/October 2020 or 2021 I wasn't sure

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □	



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS316

Clinical Audit Title	Has COVID-19 influenced the referral pattern within a tertiary physiotherapy spinal triage service.		
Date audit complete	31/05/2021	Date action plan completed	
Auditor		Name of policy / guideline	
Division	Neurosurgery	Source of policy / guideline	

#### Audit Rationale:

Please summarize the rationale of the audit for the members of the Clinical Audit Group (please limit to one or two sentences)

The Covid-19 pandemic forced healthcare to rapidly adopt telehealth into normal practice to prevent the spread of infection to patients and staff. The aim of this study was to determine if there was a change in referral pattern pre Covid-19 when all consultations were face-to-face compared to post Covid-19 when all consultations were telephone consultations.

## **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- Covid-19 influenced the referral pattern in a spinal tertiary Physiotherapy MCAS service
- A reduced number of patients were discharged post Covid-19 compared to the pre Covid-19 period.
- The number of follow up appointments increased post Covid-19
- The reasons for some patients to be seen face-to face post Covid-19 were to aid diagnosis (93.8%) and patient preference/request (6.2%)
- The numbers of patients seen post Covid-19 who were discharged were less than the pre Covid-19 group.

## Key success:

Please concisely state the key success identified by the project – if none identified please state N/A

- The study did conclude there was a change in referral pattern post Covid-19
- Some patients still wish to be seen face-to-face even if not considered necessary by the clinician, indicating some patients still wish to be seen face-to-face therefore in person consultations are still desired
- The study shows face-to-face consultations are still needed in some cases to aid diagnosis
- The study raises further questions as to which patients are more suited to telehealth consultations or face-to-face consultations, and should we be considering a more personal approach for the care of our patients and offering more patient choice in type of consultation.

Version: 2021 Review: 2022

## **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- The accuracy of data is not known as the patient outcomes are manually inputted into the system therefore, human error and quality of data cannot be guaranteed, although any missing data was hand searched by the auditor to improve the accuracy
- The results are limited to one hospital which is also a leading tertiary centre for spinal pain which may not be generalisable to other MCAS settings due to differences in populations e.g., socioeconomic status.
- More complex cases were triaged to MCAS post Covid-19 compared to pre Covid19 due to the increased waiting times for Neurosurgery, which could have influenced the referral pattern.
- Safety of telephone consultations versus face-to-face consultations regarding missed diagnosis is a concern.

#### **Recommendations discussed:**

Please concisely summarise the recommendations that were discussed following the completion of the project

- The use of telephone /telehealth consultations should be integrated into normal practice particularly as our patients are from a wide catchment area
- Patient choice of type of consultation should be considered
- The MCAS service at Walton should also consider video consultation as an alternative to face-to-face or telephone consultation

## **Presentation / Dissemination of Project**

Date findings were presented / disseminated:

Department where discussed or presented:

## Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)					
0)					
2)					

Version: 2021 Review: 2022

3)					
Re-audit date considerable amount of time. Time w	If no re-audit planned please give read ould have to be allocated to repeat the s	sons why? _This was service evaluation	the service eva	luation as part o	f my MSc. It took a
Will this be an on-going audit?	Yes □ No x□				
Are there any potential barriers / p	oblems to prevent the implementatio	n of the above action	s? Yes 🗌 N	o x	
If yes to the above please state wh	o the issues have been referred to:				
Name	<b>Designation</b> _MCAS Physiotherapis	st	Date re	eferred	
Signature:	<b>Date:</b> 28/05/1968				
Have any issues been logged on the Please provide details of issue(s) le		N/A 🗌			

Version: 2021 Review: 2022



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 317

Clinical Audit Title	Outcomes of patients with GBM treated at WCFT in 2019.  To evaluate the median survival time of patients who have undergone biopsy or surgery with Glioblastoma Multiforme at the Walton Centre.		
Date audit complete		Date action plan completed	
Auditor		Name of policy / guideline	
Division	Neurosurgery	Source of policy / guideline	

## **Summary of Findings:**

The audit looked at the outcomes for patients in 2019 and assessed the impact of various factors on the survival. The standard used for comparison was the median survival time as reported by NICE 2018, which was 14-18 months. The Shapiro-Wilk test of normality was p<.001, and therefore, this audit will comment on mean survival time instead.

The analysis revealed that the mean survival for patients with glioblastoma multiforme at the Walton Centre was 10.40 months (+/- 7.45).

Data collection included the following factors: age, gender, residence, intervention, use of 5-ALA, site of surgery, surgeon, IDH1 status, MGMT status, ATRX status and performance status. The factors that came back as statistically significant in individual Kaplan-Meier analysis (not accounting for confounding variables) were age, intervention, performance status and MGMT status. Increase in age correlates to a decrease in survival time (p=.047). Surgical intervention correlates to an increase in survival time (p<.001). Mean survival time for biopsy was 6.89 months versus 11.92 months for surgery. Better performance status correlates to an increase in survival time (p=.033). Methylated MGMT status correlates to an increase in survival time (p=.046). Mean survival time for unmethylated MGMT status was 9.19 months, versus 11.35 months for methylated MGMT status. Multivariate analysis using cox regression model, revealed female gender (p=0.29) and use of 5-ALA (p=.026) to have the most statistically significant correlation to a longer mean survival time.

## **Key success:**

- A reduction in variability between surgeons survival times.
- Consistent survival times between centres.

Key	con	cer	ns
-----	-----	-----	----

#### Recommendations discussed:

• To increase the use of 5-ALA in clinical practise alongside continuing holistic patient care

Version: 2019

Presentation / Dissemination of Project
Date findings were presented / disseminated: presented after oncology mdt Thursday 16 <sup>th</sup> Sept 2021
Department where discussed or presented:

## Actions agreed following recommendations discussed:-

\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

			ı		
Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1) Increase use of 5 ALA	Continue to support / suggest 5 ala use in neuroncology mdt	Tor dollors	Sept 2021	Improved use on further audit	(group/mounig)
Improve outcomes for tumour patients	Discuss treatments in MDT and increase enrolment into clinical trials		Discussed 16/09/21 at oncology MDT		
Re-audit date If	no re-audit planned please give reasons	why?we would	l plan to reaud	it in 2-3 yrs time.	
Will this be an on-going audit?	es X No 🗌				
Are there any potential barriers / pro	blems to prevent the implementation of the	ne above actions	? Yes 🗌 N	o 🗌	
If yes to the above please state who	the issues have been referred to:				
Name Designation Date referred					
Signature:	Date:				
Have any issues been logged on the	risk register? Yes  No No N/A				
Please provide details of issue(s) log	ged on the risk register:				

Version: 2019

Version: 2019



## **Project Prioritisation Assessment Tool**

**Audit title:** To evaluate the median survival time of patients who have undergone biopsy or surgery with Glioblastoma Multiforme at the Walton Centre.

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify what	priority level:-
Level 1 – External 'must do'	Level 2 'Internal 'must do'

Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk		(x3)
Known quality issue		(x3)
Wide variation in practice		
NICE / NCEPOD related audit		(x3)
Defined measurable standards available		
Re-audit / repeat service evaluation	Y	(x2)
Topic is a key clinical interest for the department / division	Y	(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	4	Lvl 4 Cat B

## Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
	<b>Evaluation Title:</b> To evaluate the median survival time of patients who have undergone with Glioblastoma Multiforme at the Walton Centre.
Division: Neurole	ogy □ Neurosurgery ⊠ Please specify department: MEDICAL STUDENT
Project Lead:	
Contact No: Bl	eep No:
Email address:	
Audit / service e	evaluation supervisor:
	nals involved / project team members details names and roles within the project eg data collection, analysis etc.) text.
Background / Ra	<u>ationale</u>
2017 with Gliobla	ducted in 2017 to look at the outcome of all patients treated at the Walton Centre during astoma, after which a plan was introduced to improve the overall care for these patients. It look at the outcome for the cohort in 2019 given the improved care plan.
<u>Methodology</u>	
them with the foll	ents with Glioblastoma diagnosed in 2019 using the electronic patient record and correlate owing data points: age, Welsh or English resident, biopsy or surgery, date of intervention, rgeon, IDH1, and MGMT status.
Aims / Objective	<u>es</u>
	o assess the outcome from treatment of patients with Glioblastoma at the Walton Centre rs that influence prognosis.
Standards / Crite	eria Details (service evaluation N/A)
The median survi	ival time for patients treated with Glioblastoma is 12-14 months according to the literature.
Guideline / Stan	dards available: N/A Yes □ No □
Name of Standa	rd / guideline:
Source of Stand Trust □	lard / guideline: NSF □ NICE □ Royal College □ Other □ State other: Click here to enter text.
<b>Review/assessn</b> Yes □ No □	nent of guideline/standard undertaken to ensure it is appropriate & can be measured
<b>Is the audit / ser</b> High volume High risk	rvice evaluation issue:  Yes □ No ⊠  Yes □ No ⊠

High cost Yes ☐ No ☒
Known quality issue Yes ☐ No ☒
Wide variation in practice Yes □ No ⊠
Sample No: about 100 Procedure codes to identify sample: Patient group identified from pathology records.
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size
And you release to a collision you and it for a construction findings maticulate.
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes □ No ⊠
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes $\boxtimes$ No $\square$
Is this project part of an agreed departmental rolling programme? Yes □ No ☒
Rolling programme duration (number of years): Click here to enter text.
Rolling programme frequency: Monthly $\square$ Quarterly $\square$ Biannually $\square$ Annually $\square$
Multidisciplinary: □ Single disciplinary: ⊠
<ul> <li>◆ Population Identification</li> <li>♦ Design of data collection tool</li> <li>⟨If not required please, attach a copy of the tool to be used⟩</li> <li>♦ Database design</li> <li>♦ Data entry</li> <li>♦ Analysis</li> <li>♦ Presentation</li> <li>Collection of case notes</li> <li>☐ Total number / per week</li> </ul>
Patient Contact / Involvement – (If project involves patient contact that is <u>not</u> part of the patients usual treatment or care please explain how in this section) Will the audit involve direct patient contact?  Yes □ No ⊠
How will the patient be involved?
Patient Questionnaire ☐ At clinic appointment ☐
Other (please give details) Click here to enter text.
Has approval been sought from the Patient Information Panel? Yes □ No □ N/A ⊠
Anticipated start date: Monday 5th October 2020
Anticipated project completion date: Monday 21st December 2020
Anticipated Action Plan Submission date: January 2021

• PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.

- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

			_
Departmental Clinical Audit Lead (Signature)	Date: 01/1	10/2020	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.		
Is this topic a key clinical interest for the department / division?	Yes ⊠	No □	



# **Project Prioritisation Assessment Tool**

**Audit title:** COVID-19 impact on UK neurosurgery activity – a national SBNS/BNTRC service evaluation study

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please speci	ify what priority level:-
Level 1 – External 'must do'	Level 2 'Internal 'must do'

Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk	Y	(x3)
Known quality issue		(x3)
Wide variation in practice	Y	
NICE / NCEPOD related audit		(x3)
Defined measurable standards available		
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	4	Lvl 4 Cat B

## Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated
		and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ☒
Audit / Service Eval SBNS/BNTRC servi	uation Title: COVID-19 impact on UK neurosurgery activity – a national ce evaluation study
Division: Neurology	□ Neurosurgery ⊠ Please specify department Click here to enter text.
Project Lead:	
Contact No: Bleep	No:
Email address:	
Audit / service evalu	uation supervisor:
-	involved / project team members details es and roles within the project eg data collection, analysis etc.)

## Background / Rationale

The Covid-19 pandemic has had an impact on neurosurgery services and activity across the UK. Several organisation and professional societies issued guidelines during the height of the pandemic. Several publications have reported very high mortality (~20%) for patients having surgery who then developed Covid-19 infection.[1, 2] These publications had very few neurosurgery patients and the data are therefore do not necessarily represent the realworld risk. The purpose of this service evaluation study is to capture high level surgical activity data from all UK neurosurgery units and has the backing of the SBNS and BNTRC. This investigator-led, non-commercial, noninterventional study is low risk.

## Methodology

Eligibility criteria: All patients undergoing neurosurgery (excluding isolated ICP for cranial trauma) between 1st April and 30th June in 2019 & 2020. Data for April 2020 will be put into Castor EDC, an online database custom built by the British Neurosurgical Trainees Research Collaborative. Castor EDC is a validated system approved by external auditors and complies with all applicable laws and regulations, including ICH E6 Good Clinical Practice (GCP), 21 CFR Part 11, EU Annex 11, General Data Protection Regulation (GDPR), HIPAA (US), ISO 9001 and ISO 27001. Data for the month of April 2020 will be analysed centrally and a peer-reviewed manuscript summarising activity will be published. In addition to this national project, locally we are extending data collection across May and June of 2020, and also collecting data for the equivalent period in the year prior 2019. Only anonymised data will be uploaded to the database. No patient identifiable data will be collected. We will collect data on: Age range, Sex (male / female), Type of admission (emergency / elective), Category of surgery (Cranial trauma (excluding ICP monitoring), Tumours (gliomas, metastases, meningiomas, others), Skull base (vestibular schwannoma, meningioma, others), Pituitary, Functional (DBS, SCS), Hydrocephalus, Paediatrics (use for all patients under 18 years), Spine), Pre-op Covid-19 infection (ves / no / not tested), Postop Covid-19 infection within 30 days (yes / no), Death due to Covid-19 (yes / no / not applicable / not known). Statistical analysis - Descriptive statistics will be generated to include baseline demographics, proportion of surgical categories, proportion of overall and SARS-CoV-2 infection related deaths.

### Aims / Objectives

- Determine the number of operated cases during April, May, June in 2019 & 2020
- Determine the number and timing of pre-op SARS-CoV-2 infections
- Determine the number and timing of post-op SARS-CoV-2 infections
- Establish baseline characteristics (age, sex, co-morbidities)

- Establish risk of mortality according to general scoring criteria for SARS-CoV-2 infection (4C score)[3]
- Determine the overall and SARS-CoV-2 related mortality.

N/A	
Guideline / Standards available: Yes □ No ⊠	
If yes, please attach a copy or provide web link to the most current ve	ersion: Click here to enter text.
Name of Standard / guideline: n/a	
Source of Standard / guideline: NSF □ NICE □  Trust □ Other □ State other: Click here to enter text.	□ Royal College □ <a href="https://ct.">ct.</a>
Review/assessment of guideline/standard undertaken to ensure $\mbox{\sc Yes} \ \square \ \mbox{\sc No} \ \square$	it is appropriate & can be measured
Is the audit / service evaluation issue:   High volume Yes □ No □   High risk Yes □ No □   High cost Yes □ No □   Known quality issue Yes □ No □   Wide variation in practice Yes □ No □	
Sample No: n/a Procedure codes to identify sample: n/a <a href="http://www.raosoft.com/samplesize.html">http://www.raosoft.com/samplesize.html</a> - link to tool that may be used	d to calculate sample size
Are you planning to publish your audit/service evaluation finding	gs nationally
(e.g. Medical journal)? Yes ⊠ No □	
Is this a re-audit or if service evaluation, has service been review	ved previously? Yes □ No 🛚
Is this project part of an agreed departmental rolling programme	? Yes □ No ☒
Rolling programme duration (number of years): n/a	
Rolling programme frequency: Monthly $\square$ Quarterly $\square$ Biann	ually   Annually
Multidisciplinary: $\square$ Single disciplinary: $\square$	
Is Clinical Audit Team support required?  If yes, please specify type of assistance required:  Population Identification  Design of data collection tool  (If not required please, attach a copy of the tool to be used)  Database design  Data entry  Analysis  Presentation	No ⊠

Collection of case notes    Total number	er/ per w	eek
Patient Contact / Involvement – (If project involves patient contact the or care please explain how in this section) Will the audit involve direct patient contact?  Yes	<u> </u>	the patients usual treatmen
How will the patient be involved?		
Patient Questionnaire		
Other (please give details) Click here to enter text.		
Has approval been sought from the Patient Information Panel?	Yes □	No □ N/A ⊠
Anticipated start date:ASAP		
Anticipated project completion date: 18th December		
Anticipated Action Plan Submission date: 6 MONTHS FROM ST NATIONAL TEAM RUNNING PROJECT	TART, PENDIN	NG RESULTS FROM
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT ( data points described above.)	QUESTIONNAIRE	<ul> <li>Not yet released formally,</li> </ul>
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH EVALUATION REPORT.</li> </ul>	HA COPY OF THE	PREVIOUS AUDIT OR SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEA AUDIT TEAM.</li> </ul>	AD BEFORE SUBM	IISSION TO THE CLINICAL
Departmental Clinical Audit Lead (Signature)	Date: CI	ick here to enter text.
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature) Date: Click here to enter		ick here to enter text.
Is this topic a key clinical interest for the department / division	? Yes □	No □
References		
COVIDSurg Collaborative (2020) Mortality and pulmonary complications of the control of the	ations in patient	s undergoing surgery with

- COVIDSurg Collaborative (2020) Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet (London, England). https://doi.org/10.1016/S0140-6736(20)31182-X
- 2. Lei S, Jiang F, Su W, et al (2020) Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine 21:100331
- 3. Knight SR, Ho A, Pius R, et al (2020) Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ 370:m3339



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 319

Clinical Audit Title	Service evaluation for the investigation and follow-up of subarachnoid haemorrhage patients with negative angiography					
Date audit complete	25/10/2020	Date action plan completed	20/03/22			
Auditor		Name of policy / guideline	Walton Centre NHS Foundation Trust SAH guidance			
Division	Neurovascular (surgery)	Source of policy / guideline	Trust guidelines			

## **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- There is significant heterogeneity in time interval and imaging modality chosen to investigate SAH patients with negative angiography
- <2% of angiogram-negative patients were found to have clinically relevant findings in the delayed setting (>4 weeks).
- No variables were significant predictors of detecting which patients would have clinically relevant findings on delayed imaging.
- MDT discussion will continue to be required in the follow-up of these patients until further prospective data is available.

## **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

- DSA is the highest yield modality for detecting clinically relevant findings in the setting of delayed angiography
- Perimesencephalic and 'perimesencephalic plus' patients have significantly better outcomes than others, and very few are found to have clinically relevant delayed diagnoses.
- 83% of clinically relevant findings identified at delayed angiography were found between 9 and 17 days after presentation, suggesting early repeat DSA may be of diagnostic benefit.

## Key concerns:

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

- The addition of long-term follow up data is not mandated by the guidance but is recommended and would therefore be a useful addition to future research from this database.
- The heterogeneity of this cohort means that MDT discussion will continue to be required in the follow-up of these patients until further prospective data is available.

#### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

- Continue MDT discussion for these patients in relation to delayed imaging
- There may be a greater role for early repeat DSA (2 weeks), as this interval scan had the highest detection rate for clinically relevant delayed diagnoses
- Addition of long-term data (6- and 12-month outcomes) to the centralised database would be beneficial, but at present is not feasible. May be

Version: 2019

suitable for future medical student projects.	
Presentation / Dissemination of Project Date findings were presented / disseminated: MDT 06/04/22; SBNS 15/04/21	
Department where discussed or presented: Neurovascular MDT; Neurosurgical dept.; SBNS Spring Meeting 2021	

Actions agreed following recommendations discussed:\*Please ensure each action has a named lead, timescale and reportable group stated on the action plan below. Please list the evidence of the action implementation e.g SOP, protocol, standardised template, presentation or meeting minutes etc

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
Long term outcome data collection	Not immediately actionable, nor mandatory; to consider collection of such data as potential project for medical students		n/a	Future medical student projects	Neurovascular MDT
Delayed imaging time interval	Continue prospective data collection; consider early repeat scans at 2 weeks		n/a		Neurovascular MDT
3)					
4)					
Re-audit date If no re-audit planned please give reasons why?Further prospective data required; date not set at present					
Will this be an on-going audit? Yes ☐ No X					
Are there any potential barriers / problems to prevent the implementation of the above actions? Yes \( \subseteq \text{No} \text{ X}					
If yes to the above please state who the issues have been referred to:					

Version: 2019

Name	Designation	Date referred
Signature:	Date:	
Have any issues been logged on the ris	sk register? Yes 🗌 No 🗌 N/A X	
Please provide details of issue(s) logge	ed on the risk register:	

Version: 2019



## **Project Prioritisation Assessment Tool**

**Audit title:** Investigation and follow-up of subarachnoid haemorrhage in patients with negative angiography at a tertiary centre

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify v	vhat priority level:-
Level 1 – External 'must do'	Level 2 'Internal 'must do'

Criteria	Tick all that apply	Score
High cost		(x3)
High volume	Y	(x2)
High risk		(x3)
Known quality issue		(x3)
Wide variation in practice	Y	
NICE / NCEPOD related audit		(x3)
Defined measurable standards available	Y	
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	4	Lvl 4 Cat B

## Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated
		and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

#### CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM

Ref No: -	Project Type: - Clinical Audit □	Service Evaluation ⊠		
Audit / Service Evaluation Title: Investigation and follow-up of subarachnoid haemorrhage in patients with negative angiography at a tertiary centre				
Division: Neurology [	$\sqsupset$ Neurosurgery $oxtimes$ Please specify	department Click here to enter text.		
Project Lead:				
Contact No: Bleep	No:			
Email address:				
Audit / service evalu	ation supervisor:			
•	involved / project team members es and roles within the project eg da			

### Background / Rationale

15% of subarachnoid haemorrhage are non-aneurysmal and are categorised according to the blood distribution on CT into perimesencephalic (pmSAH) and non-perimesencephalic bleeds. The pathological process underpinning each of these is unclear, but a significantly more favourable prognosis is associated with pmSAH. Determining a) whether or not to investigate these patients beyond initial angiography and b) with what imaging modality, is disputed. It is recommended that non-perimesencephalic cases undergo a second, delayed DSA (Euro Stroke Association, 2013) however a recent meta-analysis suggests that in fact a repeat DSA in this setting may be of greater risk than benefit. Clinicians may therefore opt for any of MRI, DSA or CTA, at any given period of time after presentation. Because of the wide variation in practice seen, current Trust guidance suggests that a 'case by case' approach discussed at MDT is appropriate. The MDT approach allows for comparison of different practices but is not necessarily the most efficient. At present no primary data from the centre has been analysed to determine a) the most frequently employed follow-up pathway b) the most efficient pathway or c) whether any risks are associated with the follow-up methods chosen.

#### Methodology

Data is already regularly input into Excel spreadsheets categorised by year and is therefore readily accessible. Yearly databases will be collated into a single SAH database for analysis and angiogram-negative patients will be identified within this. PACS will be used to determine which of the following were used in the follow-up of these patients: i) scan modality ii) time to delayed scan iii) number of delayed scans iv) yield of delayed scans v) complications associated with delayed scans. Data will be analysed and presented using SPSS v24.

#### Aims / Objectives

Determine which scan modalities and timings are most frequently employed in following-up angiogramnegative SAH patients at the Trust, comparing both yield and risks associated with these pathways. We aim to assess whether Trust guidance is followed for all non-perimesencephalic patients (i.e they receive at least 1 delayed DSA), and to establish whether an evidence-based pathway is possible for following up patients based on blood distribution.

#### Standards / Criteria Details (service evaluation N/A)

Trust guidance for following-up non-aneurysmal SAH revolves around a 'case by case' discussion at MDT at present, however non-perimesencephalic patients are advised to undergo at least 1 delayed DSA.

Guideline / Standards available: Yes 🗵 No 🗆	
If yes, please attach a copy or provide web link to the most current version: Walton Centre SAH guidanc on Trust intranet	Э
Name of Standard / guideline: Subarachnoid Haemorrhage Guidelines to Support Practice	
Source of Standard / guideline:       NSF       □       NICE       □       Royal College       □         Trust       ☑       Other       ☑       State other: European Stroke Association	
Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measu $_{\rm Yes}\ oxtimes\ $	red
Is the audit / service evaluation issue:  High volume Yes ☑ No ☑  High risk Yes □ No ☑  High cost Yes □ No ☑  Known quality issue Yes □ No ☑  Wide variation in practice Yes ☑ No □	
Sample No: Click here to enter text. Procedure codes to identify sample: Click here to enter text.	
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size	
Are you planning to publish your audit/service evaluation findings nationally	
(e.g. Medical journal)? Yes ⊠ No □	
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No □	₫
Is this project part of an agreed departmental rolling programme? Yes ☐ No ☒	
Rolling programme duration (number of years): Click here to enter text.	
<b>Rolling programme frequency:</b> Monthly □ Quarterly □ Biannually □ Annually □	
Multidisciplinary: □ Single disciplinary: □	
Is Clinical Audit Team support required? Yes □ No ☑  If yes, please specify type of assistance required:  ◆ Population Identification □  ◆ Design of data collection tool  (If not required please, attach a copy of the tool to be used)  ◆ Database design □  ◆ Data entry □  ◆ Analysis □  ◆ Presentation □  Collection of case notes □ Total number / per week	
Patient Contact / Involvement – (If project involves patient contact that is <u>not</u> part of the patients usual treatment or core places explain how in this section)	 nen
or care please explain how in this section)  Will the audit involve direct patient contact?  Yes □ No ☒	

How will the patient be involved?						
Patient Questionnaire						
Other (please give details) Click here to enter text.						
Has approval been sought from the Patient Information Panel?	Yes		No		N/A	$\boxtimes$
Anticipated start date:25/10/2020						
Anticipated project completion date: 05/11/2020						
Anticipated Action Plan Submission date:08/11/2020						
<ul> <li>PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUI collected and collated in an Excel spreadsheet; a blank copy of this is attached.</li> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A EVALUATION REPORT.</li> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD I AUDIT TEAM.</li> </ul>	ched COPY C	OF TH	E PRE	VIOUS	S AUDI	T OR SERVICE
Departmental Clinical Audit Lead (Signature)	Da	ate: (	Click h	nere t	o ente	er text.
Comments Click here to enter text.						
Divisional Clinical Audit Lead (Signature)	Da	ate: (	Click h	nere t	o ente	er text.
Is this topic a key clinical interest for the department / division?	Yes			Ν	lo 🗆	



## **Project Prioritisation Assessment Tool**

Audit title: 72 hours MRI for Glioma surgery

If the project is mandatory please specify what priority level:-

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

Level 1 – External 'must do' Level 2 'Inter	rnal 'must do'	
Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk		(x3)
Known quality issue	Υ	(x3)
Wide variation in practice	Υ	
NICE / NCEPOD related audit	Υ	(x3)
Defined measurable standards available	Υ	
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	8	Lvl 4 – Cat B

## Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4-9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type:	- Clinical Audit ⊠	Service Evaluation	า 🗆	
Audit / Service Eval	uation Title: 7	2 hours MRI for Gli	oma surgery		
Division: Neurology	□ Neurosurge	ry ⊠ Please specify	department Click	here to enter text.	
Project Lead:					
Contact No: Bleep	No:				
Email address:					
Audit / service eval	uation supervi	sor:			
Other professionals (Please provide nam				sis etc.)	
this reason it is recommon for prognostication and	evidence that ex mended an early d indication of ac	post-op MRI scan with djuvant therapies. Hov	n and without contras vever, extent of resect	outcome in glioma surget to assess the extent of tion will be difficult to as which can be misinterp	resection ssess on
<u>Methodology</u>					
Electronically assess MRI was performed v	•		nas between Dec 20	19 and Febr 2020 if p	ost-op
Aims / Objectives					
Compliance with NIC and formulate recom			ntify any departmen	tal difficulties in achie	ving this
Standards / Criteria	Details (servi	ce evaluation N/A)			
According to NICE g first 72 hours following	•	ient undergoing glio	ma surgery should h	nave a post-op MRI wi	thin the
Guideline / Standar	ds available:	Yes ⊠ No			
If yes, please attach https://www.nice.org.				o-for-glioma	
Name of Standard /	<b>guideline:</b> Brai	in tumours (primary) a	and Brain metastasis ir	adults – Section 1.3.7	
Source of Standard	/ guideline: Other □	NSF □ State other: Click he	NICE ⊠	Royal College	

Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured

Version 2019

Review date: 2021

Yes ⊠ No □
Is the audit / service evaluation issue:   High volume Yes No   High risk Yes No   High cost Yes No   Known quality issue Yes No   Wide variation in practice Yes No
Sample No: Click here to enter text. Procedure codes to identify sample: Click here to enter text.
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size
Are you planning to publish your audit/service evaluation findings nationally
(e.g. Medical journal)? Yes ⊠ No □
Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ☒
Is this project part of an agreed departmental rolling programme?  Yes □ No ☒
Rolling programme duration (number of years): Click here to enter text.
Rolling programme frequency: Monthly □ Quarterly □ Biannually □ Annually □
Multidisciplinary: ☐ Single disciplinary: ⊠
Is Clinical Audit Team support required? Yes □ No ☑  If yes, please specify type of assistance required:  ◆ Population Identification □  ◆ Design of data collection tool □  (If not required please, attach a copy of the tool to be used)  ◆ Database design □  ◆ Data entry □  ◆ Analysis □  ◆ Presentation □  Collection of case notes □ Total number / per week
Patient Contact / Involvement - (If project involves patient contact that is <u>not</u> part of the patients usual treatment or care please explain how in this section) Will the audit involve direct patient contact?  Yes □ No ☒
How will the patient be involved?
Patient Questionnaire
Other (please give details) Click here to enter text.
Has approval been sought from the Patient Information Panel? Yes $\square$ No $\boxtimes$ N/A $\square$
Anticipated start date:7/10/2020
Anticipated project completion date: 25/10/2020
Anticipated Action Plan Submission date: Click here to enter text.

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: 9/10	)/20	
Comments Click here to enter text.			
Divisional Clinical Audit Lead (Signature)	Date: Click	here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □	



#### Clinical Audit / Service Evaluation Action Plan

Ref no: 322

Clinical Audit Title	Review of overall activity regarding shunt admissions and procedure at WCNN during 01.04.2019 – 31.03.2020		
Date audit complete	01/12/2020	Date action plan completed	
Auditor		Name of policy / guideline	UK Shunt Registry
Division	Neurosurgery	Source of policy / guideline	UK Shunt Registry

### **Summary of Findings:**

Please concisely state the main conclusions of the project using bullet points

- The primary finding of this audit is that reporting of local procedure data to UKSR through Orion has significantly improved and is close to 100%.
- Where under-reporting was found, this has been highlighted to the clinical outcomes team and Orion records are being updated. These under-reporting may be attributed to the limitations of retrospective data collection.

### **Key success:**

Please concisely state the key success identified by the project – if none identified please state N/A

• Reporting of local procedure data to UKSR through Orion has significantly improved and is close to 100%. This is a significant improvement from previous audit completed by Anca Merla on 01/09/2019 which identified a serious failing in data reporting in WCNN

## **Key concerns:**

Please concisely state the key concerns identified by the project using bullet points—if none identified please state N/A

N/A

### Recommendations discussed:

Please concisely summarise the recommendations that were discussed following the completion of the project

• Shunt procedures completed from 2020 onwards will have been prospectively added onto the UKSR as outlined in the SOP; which will further increase compliance with reporting into the future.

Version: 2019

Presentation / Dissemination of Proj	iort				
Date findings were presented / dissem					
Sate manage were presented / diesem					
Department where discussed or preser	nted:				
	mendations discussed:- named lead, timescale and reportable group standardised template, presentation or mee		on plan below.	Please list the e	vidence of the action
Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)
1)					<b>3</b>
2)					
3)					
4)					
Re-audit date If onto Orion prospectively to further ens	no re-audit planned please give reasons ure no patient data is missed from inclusion	why? Shunt repo on this national re	orting is exceller egistry.	nt at WCFT and	data will be added
Will this be an on-going audit?	es 🗌 No 🛚				
Are there any potential barriers / pro	oblems to prevent the implementation of	the above actions	s? Yes 🗌 N	o 🛚	
If yes to the above please state who	the issues have been referred to:				
Name	Designation	Date referre	ed		

Version: 2019

Signature: Date:	
Have any issues been logged on the risk regis	er? Yes 🗌 No 🗌 N/A 🛛
Please provide details of issue(s) logged on th	e risk register:

Version: 2019



## **Project Prioritisation Assessment Tool**

**Audit title:** Review of overall activity regarding shunt admissions and procedure at WCNN during 01/04/19 – 30/09/19

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify w	hat priority level:-
Level 1 – External 'must do'	Level 2 'Internal 'must do'

Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk		(x3)
Known quality issue		(x3)
Wide variation in practice		
NICE / NCEPOD related audit		(x3)
Defined measurable standards available		
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
- · ·		
Total	n/a – Parts of form	
	incomplete	

## Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

## **CLINICAL AUDIT / SERVICE EVALUATION PROJECT REGISTRATION FORM**

Ref No: -	Project Type: - Clinical Audit ⊠ Service Evaluation □
Audit / Service Eval WCNN during 01/04/	<b>uation Title:</b> Review of overall activity regarding shunt admissions and procedure at 19 – 30/09/19
Division: Neurology	$\square$ Neurosurgery $\boxtimes$ Please specify department $Click$ here to enter text.
Project Lead:	
Contact No: Bleep	No:
Email address:	
Audit / service evalu	uation supervisor:
-	s involved / project team members details es and roles within the project eg data collection, analysis etc.)
procedures, revisions a 1.09.19, a number of m	nale leted at The Walton Centre NHS Foundation Trust shows significant under-reporting of shunt and complications to the national shunt registry. Since the initial audit was completed in neasures have been introduced to improve reporting. This re-audit will evaluate whether this porting standards and whether further measures are necessary.
<u>Methodology</u>	
locally stored data. R	assessing shunt records within the national Orion shunt registry and comparing this to tesults will be presented as frequencies. Finally, an analysis will be provided which wement/worsening of reporting standards since that last audit period. The period to be 01.04.19 to 30.09.19.
Aims / Objectives	
- Re-audit the re national shunt	eporting of shunt procedures, revisions, and complications at The Walton Centre to the registry.
Standards / Criteria	Details (service evaluation N/A)
Click here to enter text	
Guideline / Standard	ds available: Yes   No
If yes, please attach	a copy or provide web link to the most current version: Click here to enter text.
Name of Standard /	guideline: Click here to enter text.
Source of Standard Trust □	/ guideline: NSF □ NICE □ Royal College □ Other □ State other: Click here to enter text.
Review/assessment	t of guideline/standard undertaken to ensure it is appropriate & can be measured

Is the audit / service evaluation High volume High risk High cost	tion issue: Yes  No   Yes  No   Yes  No			
, ,	Yes □ No □			
Wide variation in practice Yes □ No □				
Sample No: Click here to ente	er text. <b>Procedure co</b>	des to identify sa	ample: Click here to	o enter text.
http://www.raosoft.com/samp	<u>lesize.html</u> - link to to	ol that may be use	ed to calculate san	nple size
Are you planning to publish	n your audit/service	evaluation findin	gs nationally	
(e.g. Medical journal)?	Yes □ No ⊠			
Is this a re-audit or if service			•	
Is this project part of an ag	•			□ No □
Rolling programme duratio				
Rolling programme frequer	ıcy: Monthly □ Qı	uarterly 🗆 Bian	nually 🗆 Annua	ally 🗆
Multidisciplinary:	Single	e disciplinary:	]	
Is Clinical Audit Team supp If yes, please specify type of  ◆ Population Identification  ◆ Design of data collection (If not required please, attach  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation Collection of case notes	assistance required: tool		No □	
Patient Contact / Involvement or care please explain how in the Will the audit involve direct	is section)	s patient contact tha Yes □		oatients usual treatment
How will the patient be invo	olved?			
Patient Questionnaire	At clinic appointme	nt 🗆		
Other (please give details) Click	here to enter text.			
Has approval been sought	from the Patient Info	ormation Panel?	Yes □ No	□ N/A ⊠
Anticipated start date: 01.1	0.2020			
Anticipated project comple	tion date: 01.12.2020	0		
Anticipated Action Plan Su	bmission date: 01.12	2.2020		

- PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.
- FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.
- PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Departmental Clinical Audit Lead (Signature)	Date: Click here to enter text.	
Comments Click here to enter text.		
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.	
Is this topic a key clinical interest for the department / division?	Yes □	No □



## **Project Prioritisation Assessment Tool**

Audit title: Lumbar Puncture Proforma – An Audit to Improve Patient Safety

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify what	priority level:-		
Level 1 – External 'must do'	Level 2 'Inter	nal 'must do'	
Criteria		Tick all that apply	Score
High cost			(x3)
High volume			(v2)

Criteria	Tick all that apply	Score
High cost		(x3)
High volume		(x2)
High risk	Y	(x3)
Known quality issue	Y	(x3)
Wide variation in practice	Y	
NICE / NCEPOD related audit		(x3)
Defined measurable standards available		
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
		, ,
Total	7	Lvl 4 Cat B

## Priority levels and audit team support

Priority level	Priority score	
Level 1 – External 'must do'	Category A	
Level 2 – Internal 'must do'	Category A	
Level 3 – High local priority	> 10	
Level 4 – Medium local priority	4 – 9	
Level 5 – Low local priority	< 4	

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

Ref No: - Project Type: - Clinical Audit ⊠ Service Evaluation □

Audit / Service Evaluation Title: Lumbar Puncture Documentation Audit

**Division:** Neurology ⊠ Neurosurgery ⊠ Please specify department Click here to enter text.

**Project Lead:** 

**Contact No: Bleep No:** Click here to enter text.

**Email address:** 

Audit / service evaluation supervisor:

Other professionals involved / project team members details

(Please provide names and roles within the project eg data collection, analysis etc.)

### **Background / Rationale**

Lumbar puncture is one of the most common procedures performed in the both neurology and neurosurgery. Despite being a relatively simple procedure, complications may arise including headache, persistent spinal fluid leak, brain herniation, bleeding, and infection. These complications are mostly preventable if proper pre-procedure, procedure and post-procedure checks and documentations are strictly adhered. In many areas of medicine and surgery, proformas have proved to increase the quality of documentation and often reminds the physician of checks to be done which were otherwise missed. This greatly improves the accuracy and consistence of service delivery for patients. In our trust, although we have a good LP protocol, documentation could sometimes be an issue. We do actually have 5 proformas in EP2 namely: Lumbar Puncture – Observations, Lumbar Puncture - Pre-Procedure Checks, Lumbar Puncture - Risk Assessment, Lumbar Puncture - Procedure / Post Procedure, Lumbar Puncture - Discharge Needs. However, these are not being used routinely by the doctors performing the LPs. This could potentially cause gaps in patient care and inability to perform the necessary check

### **Methodology**

This project will involve retrospective audit of documentation of previous lumbar punctures done in the trust using previous case notes from patients' charts. We will include auditing at least 20 previous LPs and see whether they adhered with the minimum documentation in EP2. The parameters that should be included in the documentation (mentioned in the Standards / Criteria Details below) will be checked.

A proforma that includes pre-procedure, within the procedure and post-procedure checks will then be developed. This will be a simple, single paged proforma that needs to be compiled in patient's notes or filled-up in EP2 to endure better documentation. This form will be produced and circulated for comments within the surgical medical and nursing groups and a new form then developed.

Doctors performing the lumbar punctures will be briefed with this proforma and education sessions will be conducted regarding the importance of documentation and safety check before, during and after the procedure. A post-implementation audit will be conducted after in at least 20 LPs to check improvements in practice of documentation.

### **Aims / Objectives**

To audit and improve the practice of documentation and safety checks of lumbar punctures in the trust and to introduce a proforma.

# Standards / Criteria Details (service evaluation N/A)

The following areas of best practice for lumbar were identified though thorough literature review and should be included in the proforma:

- 1. Pre-procedure checks: indication, any contraindications, imaging reviewed, anticoagulants/clotting reviewed, history, consent taken
- 2. Procedure checks: Patient position, sterility/skin preparation, anaesthetic type and dose, procedure site, needle size or type, number of attempts, opening pressure, CSF appearance, total volume taken, stylet reinserted prior to needle withdrawal
- 3. Post-procedure checks: Specimen sent for which test, any complications, did patient tolerate the procedure, post-procedure advice given
- 4. Signature Physician name and grade.

Guideline / Standards available	Yes		No	$\boxtimes$			
If yes, please attach a copy or pro	vide web	link to	the mos	t current	version: Clicl	k here to enter text	•
Name of Standard / guideline: C	lick here t	to enter t	text.				
Source of Standard / guideline: Trust □ Other □	NSF State	other: 0	Click here	NICE to enter	□ text.	Royal College	
Review/assessment of guideline Yes $\boxtimes$ No $\square$	e/standa	ard unde	ertaken	to ensui	re it is appro	opriate & can be	measured
3	□ No						
3	⊠ No						
High cost Yes		_					
Known quality issue Yes							
Wide variation in practice Yes	⊠ No	Ш					
Sample No: Click here to enter text	. Proce	dure co	des to	dentify s	sample: Clicl	k here to enter text	
Are you planning to publish you	ır audit/	service	evaluat	ion findi	ings nationa	ally	
(e.g. Medical journal)? Yes	$\boxtimes$	No □	]				
Is this a re-audit or if service ev	aluation	, has se	ervice b	een revi	ewed previo	ously? Yes 🗆	No ⊠
Is this project part of an agreed	departn	nental r	olling p	rogramn	ne?	Yes □ No 🗵	]
Rolling programme duration (nu	ımber o	f years)	: ongoin	g			
Rolling programme frequency:	Monthly	□ Q	uarterly	□ Bia	nnually 🗆	Annually □	
Multidisciplinary: ☐ Clinical Audit Registration Form Vers	on 3 - 20	•	e discipli	nary:			

Rolling programme duration (number of years):	: ongoir	ng					
Is Clinical Audit Team support required?  If yes, please specify type of assistance required:  Population Identification  Design of data collection tool  (If not required please, attach a copy of the tool to  Database design  Data entry  Analysis  Presentation  Collection of case notes		,	mber	No / per	□ week _		
Patient Contact / Involvement – (If project involves or care please explain how in this section) Will the audit involve direct patient contact?	s patien	t contac	ct that is	not part	of the pa	atients usu	ual treatmer
How will the patient be involved?							
Patient Questionnaire   At clinic appointmen	nt 🗆						
Other (please give details) Click here to enter text.							
Has approval been sought from the Patient Info	rmatio	n Pan	el? Ye	es 🗆	No [	□ N/A	$\boxtimes$
Anticipated start date: 1 November 2020							
Anticipated project completion date: March 202	<u> </u>						
Anticipated Action Plan Submission date: Dece	mber 2	2020					
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION	ON TOOL	/ PATIE	NT QUES	TIONNAI	RE.		
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATI EVALUATION REPORT.</li> </ul>	ONS PLE	ASE ATT	ACH A C	OPY OF T	HE PREVI	OUS AUDIT	OR SERVICI
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DI AUDIT TEAM.</li> </ul>	VISIONA	L AUDIT	LEAD BE	FORE SUI	BMISSION	I TO THE C	LINICAL
Departmental Clinical Audit Lead (Signature)				Date:	Click he	re to ente	r text.
Comments Click here to enter text.							
Divisional Clinical Audit Lead (Signature)				Date:	Click he	re to ente	r text.
Is this topic a key clinical interest for the depar	tment /	divisi	on?	Yes □		No □	

# **Project Prioritisation Assessment Tool**

Audit title: Generation of baseline audit data of meningioma patients treated at The Walton Centre NHS Foundation Trust.

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please specify v	what priority level:-
Level 1 – External 'must do'	Level 2 'Internal 'must do'

Criteria	Tick all that apply	Score
High cost		(x3)
High volume	Y	(x2)
High risk	Y	(x3)
Known quality issue		(x3)
Wide variation in practice	Y	
NICE / NCEPOD related audit		(x3)
Defined measurable standards available		
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	6	Lvl 4 Cat B

# Priority levels and audit team support

Priority level	Priority score
Level 1 – External 'must do'	Category A
Level 2 – Internal 'must do'	Category A
Level 3 – High local priority	> 10
Level 4 – Medium local priority	4 – 9
Level 5 – Low local priority	< 4

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

Ref No: -	Project Type: - Clinical Audit □ Service Evaluation ⊠
	uation Title: Generation of baseline audit data of meningioma patients treated a NHS Foundation Trust.
Division: Neurology	□ Neurosurgery ⊠ Please specify department Click here to enter text.
Project Lead:	
Contact No: Bleep	No:
Email address:	
Audit / service evalu	uation supervisor:
-	involved / project team members details es and roles within the project eg data collection, analysis etc.)

### **Background / Rationale**

Meningiomas are the most common intracranial tumour, but only in more recent years has there been interest even comparable to other intracranial tumours. The European Association of Neuro-Oncology published guidelines for the diagnosis and treatment of meningiomas in 2016, and while the guideline does not provide audit criteria per se, it provides a framework that suggests current best practice. This **service review** aims to generate baseline audit data for meningioma patients treated at The Walton Centre. In order to evaluate the service we provide, we first need to review how meningioma patients are treated at The Walton Centre.

### Methodology

This **service review** will be completed by populating an existing database built in Microsoft Access. The database contains tables that allow the following baseline data to be recorded:

Demographics and baseline co-morbidities

Details of patient's presentation at the time of diagnosis

Radiological details documenting number, location, size, and other imaging characteristics

Timeline summary of interventions (including surgery, SRS, radiotherapy)

Morbidity associated with surgical intervention (Surgical, neurological, medical)

Histopathological data from surgical patients

### **Aims / Objectives**

To populate a meningioma database with baseline audit data for the purposes of evaluating the service provided to meningioma patients at The Walton Centre.

# Standards / Criteria Details (service evaluation N/A) N/A Guideline / Standards available: No XYes If yes, please attach a copy or provide web link to the most current version: Click here to enter text. Name of Standard / guideline: n/a Source of Standard / guideline: **NSF** NICE Royal College Trust Other State other: Click here to enter text. Review/assessment of guideline/standard undertaken to ensure it is appropriate & can be measured Yes □ No □ Is the audit / service evaluation issue: Yes ⊠ No □ High volume High risk Yes ⊠ No □ High cost Yes □ No ☒ Known quality issue Yes □ No ☒ Wide variation in practice Yes ⊠ No □ Sample No: n/a Procedure codes to identify sample: n/a http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size Are you planning to publish your audit/service evaluation findings nationally No □ (e.g. Medical journal)? Yes ⊠ Is this a re-audit or if service evaluation, has service been reviewed previously? Yes ⊠ No □ Multiple meningioma databases have been built over the past 10 years at The Walton Centre, but they all concern a specific data point (for instance patients with seizures, or patients with incidental meningioma). This work proposes to record details for all meningioma patients, without stratification. Is this project part of an agreed departmental rolling programme? Yes □ No 🛛 However, once the database has been populated, we will propose further discussion regarding an annual update of the database in order to maintain a prospective meningioma database. Rolling programme duration (number of years): n/a **Rolling programme frequency:** Monthly \( \square \) Quarterly \( \square \) Biannually \( \square \) Annually \( \square \)

Single disciplinary:

Multidisciplinary:

Is Clinical Audit Team support required?  If yes, please specify type of assistance required:	Yes	$\boxtimes$		No			
<ul> <li>Population Identification</li> </ul>							
Design of data collection tool							
(If not required please, attach a copy of the tool to	be use	d)					
◆ Database design							
◆ Data entry							
♦ Analysis							
Presentation				,			
Collection of case notes	⊔ То	otal nun	nber 60	/ per w	еек		
Patient Contact / Involvement – (If project involves or care please explain how in this section)	s patien	t contac	t that is	<u>not</u> part	of the p	atients usı	ual treatment
Will the audit involve direct patient contact?		Yes		No	$\boxtimes$		
How will the patient be involved?							
Patient Questionnaire	nt 🗆						
Other (please give details) Click here to enter text.							
Has approval been sought from the Patient Info	rmatio	n Pane	el? Ye	es 🗆	No	□ N/A	$\boxtimes$
Anticipated start date:ASAP							
Anticipated project completion date: 18th Dece	mber						
Anticipated Action Plan Submission date: 6 MC NATIONAL TEAM RUNNING PROJECT	NTHS	FROM	STAR	Γ, PENI	OING R	ESULTS	FROM
PLEASE ATTACH A COPY OF YOUR DATA COLLECTIC above.	N TOOL	/ PATIE	NT QUES	TIONNAI	RE – Basi	c data poin	ts described
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATI EVALUATION REPORT.</li> </ul>	ONS PLE	ASE ATT	ACH A C	OPY OF T	HE PREV	IOUS AUDIT	OR SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DI AUDIT TEAM.</li> </ul>	VISIONA	L AUDIT	LEAD BE	FORE SU	BMISSIO	N TO THE C	LINICAL
Departmental Clinical Audit Lead (Signature)				Date:	Click he	ere to ente	r text.
Comments Click here to enter text.							
Divisional Clinical Audit Lead (Signature)				Date:	Click he	ere to ente	r text.
Is this topic a key clinical interest for the depar	tment	divisi	on?	Yes □		No □	

# **Project Prioritisation Assessment Tool**

**Audit title:** An assessment of patient outcomes following clipping of aneurysms previously treated with endovascular intervention

The below table provides a system for prioritising locally conceived projects and what level of clinical audit team resource should be offered / provided.

If the project is mandatory please	specify what priority level:-
Level 1 – External 'must do'	Level 2 'Internal 'must do'

Criteria	Tick all that apply	Score
High cost	Y	(x3)
High volume		(x2)
High risk	Y	(x3)
Known quality issue		(x3)
Wide variation in practice	Y	
NICE / NCEPOD related audit		(x3)
Defined measurable standards available		
Re-audit / repeat service evaluation		(x2)
Topic is a key clinical interest for the department / division		(x2)
Multidisciplinary project		
National / regional or multicentre project		(x2)
Total	7	Lvl 4 Cat B

Priority levels and audit team support

mornly receive area area teams completely			
Priority level	Priority score		
Level 1 – External 'must do'	Category A		
Level 2 – Internal 'must do'	Category A		
Level 3 – High local priority	> 10		
Level 4 – Medium local priority	4 – 9		
Level 5 – Low local priority	< 4		

Priority level	Audit team resource	
Level 1, 2 & 3	Category A – Full support	Full practical assistance offered
Level 4	Category B – Moderate support	Level of practical assistance will be negotiated and agreed with project lead
Level 5	Category C – Minimal support	Advice, registration and monitoring

Ref No:	_ <b>Project Type: -</b> Clinical Audit ☐ Service Evaluation ⊠			
Audit / Service Eval An assessment of pa endovascular interve	tient outcomes following clipping of aneurysms previously treated with			
Project Lead: Conta	act No: Bleep No:			
<b>Division:</b> Neurology ☐ Neurosurgery ⊠ Please specify department				
Email address:				
Audit / service evaluation supervisor: Supervisor signature:				
	involved / project team members details and roles within the project eg data collection, analysis etc.)			

## **Background / Rationale**

Endovascular treatment is the initial consideration for treatment of intracranial aneurysms. However, for some aneurysms with complex anatomy, clipping remains an option. Clipping of an aneurysm that has previously been treated with endovascular intervention is more challenging than primary clipping and is associated with increased risk of complications. We therefore aim to assess the outcomes and complications in patients who have had clipping with a previous history of coiling.

### **Methodology**

Retrospective analysis of all patient who received clipping of an aneurysm at the Walton Centre from 2005 to date.

For all patients, past imaging will be screened for evidence of endovascular treatment. If previous endovascular treatment found, patients to be included in the study.

Data to be collected:

- Patient demographics: age at clipping, gender, smoking Hx, Family Hx,
- Presentation (Incidental, symptomatic or ruptured)
- Coiled aneurysms details: location of aneurysm(s), endovascular treatment type, and recurrence
- Operative details: Clipped aneurysm location, clips used, obliteration of aneurysm intraoperatively, obliteration of aneurysm post-op on CTA/DSA
- Post-op complications including: stroke, seizures, CSF leak etc

## Aims / Objectives

Assess the outcomes for patients treated with clipping of intracranial aneurysms with a previous history of endovascular treatment to the same aneurysms.

Care Quality Commission: The CQC assess the quality and safety of the care provided, they will look at whether the service is:				
Safe ⊠ Effective ⊠ Caring □ Responsive to people's needs □ Well-led □				
* Please tick which category this audit /	service evaluation will fall i	nto *		
Service evaluation – no standards against	which to compare.			
Standards / Guidelines / Criteria to be me evaluation N/A)	easured by audit project (so	ervice		
Guideline / Standards available: Yes	□ No ⊠			
If yes, please attach a copy or provide web	link to the most current version	on:		
Name of Standard / guideline:				
Source of Standard / guideline: NSF College	NICE Other:	Royal		
Review/assessment of guideline/standa & can be measured Yes No	rd undertaken to ensure it is	s appropriate		
Is the audit / service evaluation issue:	High volume	Yes No		
	High risk	Yes ⊠ No		
	High cost	Yes ⊠ No		
	Known quality issue	Yes 🗌 No		
	Wide variation in practice	Yes ⊠ No		
http://www.raosoft.com/samplesize.html - link to tool that may be used to calculate sample size				
Sample No: Aim to catch all eligible patient	s Procedure codes to identif	y sample: L332		

Are you planning to publish your audit/service evaluation findings nationally (e.g. Medical journal)?				
Yes ⊠ No □				
Is this a re-audit or if service evaluation, has service been reviewed previously?  Yes No No				
Will this be an on-going audit/service evaluation? Yes ⊠ No □				
Multidisciplinary: Single disciplinary:				
Is Clinical Audit Team support required? Yes ⊠ No □				
If yes, please specify type of assistance required:  ◆ Population Identification				
◆ Design of data collection tool				
(If not required please, attach a copy of the tool to be used)  ◆ Database design   □				
◆ Database design     ◆ Data entry				
♦ Analysis				
♦ Presentation				
♦ Collection of case notes				
Total number of case notes – All eligible patients to be included, after screening of radiology				
Number to be collected per week – aim for 20 per week, following screening to identify eligible patients				
Patient Contact / Involvement				
Will the audit involve direct patient contact? Yes ☐ No ☒				
How will the patient be involved?  ◆ Patient Questionnaire				
Has approval been sought from the Patient Information Panel? Yes ☐ No ☐ N/A ☐				
Date submitted to Audit team: 15/10/2020 Anticipated start date: 22/10/2020				
Anticipated project completion date:				
Anticipated Action Plan Submission date:				
Proposer (Signature) Date Departmental Clinical Audit Lead (Signature)				
Comments				
Divisional Clinical Audit Lead (Signature) Date No				

PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT QUESTIONNAIRE.

FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH A COPY OF THE PREVIOUS AUDIT OR SERVICE EVALUATION REPORT.

PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEAD BEFORE SUBMISSION TO THE CLINICAL AUDIT TEAM.

Ref No: -	Project Type: - Clinical Audit X	Service Evaluation □			
Audit / Service Evaluation Title: Management and outcome of intracranial infections with frontal sinus or mastoid source.					
Division: Neurology	<b>Division:</b> Neurology □ Neurosurgery <b>X</b> Please specify department Click here to enter text.				
Project Lead:					
Contact No: Bleep No:					
Email address:					
Audit / service evaluation supervisor:					
Other professionals involved / project team members details (Please provide names and roles within the project eg data collection, analysis etc.)					

### **Background / Rationale**

Management of uncomplicated frontal sinusitis and mastoiditis is often conservative, a more aggressive approach is often advocated for frontal sinusitis and mastoiditis complicated by intracranial infection. It is possible that delayed surgical treatment of mastoiditis and frontal sinusitis may complicate the management of intracranial infection. This audit will appraise the current practice in the Walton Centre and aims to identify the potential risk factors for poor patient outcome and potential improvement for the pathway for this condition cared jointly with ENT.

### **Methodology**

- 1. Acquire list of all admitted patients from 2000 to 2020 diagnosed with the following (diagnostic codes attached):
  - a. Mastoiditis
  - b. Frontal Sinusitis
  - c. Intracranial Abscess/Empyema
- 2. Acquire list of all admitted patients who underwent the following procedures (operation codes attached):
  - a. Mastoidectomy
  - b. Drainage of Cerebral Abscess/Empyema
  - c. Sinus Infection Washout
- 3. Review imaging, case, and patient notes for:
  - a. Patient details (including co-morbidity, symptoms and timeline of presentation)
  - b. Timing of referral
  - c. Details and timing of Surgery (Neurosurgery and/or ENT procedure)
  - d. Antibiotics
  - e. Outcome
    - i. Mortality (30 day and 6 months)
    - ii. Organism Cultured
    - iii. Functional outcome
    - iv. Length of stay
    - v. Discharge location (home/care/local hospital)

### **Aims / Objectives**

Review management of intracranial infections with frontal sinus or mastoid source. Identify relationship between organism, timing of surgery and outcome, if potential delays to treatment could be improved.

### Standards / Criteria Details (service evaluation N/A)

Compare cases managed early vs. la	ite.							
Guideline / Standards available:	Yes	Х	No					
If yes, please attach a copy or provide <a href="https://www.entuk.org/sites/default/files/">https://www.entuk.org/sites/default/files/</a>								
Name of Standard / guideline: Britis	sh Soci	ety o	f Otology	Acute ma	stoiditis gu	ideline		
· ·	NSF State o	□ other:	British S	NICE ociety of C	□ tology	Royal Colle	ge	
Review/assessment of guideline/st $_{\rm Yes}$ X $_{\rm No}$ $\Box$	tandar	d und	dertaken	to ensure	e it is appr	opriate & can	be m	easured
Is the audit / service evaluation iss High volume Yes □ High risk Yes X High cost Yes X Known quality issue Yes X Wide variation in practice Yes X	No X No 🗆 No 🗆 No 🗆							
Sample No: Click here to enter text. P	roced	ure c	odes to	identify s	ample: Clic	k here to enter	text.	
http://www.raosoft.com/samplesize.ht	<u>tml</u> - lir	nk to 1	tool that	may be use	ed to calcu	late sample siz	ze	
Are you planning to publish your a	udit/o	orvio	o ovolua	tion findin	as nation	ally		
	iuuii/Si			illon illian	igs nation	ally		
, ,		No						v
Is this a re-audit or if service evalu	ation,	has	service I	oeen revie	wed previ	ously? Yes		No X
Is this project part of an agreed de	partme	ental	rolling p	orogramm	e?	Yes □ No	o X	
Rolling programme duration (number	ber of	years	s): Click h	ere to ente	r text.			
Rolling programme frequency: Mo	onthly		Quarterly	⊓ Bian	nually $\square$	Annually $\square$		
Multidisciplinary:		Sing	le discip	linary:	]			
Rolling programme duration (number	ber of	years	s): Click h	ere to ente	r text.			
Is Clinical Audit Team support required from the population Identification  ◆ Population Identification  ◆ Design of data collection tool  (If not required please, attach a copy  ◆ Database design  ◆ Data entry  ◆ Analysis  ◆ Presentation  Collection of case notes	ice req	uired	X  o be use  X	<b>X</b> d)  al number	No 30			

Comparisons of the management outcomes of patients with intracranial infections with frontal sinus or mastoid source jointly managed with ENT from guidelines and literature.

Patient Contact / Involvement – (If project involves patient or care please explain how in this section)	contact	that is	<u>not</u> part (	of the patients usual treatment
Will the audit involve direct patient contact?	Yes		No	X
How will the patient be involved?				
Patient Questionnaire				
Other (please give details):				
Has approval been sought from the Patient Information	Panel	<b>?</b> Ye	s 🗆	No X N/A X
Anticipated start date: 20/11/2020				
Anticipated project completion date: 20/05/2021				
Anticipated Action Plan Submission date: TBC				
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL /	PATIEN	r QUEST	TIONNAIR	RE.
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEA EVALUATION REPORT.</li> </ul>	SE ATTA	CH A CC	PY OF TH	HE PREVIOUS AUDIT OR SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT TEAM.</li> </ul>	AUDIT L	EAD BEI	FORE SUB	MISSION TO THE CLINICAL
Departmental Clinical Audit Lead (Signature)		_	Date:	Click here to enter text.
Comments Click here to enter text.				
Divisional Clinical Audit Lead (Signature)		_	Date:	Click here to enter text.
Is this topic a key clinical interest for the department /	divisio	n?	Yes □	No □

# Is it acute mastoiditis +/-periostitis/osteitis?

<u>Symptoms-</u> Otalgia/ headache/fever <u>Signs</u>

- 1. Protrusion of the pinna, loss of post-auricular sulcus (95-100%)
- 2. Post-auricular swelling (80-95%), erythema, mass or fluctuance
- Otoscopy (uni or bilateral findings) Posterior/superior canal swelling +/-bulging/ erythematous tympanic membrane +/- purulent discharge (30%) or normal otoscopy
- 4. Pyrexia (81%); less common if antibiotics

Outpatient

Admission

Medical Mx

**Imaging** 

Surgical Mx

# Admit + Baseline investigations

- 1. FBC, U&E, CRP
- 2. Blood cultures (if pyrexia)
- 3. Ear swab if discharge present

# Discharge (all criteria to be met)

- Swelling has resolved
- 2. No signs of complications
- Pyrexia settled, eating and drinking, no parental concerns and patient established on oral antibiotics.

# Medical management

- IV Ceftriaxone OD + IV Metronidazole TDS (or as per local guideline) If penicillin allergy discuss with Microbiology
- Microbiology advice for: antibiotic sensitivities/if deteriorating/ treatment duration /de-escalation from IV to PO therapy
- 3. Consider topical treatment: e.g. topical ear antibiotic drops e.g. Ciprofloxacin 2 drops TDS
- 4. 4 hourly vital signs and review by nursing staff, and regular observations by the medical team

# Indications for imaging

- Clinical findings suggesting extracranial complications (postauricular abscess, neck mass, CN deficits, retro-orbital pain, vertigo, nystagmus)
- Clinical findings suggesting intracranial complications persistent headache OR pyrexia (meningeal signs, CN deficits, focal neurology, altered consciousness)
- Severe illness or toxic appearance, persistent pain/malaise or AOM not responding to antibiotics
- 4. Failure to improve after 24hrs IV antibiotics

Discuss with microbiology +/- consider re-imaging

Yes

(contrast enhanced MRI petrous bones)

No

Improvement in 36-48 hours

# Contrast enhanced CT petrous bones and brain

NB: presence of opaque air cells in the mastoid antrum does not warrant urgent intervention in the absence of other signs \* see note 4 for details on imaging findings

No subperiosteal abscess

Continue medical management

If failure to improve after 24 hours consider surgical intervention +/- contrast enhanced MRI petrous bones

# Surgical management

Subperiosteal abscess

Myringotomy/ grommet + cortical mastoidectomy
NB: Send pus /tissue samples for microbiology and histology

# Other complications:

<u>Intracranial abscess</u>: seek Neurosurgical opinion + cortical mastoidectomy
<u>Neck abscess</u>: Incision and drainage of neck abscess + cortical mastoidectomy
<u>Venous sinus thrombosis</u>: seek Haematology opinion regarding anticoagulation + cortical mastoidectomy

<u>CNVII palsy/Gradenigo's syndrome:</u> myringotomy/ grommet + cortical mastoidectomy

# **OPERATION AND DIAGNOSIS CODES**

# **Operation Codes**

Mastoidectomy D10.1 – D10.9

Drainage Abscess D04.2

Mastoid Operation D12.1 – D12.9

Frontal Sinus E14.1 – E14.9

Maxillary Antrum E13.1 – E13.9

E16.1 - E16.9

E17.1 – E17.9

Drainage abscess A05.1

A41.2

A40.8 - A40.9

# **Diagnosis Codes**

 $Mastoiditis \qquad \qquad H70.0-H70.9$ 

Frontal Sinusitis J32.0 – J32.9

J01.0 - J01.9

Empyema G06.0, G06.2



#### Clinical Audit / Service Evaluation Action Plan

Ref no: NS 341

Clinical Audit Title	The use of suction drains in neurosurgery				
Date audit complete	04th Jan 2021	Date action plan completed	20 <sup>th</sup> April 2021		
Auditor		Name of policy / guideline	N/A, service evaluatiion		
Division	Neurosurgery	Source of policy / guideline	N/A, service evaluation		

# **Summary of Findings:**

- The use of drains, including suction drains in neurosurgery is individual preference-based, rather than scientific evidence-based.
- Furthermore, the use of suction drains has been associated with significant risks to patients, including sudden death.
- We presented 2 cases of unfortunate sudden deaths following uneventful cranioplasty procedures, both of which were associated with the use of a suction drain.
- We have reviewed the use of suctions drains at our institution following both craniotomy and cranioplasty procedures in 2016 and 2017 (the period over which our reported cases occurred). During this time, 1395 craniotomies and 51 cranioplasties were performed. Suction drains were used in 28 (2%) of craniotomies and in 9 (17.6%) of cranioplasties. We did not observe any sudden deaths following craniotomy when suction drains were used, and noted only the 2 fatalities after cranioplasty.
- We also reviewed the literature focusing on the benefits and risks in the use of suction drains, and discussed pathophysiological mechanisms underlying sudden death associated with their use.
- There is no substantial evidence to support the use of suction drains in neurosurgery. Furthermore, they have been associated with significant complications, including risk to life.

# Key success:

• Peer-reviewed manuscript describing these findings has been published.

### **Key concerns:**

• Our experience and literature review suggest that the risk of sudden death is disproportionately higher following cranioplasty.

### Recommendations discussed:

• We do not recommend the use of suction drains in cranial neurosurgery, and we strongly recommend against their use in cranioplasty procedures.

Version: 2019

Review: 2020

Presentation	/ Dissemination	of Project
riesellialion	/ Dissellillation	OI FIOIECE

Presentation / Dissemination of Project
Date findings were presented / disseminated: Manuscript published
Department where discussed or presented: Neurosurgeon's Consultant meeting

# Actions agreed following recommendations discussed:-

Issue	Action required	Named lead for action	Timescale	Evidence	Reportable to (group/meeting)	
Risk of sudden death is disproportionately higher following cranioplasty, strongly recommend against the use of suction drains	Change in practice – not to use suction drains		Completed		NS Risk and Governance	
	Publish results and feedback in the Neurosurgeon Consultants meeting		Completed		NS Risk and Governance	
Re-audit date	If no re-audit planned please give reasons	why?			·	
Will this be an on-going audit?	Yes ☐ No ⊠					
Are there any potential barriers / p	roblems to prevent the implementation of	the above action	s? Yes 🗌 N	o 🗌		
If yes to the above please state wh	o the issues have been referred to:					
Name	lame Designation Date referred					
Signature:	Date:					
Have any issues been logged on the	he risk register? Yes 🔲 No 🗌 N/A					
Please provide details of issue(s)	logged on the risk register:					

Version: 2019

Review: 2020



# Clinical Audit / Service Evaluation Registration Form

### **Clinical Audit definition**

Clinical Audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change. Aspects of the structure, processes and outcomes of care are selected and systematically evaluated against explicit criteria. Where indicated, changes are implemented at an individual, team or service level and further monitoring is used to confirm improvement in healthcare delivery.

# **Service evaluation**

Service Evaluation is undertaken to benefit those who use a particular service and is designed and conducted to define or judge current service. Your participants will normally be those who use the service or deliver it. It involves an intervention where there is no change to the standard service being delivered (e.g. no randomization of service users into different groups). This does not require ethical approval.

It is possible to use data collected from participants during a service evaluation for later research as long as:

- the data is completely anonymous;
- it is not possible to identify participants from any resulting report;
- use of the data will not cause substantial damage and distress

Please note that to complete this form your project <u>must be clinical audit or service evaluation</u>. If you are unsure whether your project is clinical audit, service review or research brief definitions are given below as a guide:

#### **Clinical Audit**

Measures existing practice against **best practice**, **evidence based clinical standards** (this may include Royal College, British Association, NICE or Local guidance etc.)

### Research

Generates new knowledge where there is no or limited research evidence available and which has the potential to be generalisable.

#### Service Evaluation:

Seeks to evaluate the effectiveness or efficiency of a new or existing service to help inform local decision making (has been also referred to as service review, benchmarking or a baseline audit). This includes patient or staff satisfaction surveys.

Ref No: -	Project Type: - Clinical Audit ☐ Service Evaluation ⊠
	uation Title: The historical use of suction drains after cranial neurosurgery at NHS Foundation Trust.
Division: Neurology	$\square$ Neurosurgery $\boxtimes$ Please specify department $Click$ here to enter text.
Project Lead: /Ajay	Sinha
Contact No: Bleep	No:
Email address:	
Audit / service evalu	uation supervisor:
-	involved / project team members details es and roles within the project eg data collection, analysis etc.)

# **Background / Rationale**

The use of drains after cranial neuro surgery, including suction drains is highly variable across neurosurgical units within the UK and other countries. There is increasing recognition that suction drains in particular offer no added benefit over non-suction drains, and may be associated with harm, including death. There are multiple reports within the literature of sudden death associated with their use and there seems to be a general trend away from their use.

We (The Walton Centre) currently have a manuscript under review with the British Journal of Neurosurgery describing two unfortunate deaths from our own trust that occurred following cranioplasty, in the time period 2016-2017. Like many case reports describing this event, suction drain use seems to be an associated risk factor, but by no means a definitive cause of sudden death.

The editor of the British Journal of Neurosurgery, like ourselves recognises that the literature (including our two unpublished cases) seems to demonstrate that sudden death associated with the use of suction drains is more prevalent after cranioplasty in particular. This is a novel observation which they are keen to publish in their journal. The editor — Patrick Mitchell has requested that we supplement the manuscript with a description of the prevalence of the use of suction drains across cranial neurosurgery in general. We know anecdotally that the use of suction drains has probably diminished within this trust. However, the editor requests historical data on their use. Therefore, I intend to identify from a sample of craniotomies, cases where suction drain use is described in the operation notes, and any unexpected hyperacute/acute clinical deterioration with their use.

There are a number of clear limitations with this work, principally that drain use description in operation notes may be limited, absent, or not representative of the drain used, including suction. This work does not intend to prove any association of the use of suction drains as a cause of sudden death. The only intention is to appreciate the prevalence if their use over a historical time-period.

This work is principally to supplement the manuscript under final review with the aforementioned journal, which we are of course keen to publish in order to make this important observation for the global neurosurgery community. However, it would be of interest to ourselves to repeat this piece of work to confirm if in fact the use of suction drains after cranial neurosurgery has indeed diminished within our trust. This could then be presented for educational purposes within the trust and as a national service evaluation.

# **Methodology**

- 1) Identify operative cases coded as craniotomy in the years 2016-2017
- 2) Identify from operation notes descriptions of suction drain use post-operatively.
- 3) Identify from EP2 and description of hyperacute/acute clinical deterioration or death.
- 4) Identify proportion of cranioplasty cases (already completed from prior work)

Aims / Objectives					
Identify the prevalence of th cranioplasty over the years			•	a particular empha	sis on
Specifically:					
a) the number of craniotomi of suction drains, c) Sudder cranioplasties from the above	death in any of t				
Standards / Criteria Detail	s (service evalu	ation N/A)			
N/A					
Guideline / Standards ava		□ No			
If yes, please attach a copy	or provide web li	nk to the most	current version: Click	here to enter text.	
Name of Standard / guidel	<b>ine:</b> n/a				
Source of Standard / guide Trust		□ t <b>her</b> : Click here	NICE □ to enter text.	Royal College	
Review/assessment of gu $_{\rm Yes} \ \square \ {\rm No} \ \square$	ideline/standard	l undertaken	to ensure it is appro	priate & can be m	easured
Is the audit / service evalu					
High volume High risk	Yes □ No □ Yes ⋈ No □				
High cost	Yes □ No ⊠				
Known quality issue	Yes ⊠ No □				
Wide variation in practice					
Sample No: n/a Procedur	e codes to ident	ify sample: n	/a		
http://www.raosoft.com/sam	<u>plesize.html</u> - linl	k to tool that m	nay be used to calcula	ite sample size	
Are you planning to public	sh your audit/se	rvice evaluat	ion findings nationa	lly	
(e.g. Medical journal)?	Yes ⊠	No 🗆			

Is this a re-audit or if service evaluation, has service been reviewed previously? Yes □ No ☒

Is this project part of an agreed departmental rolling programm	ne? Yes □ No ⊠
Rolling programme duration (number of years): n/a	
Rolling programme frequency: Monthly $\square$ Quarterly $\square$ Biar	nnually $\square$ Annually $\square$
Multidisciplinary:	
Is Clinical Audit Team support required?  If yes, please specify type of assistance required:  Population Identification  Design of data collection tool  (If not required please, attach a copy of the tool to be used)  Database design  Data entry  Analysis  Presentation  Collection of case notes	No ⊠
Patient Contact / Involvement – (If project involves patient contact the or care please explain how in this section) Will the audit involve direct patient contact?  Yes	nat is <u>not</u> part of the patients usual treatment □ No ⊠
How will the patient be involved?	
Patient Questionnaire $\ \square$ At clinic appointment $\ \square$	
Other (please give details) Click here to enter text.	
Has approval been sought from the Patient Information Panel?	Yes □ No □ N/A ⊠
Anticipated start date: ASAP	
Anticipated project completion date: 18th December	
Anticipated Action Plan Submission date: 1 month from compl	etion date
PLEASE ATTACH A COPY OF YOUR DATA COLLECTION TOOL / PATIENT (above.)	QUESTIONNAIRE – Basic data points described
<ul> <li>FOR ALL RE-AUDITS OR REPEAT SERVICE EVALUATIONS PLEASE ATTACH EVALUATION REPORT.</li> </ul>	H A COPY OF THE PREVIOUS AUDIT OR SERVICE
<ul> <li>PLEASE ENSURE THIS FORM IS SIGNED BY YOUR DIVISIONAL AUDIT LEA AUDIT TEAM.</li> </ul>	AD BEFORE SUBMISSION TO THE CLINICAL
Departmental Clinical Audit Lead (Signature)	Date: Click here to enter text.
Comments Click here to enter text.	
Divisional Clinical Audit Lead (Signature)	Date: Click here to enter text.
Is this topic a key clinical interest for the department / division	? Yes □ No □